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BACKGROUND
Haematological diseases account for approximately 8% of all malignant tumours that are 
diagnosed each year in the Netherlands. Between 2006 and 2011 the number of new adult 
patients with haematological malignancies increased from 7,000 to 8,200 per year. Most of 
these patients were aged between 60 and 75 years 1.
Haematological malignancies originate in the bone marrow and lymph nodes and include 
leukaemia, lymphoma and myeloma. Mature B-cell malignancies affect by far the largest 
group of patients, with non-Hodgkin lymphoma being the most common, followed by 
multiple myeloma and chronic lymphocytic leukaemia 1. Just fifty years ago there was no 
cure for disseminated malignant disease. The first successes for chemotherapy were made 
in the 1960s and further escalation of the dosage and intensity of the cytostatic drugs led to 
better results. In fact, chemotherapy is still the most important modality for treating haema-
tological cancers.
TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
Several cycles of treatment with chemotherapy are necessary to obtain remission from 
haematological malignancies as only a certain proportion of cancer cells will be killed with 
each successive cycle. The first cycle of treatment of acute myeloid leukaemia is referred 
to as remission-induction therapy and aims to destroy leukaemic cells. As remission-in-
duction seldom destroys all the leukaemic cells, consolidation treatment is necessary to 
reduce the risk of the disease recurring.
Once remission is achieved, haematopoietic stem cell transplantation (HSCT) is frequently 
the way to achieve the best long-term outcome. This HSCT requires a conditioning regimen 
consisting of high doses of chemotherapy, with or without total body irradiation (TBI), to 
eliminate residual bone marrow stem cells. This regimen is then followed by either an allo-
geneic (from a related or unrelated donor) or autologous (patient’s own) stem cell trans-
plant to restore blood stem cell production and immune defences.
Allogeneic HSCT is highly effective, resulting in increased definitive cure rates and extended 
disease-free survival in various high-risk haematological diseases 2. Allogeneic HSCT relies 
on immune-mediated effects to control the underlying malignant disease. The rationale 
for using immunotherapy to prevent and/or treat the re-emergence of malignancy is based 
upon the observations that graft-versus-tumour (GVT) effect plays a major role in reducing 
the risk of relapse following an allogeneic HSCT. The importance of a graft-versus-tumour 
effect has encouraged the use of various strategies which optimise an immunologically- 
mediated anti tumour effect 3.
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1CHEMOTHERAPY-INDUCED TOXICITY
The efficacy of chemotherapy comes at a price. Several side-effects are known and can be 
as severe and life-threatening as the haematological disease itself.
— Haematological toxicity
Administration of chemotherapy is associated with haematological toxicity such as 
anaemia, leukopenia and thrombocytopenia. In addition, the cytotoxic drugs suppress not 
only the haematopoiesis system, but impair other host defences as well. This can limit the 
amount of chemotherapy that can be tolerated and may result in necessary dose reductions 
or even postpone further therapy, thereby compromising patient outcome.
Neutrophils are white blood cells that play a crucial role in the killing of micro-organisms. A 
low neutrophil count, called neutropenia, is defined by absolute neutrophil count (ANC) as 
being mild (ANC = 1.0-1.5x109/L), moderate (ANC = 0.5-1.0x109/L) or severe (ANC <0.5x109/L) 
and is the most serious haematological toxicity as it increases the risk of life-threatening 
infections. Neutropenia blunts the inflammatory response to nascent infections, allowing 
bacterial multiplication and tissue invasion. The risk of infection also corresponds with the 
depth and duration of neutropenia 4.
Because neutropenia attenuates most of the signs and symptoms of infection, patients 
with neutropenia often present with fever as the only sign of infection. Fever that develops 
during neutropenia is referred to as ‘febrile neutropenia’ (FN), and requires prompt treat-
ment with broad-spectrum antibiotics and hospitalization, because the risk of death from 
rapidly spreading uncontrolled infection is high. The definition of febrile neutropenia varies, 
but is generally accepted as the presence of fever during severe neutropenia.
— Mucosal barrier injury
The mucosal barriers of the gut and lung are also injured by high-dose chemotherapy. The 
mucous membranes in the human body form a natural barrier that protects the body against 
the penetration of harmful substances as well as bacteria and fungi. Mucosal damage 
caused by chemotherapy or radiation is visible only in the mouth, but actually extends 
along the whole gastro-intestinal tract. Patients undergoing a myeloablative stem cell 
transplantation are particular vulnerable to mucosal damage because their conditioning 
consists of high-dose chemotherapy, sometimes in combination with total body irradiation.
Chemotherapeutic drugs and irradiation activate the important common transcription 
factor: nuclear factor-kappaB (NF-kB), found in epithelial and endothelial cells. Apart 
from an infection, this factor also initiates the production and release of pro-inflammatory 
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cytokines and chemokines. The mucosa may be damaged or ulcerated to such extent that 
bacteria and fungi can no longer be prevented from entering the bloodstream, which can 
lead to life-threatening infections. The degree of mucosal damage after intensive chemo-
therapy is mainly determined by the inflammatory response in general and that of cells of 
the intestinal mucosa in particular. The peak of mucosal damage typically coincides with 
the nadir of neutropenia both jeopardizing the patient at the same time. The tissue damage 
inflicted by cytotoxic therapy contributes to uncontrolled inflammation increasing the risk 
for critical illness which cannot be prevented by antimicrobial therapy. The net result is 
fever of unknown origin accompanying mucositis and elevated C-reactive protein (CRP) 
levels 5, 6 (figure 1).
NEUTROPENIC FEVER: INFLAMMATION OR INFECTION?
Fever occurs when pyrogenic factors (exogenous or endogenous toxins, such as cell wall 
components of bacteria) induce the white blood cells to release pyrogenic cytokines (such 
as interleukin 1 and 6, Tumour Necrosis Factor and Interferon). These cytokines stimulate the 
Figure 1 From cancer to criti cal illness (partly adapted from Viscoli et al. ⁷)
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hypothalamus to the release of prostaglandin E2 through which the temperature set-point 
of the hypothalamus increases. In response, the body will have an increased heat produc-
tion and heat retention resulting in an elevated core temperature. The hypothalamus is the 
thermoregulation centre of the body and is innervated by peripheral nerves that commu-
nicate with heat and cold receptors. In addition, it registers the core body temperature by 
measuring the temperature of the blood. These two signals are integrated in order to main-
tain a normal temperature and the body is able to provide additional warmth by shivering 
and increasing metabolic activity and vasoconstriction or lose heat by vasodilation and 
sweating when necessary.
In fact, only 30-50% of the febrile episodes in patients treated with high dose chemotherapy 
can be explained by proven infections, mostly bacteraemia, with the majority remaining 
unexplained  8. Unexplained (culture-negative) fever is also often referred to as ‘fever of 
unknown origin’ and may be well related to chemotherapy-induced mucositis 5. Fever can 
also develop from non-infectious causes including drug-induced side effects and transfu-
sion reactions.
TREATMENT-INDUCED TOXICITY LEADING TO INFLAMMATION
Cancer and its therapy perturb a wide range of healthy tissues including both the innate 
and adaptive immune system increasing the risk of potentially dangerous infections 
that can result in critical illness. The barrier function of the oral and intestinal mucosa is 
extremely effective, especially when one realizes that the human body hosts more than 
1014 micro-organisms. This symbiosis is normally beneficial, but it requires strict control 
by the immune system. Innate immunity plays a crucial role in maintaining this delicate 
homeostasis. Important elements of the innate immune system that play a crucial role in 
initiating inflammation are the pattern recognition receptors (PRR) such as the Toll-like, 
Nod-like and C-type lectin receptors that are involved in the recognition of pathogen-asso-
ciated molecular patterns (PAMP’s) and danger-associated molecular patterns (DAMP’s) 9. 
PRR’s are expressed on epithelial cells, endothelial cells and immune cells, mainly antigen 
presenting cells such as macrophages and dendritic cells. When the interaction of host and 
microbes dysfunctions in the presence of tissue damage the PAMP’s and DAMP’s contribute 
to the development of uncontrolled inflammation. Chemotherapy-induced disruption of the 
mucosal innate immunity also plays a major role in the development of clinical inflamma-
tion manifested in mucositis and Graft-versus-Host disease 10, 11.
TREATMENT TOXICITY LEADING TO INFECTION
Microorganisms that may cause infection of patients with cancer include bacteria, viruses, 
fungi and protozoa. Importantly, infections by microorganisms with low virulence can result 
in significant morbidity and mortality in immunocompromised patients with cancer 12. 
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Clinically documented infection (CDI) involves a site of infection identified either by phys-
ical examination or by imaging, but without a potential pathogen being detected. Micro- 
biologically documented infection (MDI) indicates that an opportunistic pathogen has been 
identified by cultures, microscopy or indirectly by the detection of antigens or nucleic acids. 
Fever of unknown origin (FUO) indicates fever without any documentation of either a clini-
cally or microbiologically documented infection 13.
Since the 1990s, Gram-positive bacteria outnumber Gram-negative organisms as infectious 
pathogens, at least in part due to the widespread use of intravascular catheters. Fungi, 
mainly Candida species and Aspergillus fumigatus also cause infections in neutropenic 
patients, especially in those who are receiving broad-spectrum antibiotics. Other risk 
factors for fungal infections include prior use of steroids, advanced age, intensity of chemo-
therapy and the presence of an indwelling central venous catheter (figure 2) 14. The six week 
mortality rate associated with fungal infections is about 1 out of 5 for HSCT recipients 15 and 
about 1 out of 4 for patients with acute myeloid leukaemia 16. The use of central vascular 
catheters (CVC) is an important risk factor for infections due to coagulase-negative staphylo- 
cocci, Staphylococcus aureus, aerobic Gram-negative bacilli and Candida albicans  14. 
Besides infection, the use of CVCs can also be complicated by thrombosis, that, in turn, 
can become infected. Septic thrombosis is a serious condition frequently associated with 
persistent bacteraemia or fungaemia.
TREATMENT TOXICITY MIGHT ESCALATE FROM SIRS TO SEVERE SEPSIS AND SEPTIC SHOCK
The most severe clinical manifestation of infection is sepsis, defined as the systemic 
inflammatory response of the host to invading pathogens. Patients with cancer are ten 
times more likely to develop sepsis than those who do not have cancer. Cancer is also asso-
ciated with a 30% higher risk for death from sepsis and, moreover, sepsis is responsible 
for approximately one in ten of all deaths due to cancer 17. Haematological malignancies 
are more frequently associated with severe sepsis than are solid tumours and show higher 
mortality rates 18. Neutropenic patients are unable to mount robust inflammatory responses 
so serious infection may be present with minimal symptoms and signs. Consequently, fever 
is often the first, and frequently the only, sign of infection 19 and therefore, fever is a critical 
factor in recognizing the systemic inflammatory response syndrome (SIRS), a complex of 
symptoms indicating systemic activation of the immune system which may result in sepsis, 
depending on the presence or absence of infection 20.
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Sepsis is the systemic immune response to infection and is initiated by invading micro-or-
ganisms. The inflammatory response, that persists after the elimination of the infection, is 
also associated with an increased mortality 21 and determines even more the prognosis of 
the patient than does the initial infection. Severe sepsis is defined as sepsis resulting in 
sepsis-induced organ dysfunction or signs of tissue hypoperfusion. Septic shock is defined 
as sepsis-induced hypotension that persists despite adequate fluid resuscitation 22. Organ 
dysfunction results from the direct toxic effects of microbial toxins as well as from dysreg-
ulation of the circulation, oxygen transport and tissue oxygenation. Restriction of global 
oxygen transport (respiratory failure, decrease in cardiac output and anaemia), and inade-
quate regional oxygen supply due to perfusion mismatch are also critical factors 23 (figure  3).
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PREVENTION AND TREATMENT OF SEPSIS
Early recognition and immediate treatment of sepsis is critically important and, since fever 
is likely to be the first sign, current guidelines recommend prompt treatment with antibac-
terials targeted against Gram-negative bacilli such as Escherichia coli at the onset of fever 
to prevent the occurrence of sepsis and septic shock in haematological patients.
 In 2004 an international group of experts in the diagnosis and management of infection 
and sepsis, representing eleven scientific organizations, published the first internationally 
accepted guideline for use at the bedside to improve outcomes in severe sepsis and septic 
shock 24. The Surviving Sepsis Campaign uses bundles to simplify the complex processes 
of caring for patients with severe sepsis. A bundle is a selected set of elements of care 
distilled from evidence-based practice guidelines that, when implemented as a group, are 
thought to be more effective than the individual elements alone. Key recommendations 
include measuring the lactate level, obtaining blood cultures before initiating treatment 
with broad spectrum antibiotics and administering crystalloid for hypotension or lactate 
≥4mmol/L. These items have to be completed within three hours. Several other treatments 
have to be completed within six hours.
Figure 3 Deﬁ niti on of sepsis and related syndromes (adapted from Dellinger et al. ²²)
Systemic inﬂ ammatory response 
syndrome (SIRS)
A clinical response arising from a non-speciﬁ c insult, 
including ≥2 of the following:
– Temperature ≥38˚C or ≤36˚C
– Heart rate ≥90 beats/minute
– Respiratory rate >20 breaths/minute or PaCO2 <33 mmHg
– White blood cell count ≥12,000/mm³ or ≤4000/mm³ or 
 >10% immature neutrophils
Sepsis
The presence (probable or documented) of infecti on 
together with systemic manifestati ons of infecti on
Severe sepsis
Sepsis plus sepsis-induced organ dysfuncti on or ti ssue 
hypoperfusion
Septi c shock
Sepsis-induced hypotension persisti ng despite adequate 
ﬂ uid resuscitati on
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
17
1
MANAGING THE CRITICALLY ILL FEBRILE NEUTROPENIC PATIENT
— Detection
Adequate interventions at an early stage offers the best chance of preventing sepsis to 
develop any further. Especially in neutropenic patients infections can progress rapidly, 
leading to hypotension or other life-threatening complications within minutes to hours. 
It is critical to recognize neutropenic fever as early as possible to allow prompt initiation 
of empirical systemic antibacterial therapy in order to avert progression to severe sepsis 
and septic shock, and possibly death 25. The efficacy of the treatment of patients with 
neutropenic fever syndromes has improved greatly as is shown by a progressive decline in 
mortality rates since the practice was implemented in the 1970s 26, 27. This has been recently 
confirmed by the results of the international Surviving Sepsis Campaign showing that 
increased compliance with sepsis performance bundles was associated with 25% relative 
risk reduction in mortality rate 28. Comparable outcomes were found for participating hospi-
tals in the Netherlands 29 demonstrating clearly that mortality reduction can be achieved by 
increased protocol compliance.
A complicating factor in the detection of fever is that it presents mostly outside of office hours 
and that the definition and methods to estimate body core temperature vary 30. Thresholds 
for defining fever are a peripheral body temperature of 37.5 - 38.5°C measured in the oral 
cavity, in the ear, under the axilla, rectally or on the surface of the skin. All these methods 
have their limitations when the aim is to reliably determine the body’s core temperature 31.
For those presenting with hypothermia or those developing less pronounced or delayed 
fever (e.g. when antipyretics or steroids are given), reliance is placed on other vital signs 
including respiratory and heart rate, blood pressure and oxygen saturation because changes 
in these signs might be the consequence of a systemic inflammatory response. Recognition 
of the systemic inflammatory response syndrome is the first step to the early recognition of 
patients with sepsis. That this is far from easy in daily practice was shown by the fact that, 
even after an effective sepsis training programme, only half to two-thirds of the physicians 
could define severe sepsis and septic shock, respectively 32, 33. Nurses also experience diffi-
culties in recognising patients with sepsis due mainly to a lack of detailed knowledge 34. 
Moreover, the applicability of Surviving Sepsis Campaign definitions for inflammation in 
clinical practice can be questioned as the immune response of haematological patients 
is different from that of other patients. A window of three hours to initiate antibacterial 
treatment for febrile neutropenia, as advocated in the surviving sepsis guidelines, is also 
unlikely to be appropriate for the haematological population.
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— Selection
Sepsis is a serious condition caused by an overwhelming immune response to infection. 
Immune chemicals released into the blood to combat the infection trigger widespread 
inflammation, which leads to blood clots and increased capillary permeability. This results 
in impaired blood flow, which damages the body’s organs by depriving them of nutrients 
and oxygen. In severe cases, one or more organs fail. In the worst cases, blood pressure 
drops, the heart fails and the patient spirals toward septic shock. Once this happens, 
multiple organ failure may occur and the patient is likely to die.
One might argue that these patients need intensive care treatment. However, treating 
groups of patients with conditions associated with high mortality rates on an Intensive 
Care Unit (ICU) poses significant ethical difficulties. Intensive care treatment is a burden 
for the patient and her/his relatives because of the discomfort associated with it and is 
becoming increasingly burdensome to health care systems. These issues become more 
important when high mortality is anticipated 35, 36. Clearly, ICU survival strongly depends 
on the selection of patients who are actually offered ICU treatment. Therefore, the decision 
to admit these patients to the intensive care is challenging since subjecting every patient 
will lead to futile treatment and prolonged suffering for patients and their families. On the 
other hand, if the selection of patients is too strict and based solely on the level of risk, it 
will inevitably lead to inadequate treatment and unnecessary deaths. Optimal selection of 
suitable candidates for the ICU is also hampered by the fact that there is no standard for 
objectively assessing prognosis. Hence we need to select which patients are not eligible for 
ICU admission and determine triggers to initiate in a timely manner an adequate level of 
intensive supportive care for those who are.
— Action
Time is of the essence for patients with severe sepsis or septic shock, since they have better 
chance of survival if sepsis is treated adequately at an earlier stage to prevent progression 
from sepsis to severe sepsis and septic shock 22. Besides reduction in mortality, optimal 
guideline based treatment of sepsis might also lead to fewer days with fever, reduction of 
antibiotic use, a shorter length of hospital stay, less aggressive supportive care and less 
infection-related costs. However, the identification of patients with sepsis can be difficult in 
daily practice as the signs of systemic inflammation response syndrome are not specific 37. 
Antibacterial therapy is the most important treatment for sepsis. The choice of antibacterial 
therapy mainly depends on the suspected site of infection and the antimicrobial suscep-
tibility of the expected pathogens, so therapy with broad-spectrum antibiotics is initiated 
empirically 38.
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Considering the role of inflammation due to tissue damage and disrupted innate immunity 
there might be a place for anti-inflammatory therapies in the care of critically ill haematology 
patients. Data are however scarce and there remains a general concern regarding the risk of 
worsening infectious complications when embracing such an approach. Nevertheless, the 
use of corticosteroids has already shown beneficial in specific situations, including acute 
respiratory distress syndrome (ARDS) during streptococcal bacteraemia, Pneumocystis 
jirovecii pneumonia and immune reconstitution inflammatory syndrome (IRIS).
MANAGEMENT OF THE CRITICALLY ILL HAEMATOLOGICAL PATIENT
The decision to admit haematological patients to an ICU for continuous monitoring of the 
vital functions or for intensified supportive care treatment including organ support often 
presents difficult ethical issues as high mortality rates underlie a reticent attitude among 
both haematologists and intensivists 39. A taskforce of the American College of Critical Care 
Medicine concluded less than two decades ago that patients with haematological malig-
nancies were poor candidates for ICU admission 40. In the last decade, the body of evidence 
has grown that survival of patients with haematological malignancies is improved when 
they are admitted to the ICU, which has led to an improved awareness of the benefits of 
early admission to an ICU 41. However, there are still considerable inter- and intraregional 
disparities regarding the ICU admission policy of haemato-oncological patients in the Nether- 
lands. A survey, entitled ‘the vision of the Dutch haematologist on the role of intensive care 
in the care of haematological patients’ was conducted in February 2012 and consisted of a 
web-based questionnaire that was distributed through the Haemato-Oncology Foundation 
for Adults in the Netherlands (HOVON) mailing list (unpublished). Briefly, 23 hospitals (7 
university medical centres (HOVON level A) and 16 general hospitals (7x level C and 9x level 
D)) have responded. A ‘no-ICU’ policy was based primarily on the haematological prog-
nosis (17x). Three hospitals registered the numbers of ICU transfers but thirteen hospitals 
reported an increase and seven reported a constant number of ICU transfers. The majority 
of hospitals mentioned the use of predefined criteria for consultation with an intensivist 
and ICU transfer. In seven hospitals there was no medical emergency intervention team 
available. In general, although there was a greater willingness among intensivists to admit 
haematological patients, important differences between centres concerning ICU admission 
policies exist. Consequently, more evidence is needed to show that ICU treatment of this 
specific transplant group may not be futile.
To conclude, treatment for patients with haematological malignancies has improved over the 
recent years, which has led to increased survival rates. Nevertheless, side-effects of these 
intensive chemotherapy regimens frequently occur. Supportive care aimed to manage the 
inevitable inflammatory complications of these intensive treatments is no longer restricted 
to haematological wards. However, we need to learn more about the optimal detection of 
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sepsis, the selection of patients who should be offered ICU treatment, and the timeframes 
within which appropriate action should be taken to attain optimal survival while preserving 
an acceptable quality of life.
With this thesis we address the following questions:
1. Can we further improve our standards of care in the management of fever in neutro-
penic haematological patients?
2. What are the trends in ICU admissions of critically ill haematological patients and 
what is their outcome?
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AIMS AND OUTLINE OF THE THESIS
The thesis consists of two complementary parts addressing the management of the critically 
ill neutropenic haematological patient. The overall objective of the research presented in 
this thesis was to obtain insight in characteristics of patients during treatment for a haema-
tological malignancy who are at risk for inflammatory complications and to investigate the 
trends in ICU admissions of critically ill haematological patients and their outcome.
The first part of the thesis focuses on improving our standards of care in the management 
of fever among neutropenic patients. Which factors in the detection of fever and instituting 
adequate action can be improved? With fever being the most common early manifesta-
tion of sepsis, clinical practice guidelines emphasise the prompt institution of empirical 
broad-spectrum antibacterial therapy at the onset of fever as this has been shown to be 
crucial to patient survival. In Chapter 2 we assess the feasibility and validity of a method 
for continuously monitoring the skin temperature of adults, admitted to the haematology 
ward for an HSCT, in order to detect fever at its onset. Subsequently, Chapter 3 focuses on 
interventions to avoid delay in initiating empirical antibacterial treatment at the onset of 
fever, as this is the cornerstone for preventing sepsis during neutropenia. In Chapter 4 we 
explore the value of two instruments, SIRS and R-MEWS to recognise the changes in vital 
signs associated with systemic inflammation. We also investigated whether chemotherapy 
treatment was related to persistent fever in patients treated for haematological malignan-
cies. Since central venous catheters (CVCs) are widely used in the management of patients 
receiving intensive chemotherapy, with some being related to infection and thrombosis, 
we present in Chapter 5 a retrospective analysis to investigate the risk factors for persistent 
coagulase-negative staphylococci bacteraemia and central venous catheter related throm-
bosis and their relationship to each other.
The second part of the thesis focuses on the critically ill patient and the trends over time 
in ICU admission policies and clinical outcomes. In Chapter 6 we investigate the changes 
over time in the ICU and hospital mortality as well as the 100 day post-HSCT mortality for 
three cohorts of HSCT recipients admitted to our ICU, compared to those who were not. 
In Chapter 7, we explored trends over time in admission prevalence and outcome of 1,741 
critically ill haematological patients in the Netherlands by using the National Intensive Care 
Evaluation database. In Chapter 8 we describe the long-term self reported health related 
quality of life, including fatigue, cognitive functioning and anxiety and depression, of 
patients being treated for a haematological disease who received intensive care treatment 
compared to those who did not. We also included a group of non-haematological general 
medical ICU patients as a control group. Chapter 9 contains the summary of the thesis as 
well as a general discussion and future perspectives.
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ABSTRACT
GOALS OF WORK 
Empirical antibiotic therapy is usually started in patients who are neutropenic following 
treatment with cytostatic chemotherapy for a haematological malignancy as soon as fever 
develops to forestall fulminant sepsis. Hence, accurate and timely detection of fever is 
crucial to the successful management of infectious complications in these patients. We 
report an investigation of the feasibility and validity of continuous non-invasive body 
temperature measurement.
PATIENTS AND METHODS 
The feasibility of non-invasive continuous measurement of the skin temperature was inves-
tigated using the Propaq® device in a cohort of 33 patients receiving an allogeneic HSCT 
who were all at risk of developing a febrile episode. Non-invasive continuous measurement 
of the skin temperature (CST) was compared with a standard episodic axillary tempera-
ture measurement (EAT) five times daily using a Terumo® device. The study period entailed 
monitoring during the ten or twelve days that profound neutropenia was expected to be 
present.
MAIN RESULTS 
Measuring the skin temperature continuously and accurately by using the Propaq® was 
feasible. The CST correlated well with the EAT measurements (Pearson r=0.782). Compared 
to EAT, the start of empirical therapy could be started 2.5 h earlier when relying on conti- 
nuous measurements than was possible with EAT.
CONCLUSION 
Continuous skin temperature measurements are feasible and valid compared to the conven-
tional temperature measurement and may improve the management of infections by earlier 
detection of fever in neutropenic patients.
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INTRODUCTION
Approximately 90% of cycles of intensive chemotherapy used to treat acute leukaemia 
are complicated by prolonged and profound neutropenia that is usually accompanied by 
fever and infections 1. Neutropenic patients who are febrile are at high risk for developing 
sepsis, which often necessitates acute admission to the Intensive Care Unit (ICU) and is 
associated with a high mortality 2. Fever is usually the most obvious sign of a systemic 
inflammatory response 3, so measuring the body temperature is one of the most important 
nursing tasks. Instituting empirical broad-spectrum antimicrobial therapy promptly at the 
first sign of fever has been shown crucial to patient survival and remains the cornerstone of 
infection management 4-6. Mortality associated with fever and neutropenia has dramatically 
decreased over the last three decades and is, in no small measure, the result of general 
adherence to the concept of giving empirical therapy with broad-spectrum antibiotics 
promptly at the onset of fever 7. Needless to say this approach hinges upon the early detec-
tion of fever by measuring the body temperature.
A variety of methods are used to measure body temperature, involving different sites, instru-
ments and techniques. The core temperature is best measured in the pulmonary artery 
using a Swan-Ganz catheter 8, 9, but this is impossible to employ on a haematology ward 
in daily clinical practice. Mercury thermometers are now obsolete and have been replaced 
by electronic devices. These thermometers accurately predict temperature and can be 
adapted for use at different body sites to measure temperature orally, axillary, tympani-
cally or rectally 10. However, the choice of sites for adults on a haematology ward is limited. 
Temperature is most often measured orally although oral mucositis results in erroneous 
measurements 11. Rectal measurement during thrombocytopenia is too dangerous because 
of the risk of rectal bleeding. There are convincing data to show that tympanic temperature 
measurement is reliable, but the results are more variable than found with rectal or oral 
readings 12. For these reasons, we have continued to measure the axillary temperature for 
our adult population 13.
For continuous measurements, a temperature sensor connected to the Welch-Allyn® 
Propaq monitor was used. This device is able to measure temperature continuously. In this 
audit, 24 h non-invasive measurement of skin temperature was explored. The goals were:
1. To assess the feasibility of continuously monitoring the skin temperature of adults 
admitted to the haematology ward for an HSCT.
2. To assess the validity of the data by calculating the correlation between the values 
measured by the continuous device and the axillary measurements.
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PATIENTS AND METHODS
PATIENT POPULATION
The audit was carried out on the haematology ward of the Radboud University Nijmegen 
Medical Centre where 33 patients admitted to receive an HLA compatible allogeneic haema-
topoietic stem cell transplant (HSCT) from a sibling or a voluntary unrelated donor, consented 
verbally to participate. Ethics Committee approval was not required. Both myeloablative or 
non-myeloablative conditioning was used for prepatory regimen. Demographic data of the 
patients are shown in table 1.
PROCEDURE
Participating patients had their body temperature measured simultaneously by two 
different instruments. This period was defined as the first ten days post-transplant or, in 
the case of idarubicin, two days before HSCT until ten days post-transplant as this drug was 
given two weeks before transplant whilst others were given within a week. Temperature was 
scheduled to be registered five times daily at fixed times: 03:00, 08:00, 13:00, 18:00 and 
22:00. The maximum interval between two measurements was 5 h.
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Gender 14 Male
19 Female
Age Mean 48.0 years and range 22-64 years
Type of transplant 17 Sibling HSCT
16 Voluntary Unrelated Donor HSCT
Underlying disease 10 Acute Myeloid Leukaemia
5 Myelodysplasti c syndrome
4 Severe aplasti c anaemia
3 Chronic lymphocyti c leukaemia
4 Non-Hodgkin’s lymphoma
3 Acute lymphocyti c leukaemia
1 Multi ple myeloma
1 Chronic myeloid leukaemia
1 Myeloﬁ brosis
1 Acute basophile leukaemia
Conditi oning regimen Myeloablati ve
 – 9 Idarubicin-cyclophosphamide-total body irradiati on (TBI)
 – 11 ATG-cyclophosphamide-TBI
 – 4 ATG-cyclophosphamide-ﬂ udarabine
 – 1 Idarubicin-busilvex-cyclophosphamide
Nonmyeloablati ve
 – 2 Cyclophosphamide-ﬂ udarabine-TBI
 – 3 Cyclophosphamide-TBI
 – 2 Cyclophosphamide-ﬂ udarabine
 – 1 Cyclophosphamide-TLI
Table 1 Demographic data
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INSTRUMENTS
— EAT
We used a Terumo® axillary thermometer, type C202, to measure axillary temperature. The 
device was calibrated for the range of 32.0–42.0°C, in steps of 0.5°, by means of a warm 
water bath. The maximum deviation after 90 s was 0.02°, as was internally validated by the 
technical service (data not shown). The Terumo thermometer predicts the axillary tempera-
ture after approximately 60 seconds.
— CST
Continuous measurement was achieved by using a temperature sensor connected to the 
Welch-Allyn® Propaq monitor. This device measures temperature continuously preferably 
in a body cavity that is least exposed to ambient air. Patients were asked to carry the sensor 
either in their groin or axilla, though the former was preferred as it is least influenced by the 
patient’s movements.
SUPPORTIVE CARE
Empirical therapy was started once when the axillary temperature as measured by episodic 
axillary temperature (EAT) was equal to, or exceeded, 38.5°C. When continuously measured 
skin temperature (CST) indicated T≥ 38.3°C axillary measurement was performed to see 
if EAT confirmed this. At the onset of fever, blood was obtained for cultures, ceftazidime 
was administered empirically, and the attending physician was alerted. A blood culture 
was considered positive if one or more cultures yielded a microorganism, except for 
coagulase-negative staphylococci, for which two separate positive blood cultures yielding 
the same strain were required to be considered to represent bacteraemia 14.
AUDIT
Feasibility was tested in the first six patients, and a go/no-go decision to continue the audit 
was made. Carrying the device was found feasible when five of the six patients could bear 
the sensor during the day, and the monitor reflected the body temperature. Patients were 
interviewed to assess the feasibility of carrying a temperature device on the body during 
the day. The validity of the continuous measurements was assessed by comparing pairs of 
simultaneously measured values and calculating the correlation and regression between 
them.
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DATA ANALYSIS
Data on the validity of the measurements were collected by the nurses of the ward. A regis-
tration form was specially developed to record the data. All temperature measurements 
were recorded during ten or twelve days of observation.
 Data were imported in SPSS version 14.0 for data analysis. Correlation and regression 
analysis were performed to assess validity of the experimental measurements. The outliers 
in temperature difference, defined as a 0.5° difference (ΔT) or more between the two simul-
taneously used methods were analysed on possibly confounding factors age, BMI and 
gender.
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RESULTS
FEASIBILITY
Feasibility was assessed after the first six patients had been observed, and the decision 
was made to continue when five patients had been shown to have no problems carrying the 
CST device. A total of 33 patients were included and 29 completed the observation period 
successfully. Each patient could move around freely as the sensor was not attached to their 
body and could easily be disconnected temporally when desired. During the audit, one 
patient was uncomfortable carrying the device during the day and withdrew from the study 
for that reason. Three patients complained about the sensor and considered abandoning 
the study but decided to continue. The CST did not reflect the body temperature in one case 
as the patient’s physique did not permit sufficient isolation from ambient air.
VALIDITY OF THE CST RELATED TO THE EAT
Regarding the difference in the simultaneously measured body temperature between the 
EAT and the CST (ΔT), 1,409 values were valid for evaluation as missing values were not 
properly recorded on the registration form. As shown in figure 1, 90% of the differences in 
measurements are located in a range of −0.5°C to 0.9°C. The CST measured both higher 
and lower temperatures than was recorded for EAT and frequency, the values of both were 
distributed in a Gaussian fashion though EAT was on average 0.23° higher (figure 1).
There was a good correlation between the two methods (figure 2; Pearson correlation of 
0.782, p ≤0.01). Regression analysis yielded an R2 of 0.612 and the intercept and slope 
indicated that ΔT was most pronounced at higher values: y=0.934*x+2.259. For an axillary 
temperature of 36°C, the mean deviation of the CST was 0.12°; for an axillary temperature 
of 40.5°C, the mean deviation of the CST was 0.41°.
ΔT was 0.5 or more in 29.5% of all cases. Per patient, a ΔT≥0.5 was found in 2% to 69% of the 
total number of measurements suggesting that patient characteristics played a considerable 
role. Analysis of ‘gender’ and ‘ΔT≥0.5’ showed no significant difference between the 
groups (p=0.309), and there was no influence of either BMI (p=0.227) or age (p=0.614). 
 In 78% of patients, bacteraemia was detected during the initial febrile episode during 
neutropenia justifying the decision to start broad-spectrum antibiotic treatment.
 Although it was not the primary object of the study, we noted that antibiotics were started 
over 2.5 hours earlier for twelve out of fourteen evaluable patients as a result of earlier 
detection of fever by continuous measurements.
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Mean = 0.23
Std. dev. = 0.64
n = 1409
 = actual
 = expected
Figure 1 Histogram on the diﬀ erence (EAT minus CST) in simultaneously measured temperature 
by two diﬀ erent methods (outliers are left  out)
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Figure 2 Scatt ergram with regression line on the correlati on of two independent measurements 
of body temperature
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DISCUSSION
Fever is regarded as the most important means of identifying an inflammatory process 
in neutropenic patients, but there is reason for concern as the reliability of the common 
methods of temperature measurement all appears to have limitations. A high frequency 
of recording vital signs should be adopted with in every haematology ward’s daily prac-
tice where early detection of fever can be lifesaving. Surprisingly, no published data were 
available on non-invasive continuous body temperature measurement in oncology patients.
The goals of this audit were to assess feasibility and validity of continuous skin temperature 
measurement (CST). This audit found that CST is feasible in clinical haematology patients 
and is valid compared to the traditional measurements except when a patient is physically 
incapable of carrying the sensor where it can remain sufficiently isolated.
The extreme values observed (ΔT≥0.5) were likely explained by the malpositioning of either 
of the instruments. The relationships between the distribution of ΔT≥0.5 and factors of the 
human physical composition such as gender, BMI and age were explored but these did not 
explain the findings. Both the standard instructions with the Terumo (proper placement and 
drying the axilla previous to the measurement) and the continuous device (isolation from 
outside air is necessary for reliable values) are sensitive to erroneous measurement. Also, 
the positioning of the device could account for this when done by the patients themselves. 
Alternatively this may reflect a common problem, namely inconsistency in the use of ther-
mometry in daily practice.
Early detection of fever is a challenge during cycles of chemotherapy where the start of 
empirical antibiotic therapy can be life-saving during neutropenia. All guidelines empha-
sise the immediate start of empirical therapy at the onset of fever so it makes sense to 
increase the frequency of measurements to increase the chance that the onset of fever is 
detected promptly. This is not the case when the temperature is only measured every 4–6 
hours, but reliable continuous measurements allow the onset of fever to be caught in the 
act so to speak.
The fact that 78% of the patients actually had bacteraemia during the first episode of 
fever sufficiently justifies the start of broad-spectrum antibiotic treatment as soon as fever 
occurs. Hence, it could be argued that the lack of a rapid, reliable and continuous means 
of temperature monitoring may increase the risk for developing a systematic inflammatory 
response syndrome (SIRS), sepsis, shock and even death.
 Although the concept of fever is familiar to nurse, the precise definition we should adopt 
for optimal patient outcomes is far from clear as a variety of thresholds varying between 
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37.5 and 38.5 are employed, and the temperature is measured in several different ways. 
For instance, the 2002 IDSA guidelines recommends using a definition of fever as a single 
measured oral temperature of ≥38.3 or a temperature of ≥38.0 for ≥1 h 15, despite the influ-
ence of oral mucositis on oral thermometry 11. Clearly, there is still much to be done.
CONCLUSION
Continuous temperature measurement makes it possible to monitor patients intensively 
during round the clock without involving extra personnel. Continuous body temperature 
measurement is commonly used in the ICU but is alien to haematology wards. Earlier detec-
tion of the onset of fever and SIRS makes earlier initiation of empirical therapy possible 
which might lead to fewer days with fever, reduce antibiotic usage, the length of stay and 
mortality and allow better deployment of nursing staff.
FUTURE DIRECTIONS
Neither CST and EAT are considered to be the Gold standard for estimating the core tempera-
ture. Ideally, a valid means of continuously measuring temperature needs to be developed 
that is more reliably correlated to core temperature. However, it will be a challenge to find a 
method of reliably achieving this while being economic and userfriendly. In the meantime, 
further research should be done on a larger group of neutropenic patients exploring the 
consequences of earlier detection of fever on outcomes such as length of stay, costs and 
amount of antibiotics and survival.
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ABSTRACT
With fever being the most common manifestation of early sepsis, clinical practice guidelines 
emphasise the prompt institution of broad-spectrum antibacterial therapy at its onset. An 
audit was performed on the haematology ward to determine whether there was any delay 
in starting antibiotic treatment during neutropenia in clinical patients and to define the 
main reasons for this. Strategies were developed, implemented and evaluated on short- 
and long-term implications on the delay in the start of antibacterial therapy. The procedures 
specified in the protocol for starting empirical antibacterial therapy were audited to assess 
whether the target for starting therapy within 30 min of fever was achieved. Initial results 
indicated that two major changes to the protocol were necessary to achieve a reduction 
in the delay between detection of fever and starting antibacterial therapy. This modified 
protocol was evaluated four months after implementation by means of a consecutive audit. 
After three years, a third audit was performed to determine the long-term implications of 
the improved protocol. In the initial audit, the mean time interval between the onset of 
fever and the administration of antibacterial therapy was 75 minutes. With the modified 
protocol, the mean time to starting therapy was shortened to 32 minutes (p<0.05). Changing 
the protocol for starting antibacterial therapy allowed nurses to administer the first dose of 
antibiotic significantly earlier.
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INTRODUCTION
Patients who are clinically treated for haematological malignancies with high-dose chemo-
therapy or who are given myeloablative conditioning to prepare them for a haematopoietic 
stem cell transplant (HSCT) are expected to be profoundly neutropenic for at least ten days. 
Consequently, they are at high risk for developing sepsis that may require admission to the 
intensive care unit and is associated with a high mortality 1. Where sepsis is defined as a 
clinical response arising from confirmed infection, it will always be preceded by signs of 
a systemic inflammatory response syndrome (SIRS) because confirmation of infection by 
means of blood cultures needs time 2. Sepsis is hard to recognise in the beginning so treat-
ment often starts late. With fever being the most common manifestation of early sepsis, 
clinical practice guidelines emphasise the prompt institution of empirical broad-spectrum 
antibacterial therapy promptly at the onset of fever as this has been shown to be crucial to 
patient survival 3-5, because the progression of infection can be rapid, and cannot be reliably 
distinguished from fever due to other causes. The justification for prompt empirical therapy 
is motivated in the 2002 Infectious Diseases Society of America (IDSA) guideline 6. The nurse 
plays a vital role in detecting the early signs of SIRS predicting sepsis as she or he is respon-
sible for round-the-clock monitoring of the vital signs including body temperature, pulse, 
blood pressure and respiratory rate. The optimal frequency for measuring body temperature 
has been discussed earlier 7, but experience suggests there is room for improvement in 
minimising the delay between the onset of fever and the administration of the first dose 
of an antibacterial agent 8 as the success of empirical antibacterial therapy depends not 
only on the correct choice and dosage of the drug but also on its prompt administration 6. 
However, delays can and do occur in daily practice. For example, the attending physician 
may be occupied elsewhere, obtaining venous access may prove difficult and even the day 
of the week can matter 8-10. Apart from providing a better chance of survival, there may also 
be a measurable benefit from prompt antibacterial treatment by shortening the length of 
stay 11. Our ward set itself the goal of starting antibiotics within 30 minutes after detecting 
fever in order to secure adequate treatment well within the 60 minutes proposed by the 
international Surviving Sepsis Campaign 12.
The aims of the audit were:
 ȃ to collect information on the procedures on the ward leading up to starting empirical 
antibacterial treatment during neutropenia;
 ȃ to determine the reasons for any delay in these procedures;
 ȃ to develop and implement strategies for improvement;
 ȃ to evaluate the short- and long-term effects of these strategies on the quality of proce-
dures on the ward for starting empirical antibacterial treatment during neutropenia in 
a timely fashion.
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PATIENTS AND METHODS
PATIENTS
Three groups of adults, consecutively admitted to the haematology ward, participated in 
the audit and were considered to be immunocompromised because of their underlying 
disease or its treatment with chemotherapy. Informed consent was not required because 
the usual standard of care was provided at all times. Furthermore, the data were analysed 
anonymously, and did not breach patient privacy.
SUPPORTIVE CARE
All patients were housed in single- or double-bed rooms furnished with high-efficiency 
particulate air (HEPA) filtered air to create positive pressure. Ciprofloxacin alone or co-tri-
moxazole plus colistin were given as prophylaxis to prevent infections due to Gram-nega-
tive bacilli such as Escherichia coli. Stem cell transplant recipients were managed using a 
central venous catheter for parenteral nutrition, blood drawing and for administering fluids, 
medication and transfusion products. Allogeneic stem cell transplant recipients were given 
cyclosporine as prophylaxis against graft-versus-host disease. All patients were monitored 
daily for the presence of oral mucositis and received continuously intravenous morphine 
on demand to control severe mucositis-related pain. Erythrocyte transfusions were given 
when the haemoglobin level was less than 5.5 mmol/L and platelets were transfused when 
bleeding occurred and when platelet counts fell below 10 x 109/L.
PROCEDURES
The routine protocol required the patients’ axillary temperature to be measured four times 
daily (8:00 h, 13:00 h, 18:00 h and 22:00 h). An additional measurement was done at 3:00 
h for HSCT recipients during the period of highest risk from the day of transplantation (or 
two days before if idarubicin was given as part of the conditioning regimen), until ten days 
after transplantation. Fever was defined as a single axillary body temperature measurement 
of 38.5°C or more. When fever was registered, three steps were taken: (1) The physician on 
duty was contacted to conduct a thorough comprehensive physical examination. (2) Ten 
millilitres of blood was drawn for culture by venepuncture for an aerobic and an anaerobic 
blood culture bottle (BACTEC 9000; BD Diagnostics). A second set of blood cultures was 
drawn by venepuncture 15–30 min later. (3) Ceftazidime or meropenem were ordered by the 
physician and drawn from the stock kept on the ward so that the nurse could administer 
the first dose as soon as possible. These beta-lactam antibiotics have been the mainstay of 
our empirical antibacterial therapy since their introduction 12-18. These standard procedures 
were known to the staff and available online.
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AUDIT
The key component of clinical audit is that performance is reviewed to ensure that what 
should be done is being done, and, if not, it provides a framework to enable improvements 
to be made. To attain this, the following steps were carried out (figure 1).
REGISTRATION
The data collection sheet was designed by the researcher, and was piloted for one month. 
The following data were recorded by the nurse when the patient developed fever for the 
first time: (1) the time of detection of fever; (2) the time blood cultures were drawn; (3) the 
time the physical examination was done; and (4) the time the first dose of antibiotic was 
given. The time between the detection of fever and blood culture collection was calculated 
(2-1), as were the time between detection of fever and physical examination (3-1) and the 
time between detection of fever and administration of the first dose of medication (4-1). 
Patients’ demographic data were documented on the form and there was also room allowed 
for remarks. Data were collected in three groups of patients. Data from the first group were 
collected after the pilot period. Registration was done during two months on the assump-
tion that the results from 25 episodes of fever would be sufficient to evaluate the protocol.
The results were analysed to identify those factors that led to any delay and were subse-
quently used to develop strategies for improvement. The modified protocol was then imple-
mented and monitored for four months after which a registration was done on the second 
Figure 1 Flow chart of the audit’s ti meline
Pilot
Data collecti on sheet
March 2004
Data collecti on group 1
April – May 2004
Implementati on strategies
for improvement
Data collecti on group 2
November – December 2004
Data collecti on group 3
January – December 2008
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group exactly as had been conducted for the first group using the same data collection 
sheet.
Three years after implementation of the improved protocol, a similar exercise was carried 
out once again to determine long-term compliance. The time of detection of fever and the 
time of administration of the first dose of empirical antibacterial therapy were noted for all 
consecutive patients who had received chemotherapy in hospital in 2008. This formed the 
third group that was audited.
ANALYSIS
Descriptive statistics were calculated using SPSS version 15.0 (SPSS Benelux BV). Three 
registration periods were compared to determine the differences in the delay of starting 
empirical therapy. The Student t-test for independent samples was used to compare the 
three groups. The data were presented using Box plots.
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RESULTS
Patients’ demographics are shown in table 1.
GROUP 1
During registration, a total of 23 clinical patients experienced 43 episodes of fever. Twelve 
episodes were excluded from further analyses because of incomplete data. In total, 31 
episodes were analysed with 24 (77%) happened outside office hours between 17:00 h 
and 8:00 h the following morning. Seventeen different nurses took care of the patients and 
eight different physicians were involved. The mean time between the detection of fever and 
administration of the first dose of antibiotic was 75.1 min (±SD 46.1, range 30–210 min). The 
mean time between detection of fever and blood culture collection was 22.9 min (±SD 15.4, 
range 5–60 min), and the mean time between detection of fever and physical examination 
was 44.2 min (±SD 24.2, range 0–75 min). There was a striking difference between office 
hours and shifts: during shifts the mean time between the detection of fever and the 
physical examination was 48.5 min, whereas this was 27 min during the day.
STRATEGIES FOR IMPROVEMENT
The results of the baseline registration showed that waiting for the physician to conduct 
a physical examination was the main reason for a delay in starting antibacterial therapy, 
especially out of hours. To circumvent this, we instituted a standing order that allowed the 
nurse to administer the first dose of antibacterial therapy immediately after taking blood 
cultures and before calling the physician. This required the prescription to be already 
written. To further reduce the delay, the two sets of blood cultures were collected at the 
same time by a single venepuncture to allow 30–40 mL of blood to be cultured. This was 
to ensure that the sensitivity of blood cultures remained the same by requiring the same 
volume of blood as before.
GROUP 2
During registration, 25 patients experienced 39 episodes of fever. Eleven episodes were 
excluded from further analyses because of incomplete data. In total, 28 episodes are 
analysed and fourteen nurses and eight physicians were involved. The mean time between 
the detection of fever and administration of the first dose of antibiotics was 32.0 min 
(±SD  17.6  min, p<0.05, figure 2). The mean time between detection of fever and blood 
culture collection was 12.7 min (±SD 11.0 min, p>0.05), and the mean time between detec-
tion of fever and physical examination was 55.4 min (±SD 53.7 min, p>0.05).
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Characteristi cs Group 1 (n=23) Group 2 (n=25) Group 3 (n=119)
Gender, male (%) 14 (61) 15 (60) 76 (64)
Age, mean and range (years) 48, 21-77 50, 17-65 51, 17-73
Episodes of fever reported 43 39 156
Evaluable episodes of fever 31 28 128
Episodes of fever Group 1 (n=31) Group 2 (n=28) Group 3 (n=128)
Underlying disease, n (%)
 – Acute myeloid leukaemia 13 (42) 8 (29) 46 (36)
 – Multi ple myeloma 5 (16) 9 (32) 23 (18)
 – Non-Hodgkin lymphoma 5 (16) 6 (21) 20 (16)
 – Myelodysplasti c syndrome 5 (16) 1 (4) 5 (4)
 – Acute lymphoblasti c leukaemia 1 (3) - 8 (6)
 – Aplasti c anaemia 1 (3) 2 (7) 2 (2)
 – Chronic myeloid leukaemia - 2 (7) 4 (3)
 – Other 1 (3) - 20 (16)
Type of treatment, n (%)
 – Non-transplant regimen 15 (48) 9 (32) 33 (26)
 – SIB HSCT
 - Ida-Cyclo-TBI 2 (6) 4 (14) 13 (10)
 - Other 2 (6) 1 (4) 10 (8)
 – VUD HSCT
 - ATG-Cyclo-TBI 1 (3) 4 (14) 6 (5)
 - Other - 1 (4) 8 (6)
 – Autologous HSCT
 - High dose melphalan 5 (16) 8 (29) 16 (13)
 - BEAM - - 14 (11)
 - Other 1 (3) - 3 (2)
 – No therapy preceding fever 2 (6) 1 (4) 8 (6)
 – Unknown 3 (10) - 17 (13)
Table 1 Demographic data
SIB Sibling donor
Ida Idarubicine
Cyclo Cyclofosfamide
HSCT Hematopoieti c stem cell transplantati on
TBI Total body irradiati on
VUD Volunteer unrelated donor
ATG Anti  thymocyte globuline
BEAM Carmusti ne, etoposide, cytarabine and melphalan
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GROUP 3
In the period between 1 January and 31 December of 2008, episodes of fever of all 
consecutive patients are reported by the nurses of the ward. One hundred and nineteen 
different patients experienced 156 episodes of fever. In total, 128 episodes were analysed 
because 28 episodes had to be excluded because of missing data. The mean time between 
detection of fever and administration of the first dose of antibacterial therapy was 35.0 min 
(±SD 26.4 min, p<0.05, figure 2).
Figure 2 Eﬀ ect of anti bioti c prescripti on in advance and simpliﬁ ed culture regimen on delay in 
starti ng empirical anti bacterial therapy
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DISCUSSION
In this audit, we defined the level of promptness on our haematology ward and identified 
the main reason for the delay in starting empirical antibacterial therapy, especially out of 
hours, was the necessity of waiting until the duty physician arrived. Even during office hours 
when the duty physicians are on the ward, a mean 27 min were needed to examine the 
patient. Hence, physical examination that precedes the prescription of antibiotics causes 
a considerable delay although it has no influence on the choice and dosage of the anti- 
biotics given for empirical therapy. Bishara et al. reported a similar experience on an emer-
gency department during weekends 9 and other studies have also noted considerable delay 
in daily practice 8. Consequently, the first significant improvement we found was allowing 
prescription of the antibiotic in advance at the moment the conditioning regimen was 
started.
Patients receiving high-dosed chemotherapy to treat a haematological malignancy or 
myeloablative conditioning therapy for an HSCT become profoundly neutropenic and most 
develop fever in a predictable fashion. Moreover, episodes of bacteraemia associated with 
the first fever were due to coagulase-negative staphylococci and viridans streptococci, and 
such infections are usually less severe than those due to Gram-negative bacilli 14, 16. The 
second significant improvement was the time gained by simplifying the culturing regimen, 
by omitting the 15 to 30 min interval between two sets of cultures. This was justified by 
the need for prompt administration of antibacterial therapy when blood cultures should 
be obtained simultaneously 19. These improvements allowed antibiotics to be adminis-
tered within 30 min after fever was first detected. Thereafter, the protocol was modified 
accordingly and the third audit confirmed that the changes made shortened the time taken.
The prescription in advance had important implications for the role of the physician 
especially out of hours. One untoward effect of the standing order was that physicians 
allowed themselves even more time to come and assess the patient because it was no 
longer necessary before administration of antibiotics. This finding was unexpected and 
suggests that physicians rely so much on the protocol that they no longer consider the need 
for physical examination urgent since appropriate medication was already started by the 
nurses anyway. However, thorough physical examination directly at the onset of fever is 
still required in every new case of fever to determine whether an infectious focus is present 
such as pneumonia for which additional diagnostic tests or treatment are essential. Also, 
optimal supportive care needs to be guaranteed at all times.
The method of temperature measurement is controversial as is the definition of fever which 
is defined by the IDSA as a single oral temperature of ≥38.5°C or a temperature of ≥38.0°C 
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during ≥1 h 6 despite the influence of oral mucositis on oral thermometry 20. The IDSA itself, in 
cooperation with the American College of Critical Care medicine, indicate that the definition 
of fever is arbitrary and depends on the purpose for which it is defined 18. The vulnerable 
neutropenic patient, for whom timely detection of fever and adequate administration of 
antibacterial therapy is of vital importance, needs a more consistent and logical approach.
IMPLICATIONS FOR DAILY PRACTICE
Our earlier assumption that a first dose of empirical therapy was often delayed due to 
absence of a physician was confirmed. Nurses play a critical role in monitoring the whole 
procedure because they observe and interpret the patient’s temperature and initiate further 
action round the clock and neither task requires intervention by the physician. Hence, 
reducing any delay in starting antibacterial therapy is primarily down to the nurse on duty 
who plays a key role in instituting the correct measures required to prevent SIRS evolving 
into sepsis.
The speed with which procedures were carried out could also be markedly improved by 
implementing relatively simple interventions such as preparing a written prescription in 
advance and simplifying the culture regimen. This enabled nurses to achieve the stated 
goal of administering the first dose of antibiotic therapy within 30 min after the onset of 
fever.
FUTURE RECOMMENDATIONS
A protocol is needed that guarantees starting antibiotics empirically as soon as fever 
develops during neutropenia as this remains the cornerstone for preventing sepsis during 
neutropenia. Further research needs to be done to investigate the optimal frequency, 
site and method for monitoring the body temperature of these patients. The impact of 
the nurse’s awareness of the key role he or she plays in sepsis prevention should also be 
examined. Further study should also assess the extent to which the current results repre-
sent the whole group of neutropenic patients and the impact of reduced delay on outcome, 
length of hospital stay and cost-effectiveness.
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ABSTRACT
OBJECTIVE
The aim of the study was to explore the value of two instruments, SIRS and R-MEWS, in 
recognition of the changes in vital signs associated with systemic inflammation. We also 
investigated whether chemotherapy treatment was related to persistent fever, in patients 
treated for haematological malignancies.
METHODS
A retrospective study was conducted in patients experiencing febrile neutropenia following 
intensive chemotherapy for treating haematological malignancies or to prepare for a stem 
cell transplant. Fever during neutropenia was considered due to either microbiologically 
or clinically defined infection or unknown origin. The incidence of persistent fever and the 
risk factors associated with it were assessed. Clinical manifestations of inflammation were 
graded using the Radboudumc modified early warning score (R-MEWS) and the systemic 
inflammatory response syndrome (SIRS) criteria at two time points: the onset of fever (t1) 
and the fourth day of fever (t4).
RESULTS
Fever persisted in 25 of the 113 (22%) consecutive patients for four days or more. Persistent 
fever was related to the nature of the chemotherapeutic regimens used (p=0.01) but was 
independent of the presence of a microbiologically defined infection or clinically defined 
infection at the onset of fever (p=0.47). More SIRS criteria were met and a higher R-MEWS 
was found at t4 for patients with persistent fever compared to those without (both p<0.01).
CONCLUSION
R-MEWS looks promising as a tool for determining clinical deterioration due to treatment 
related systemic inflammation in patients being treated with intensive chemotherapy.
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INTRODUCTION
Neutropenic sepsis is still the most common complication of intensive chemotherapy used 
to treat patients for haematological malignancies or to prepare for a stem cell transplant. 
This complication typically occurs during the period of profound neutropenia approximately 
ten days following the start of chemotherapy 1-3.
Sepsis is defined as the presence (probable or documented) of infection together with 
systemic manifestations of infection 4 and is associated with increased mortality, prolonged 
hospital admission, possible admission to the intensive care unit and decreased quality of 
life 5, 6. Fever is likely to be the first sign of sepsis so current guidelines still recommend 
immediate antibacterial treatment, within an hour after the onset of fever, to prevent 
patients from developing sepsis and septic shock 4, 7.
Only 30-50% of the febrile episodes in patients treated with high dose chemotherapy meet 
consensus definitions of the Immunocompromised Host Society of either microbiologically 
or clinically defined infections 8. The majority of febrile episodes remain unexplained 9 but 
may be related to chemotherapy-induced mucositis 10 or non-infectious causes including 
drug side effects and transfusion reactions.
 Early recognition of infection and selection of those at risk for escalating from sepsis to 
severe sepsis and septic shock, followed by prompt and adequate action, has the potential 
to reduce mortality, morbidity, hospital length of stay and costs 11. The criteria for systemic 
inflammatory response syndrome (SIRS) assume that the progressive pathophysiological 
derangement as seen in severe sepsis can also occur in the absence of infection 12. SIRS 
allows the level of inflammation to be determined using four dichotomous clinical criteria 
for body dysfunction 13. An alternative approach is to employ an early warning score based 
on the vital signs heart rate, respiratory rate and systolic blood pressure as well as oxygen 
saturation, amount of inspired oxygen needed and level of consciousness 14. A modified 
early warning score has recently been adopted by the Radboud university medical center 
(R-MEWS) and is being used as a track-and-trigger system on the haematology ward 15 in 
order to recognize potential clinical deterioration.
The main aim of this study was to explore the value of two instruments, SIRS and R-MEWS, 
in recognition of the changes in vital signs associated with systemic inflammation, in 
patients treated for haematological malignancies. We also investigated whether chemo-
therapy treatment was related to persistent fever.
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METHODS
STUDY POPULATION
A retrospective cohort study was conducted on the 28-bed haematology ward of the Radboud 
university medical center. All consecutive patients admitted for intensive chemotherapy for 
the treatment of a haematological malignancy or to prepare for a haematopoietic stem cell 
transplant (HSCT) between April 2007 and May 2009 were eligible for the study. Patients 
were included at the first onset of fever (a single measured axillary temperature of ≥38.5°C) 
and defined as severely neutropenic as their neutrophil count was <0.5x109/L. Patients who 
developed fever as an immediate (the same day) response to medication or irradiation 
as happens frequently after total body irradiation (TBI) or medication like anti-thymocyte 
globulins (ATG) were excluded. The period of investigation ranged from two days before the 
onset of fever until six days after.
ETHICS STATEMENT
The Committee on Research Involving Human Subjects (Arnhem-Nijmegen region CMO) 
approved the study (study number 2014/164).
SUPPORTIVE CARE
All patients were accommodated in single or double bed rooms equipped with HEPA filtered 
air to create positive pressure. Gut decontamination is largely used in the prophylaxis of 
bacterial infections in departments treating neutropenic patients, in particular those 
patients subject to profound and prolonged neutropenia, such as patients undergoing 
haematopoietic stem cell transplant or induction chemotherapy for acute leukaemia. Cipro-
floxacin was given as prophylaxis to recipients of a haematopoietic stem cell transplant 
(HSCT) to prevent infections due to Gram-negative bacilli such as Escherichia coli whereas 
co-trimoxazole combined with colistin was given to patients undergoing treatment for 
leukaemia 16. HSCT recipients were managed using a central venous catheter for parenteral 
nutrition, drawing of blood samples and for administering fluids, medication and transfu-
sion products. Erythrocyte transfusions were given when the haemoglobin level was less 
than 5.5 mmol/L and platelets were transfused when bleeding occurred and when platelet 
counts fell below 10x109/L. No mould active prophylaxis was given. Growth factors are not 
being used. A preventive approach for reducing the length of the period of neutropenia 
by the use of growth-factors, which indeed shortens the period of vulnerability for bacte-
raemia, is contraindicated for the haematological population after highly dosed chemo- 
therapeutic regimens because growth-factors also stimulate cancer cells to multiply.
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INITIATION OF EMPIRICAL ANTIBACTERIAL THERAPY AT THE ONSET OF FEVER
The protocol required the patient’s axillary temperature to be routinely measured four times 
daily (8am, 1pm, 6pm and 10pm). An additional overnight measurement was done at 3am 
during the risk period for infectious complications i.e. between day 0 and 10 of HSCT or 
when nocturnal body temperature was between 37.5°C - 38.5°C. In case of fever, the physi-
cian on duty was called to conduct a thorough comprehensive physical examination. The 
nurse obtained blood for cultures by venepuncture and through the central venous catheter 
for aerobic and anaerobic cultures (BACTEC 9000, BD Diagnostics). Empirical therapy was 
then started with ceftazidime 2g IV or meropenem 1g IV when there had been a previous 
infection due to resistant Gram-negative bacilli. Each drug was given three times a day and 
was ordered in advance by the physician and drawn from the stock kept on the ward so 
that the nurse could administer the first dose as soon as possible 17. Blood cultures were 
repeated on the fourth day of treatment to evaluate efficacy and additional diagnostic tests 
were ordered if required.
DATA COLLECTION
Age, gender, underlying disease, type of treatment, relevant laboratory results and micro-
biological data were extracted from medical files. The aetiology of fever was assigned once 
the results of the microbiological investigations were known and episodes were classified 
as due to either a microbiologically defined infection (MDI) when cultures yield an organism 
or clinically defined infection (CDI) when there was a focal site of infection without micro-
biological confirmation. All other episodes were classified as unexplained fever 8. Bacte-
raemia was documented when one or more blood cultures yielded a microorganism, except 
in the cases of coagulase-negative staphylococci, for which two separate positive blood 
cultures obtained at the same time and yielding the same strain were required 18.
Vital signs registration included body temperature, heart rate, systolic blood pressure, 
respiratory rate and oxygen saturation and were recorded at the onset of fever (t1). SIRS 
criteria are dichotomous (yes or no) and allow a score of 0-4. R-MEWS rates five physio-
logical parameters on a scale from 0-3 and has a calculated range of 0-15. R-MEWS was 
calculated (after omitting of the value for consciousness and amount of inspired O2) and the 
number of SIRS criteria were determined (table 1). The time of fever onset and the time the 
initial dose of antibiotics was given were also recorded. On the morning of the fourth day 
(t4) an identical set of vital signs was registered and SIRS and R-MEWS were assessed in the 
same way. Fever that was still present at t4 was defined as persistent fever.
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STATISTICAL ANALYSIS
The underlying diagnoses were divided into two groups: acute leukaemia (AML, ALL and 
MDS) and other haematological malignancies (e.g. lymphoma, multiple myeloma, chronic 
leukaemia). Therapeutic procedures were categorized into three groups: autologous HSCT, 
myeloablative allogeneic HSCT and chemotherapy. Continuous variables were summa-
rized by mean values and standard deviations (SD) or by median values and interquartile 
range [IQR] if the data were not normally distributed. To test differences between groups we 
applied the independent t-test or Mann-Whitney-U test for continuous variables and Fisher’s 
exact test for categorical variables. Values for SIRS and R-MEWS were calculated both with 
and without including the value for body temperature. Spearman’s correlation was used to 
compare the number of SIRS criteria with the R-MEWS score. Two-tailed p-values <0.05 were 
considered to indicate statistical significance. Statistical analyses were performed by use 
of IBM SPSS Statistics version 20.
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RESULTS
STUDY POPULATION
Initially, 155 patients were screened of which 42 had to be excluded because of missing 
microbiological data at t1 (n=10) or missing values for body temperature at t4 (n=32), 
resulting in a cohort of 113 patients. Demographic data are depicted in table 2. The main 
reason for admission was autologous HSCT (n=50, 44%) followed by allogeneic HSCT 
(29%) and chemotherapy (27%). All patients were severely neutropenic (neutrophil count 
<0.5x109/L) at the onset of fever. Complete data to compare the number of SIRS criteria with 
the value of R-MEWS was available for only 50 patients. The only statistically significant 
difference between those with completed R-MEWS and those with incomplete R-MEWS was 
that completion rates for the R-MEWS scores was significantly higher for those patients with 
persistent fever (17/50=34%) than for those with incomplete scores (8/63=13%) (table 2).
ONSET OF FEVER AND EMPIRICAL ANTIBACTERIAL THERAPY
Fever developed 13 days (SD±7) after the start of chemotherapy. For HSCT recipients (n=83) 
this was four days (SD±4) following stem cell infusion. Antibacterial treatment was started 
in every case at the onset of fever according to the protocol. The time between fever and the 
first dose of antibiotics was median 25 minutes [IQR 20-30] and most patients were initially 
treated with ceftazidime (n=106, 94%), with the remainder receiving meropenem. The 
time fever was first recorded was distributed over the whole day though only 23% occurred 
within office hours (9-5 pm).
Sample
n=113
Completed
R-MEWS
n=50
Uncompleted
R-MEWS
n=63
p-value
Demographics
Age (years, mean and sd) 51 (±14) 53 (±13) 49 (±15) 0.24a
Male gender 68 (60%) 29 (58%) 39 (62%) 0.70b
Diagnosis 0.60b
 – Acute myeloid leukaemia 46 (41%) 18 (36%) 28 (44%)
 – Acute lymphobla ti c leukaemia 7 (6%) 3 (6%) 4 (6%)
 – Myelodysplasti c syndrome 5 (4%) 3 (6%) 2 (3%)
 – Multi ple myeloma 24 (21%) 14 (28%) 10 (16%)
 – Non-Hodgkin’s lymphoma 16 (14%) 6 (12%) 10 (16%)
 – Myeloﬁ brosis 4 (4%) 3 (6%) 1 (2%)
 – Hodgkin’s lymphoma 4 (4%) 1 (2%) 3 (5%)
 – Chronic myel id leukaemia 2 (2%) 1 (2%) 1 (2%)
 – Other 5 (4%) 1 (2%) 3 (6%)
Therapeuti c procedure 0.73b
 – Autologous HSCT – HDM 25 (22%) 15 (30%) 10 (16%)
 – Autologous HSCT – BEAM 16 (14%) 7 (14%) 9 (14%)
 – Autologous HSCT – other 9 (8%) 4 (8%) 5 (8%)
 – Allogeneic HSCT – Ida/cyclo/TBI 15 (13%) 5 (10%) 10 (16%)
 – Allogeneic HSCT – ATG/cyclo/TBI 12 (11%) 7 (14%) 5 (8%)
 – Allogeneic HSCT – other 6 (5%) 3 (6%) 3 (5%)
 – Non-HSCT chemotherapy 30 (27%) 9 (18%) 21 (33%)
Origin of fever
Infecti ous 79 (70%) 33 (66%) 46 (73%) 0.54b
 – Microbiologically deﬁ ned (MDI) 70 (62%) 30 (60%) 40 (64%) 0.85b
 – Clinically deﬁ ned (CDI) 37 (33%) 14 (28%) 23 (37%) 0.42b
Persistent fever on t4 25 (22%) 17 (34%) 8 (13%) 0.01b
 – Autologous HSCT 17/50 (34%)
 – Allogeneic HSCT 6/33 (18%)
 – Non-HSCT chemotherapy 2/30 (7%)
Table 2 Demographic data for the complete sample (n=113) and the subgroups with (n=50) 
 and without (n=63) completed Radboudumc Modiﬁ ed Early Warning Scores (R-MEWS)
HSCT Haematopoieti c stem cell transplant
a Independent T-test
b Fisher’s exact test
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Sample
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CAUSES OF FEBRILE NEUTROPENIA
Fever could be explained by an infectious event in 79 cases (70%).
— Microbiologically defined infection (MDI)
A microbiologically defined infection was found in 70 patients:
 ȃ Streptococcus mitis (n=27, 40%), of which three were in combination with other 
species; Pseudomonas aeruginosa (1x), Klebsiella oxytoca (1x), Enterococcus 
casseliflavus (1x).
 ȃ Coagulase-negative staphylococci (n=19, 28%), of which two in combination with 
other species (Enterococcus faecalis (1x), Rothia mucilaginosa (1x)).
 ȃ Combination of coagulase-negative staphylococci and Streptococcus mitis (n=11, 
16%), of which one was also in combination with another species (Enterococcus 
casseliflavus). One patient also developed probable invasive aspergillosis.
 ȃ The remaining eleven patients (16%) had bacteraemia due to; viridans streptococci 
(2x), Escherichia coli (2x), Enterococcus faecalis (3x), Group G streptococcus (1x), Pseu-
domonas aeruginosa (1x), Rothia mucilaginosa (1x) and Staphylococcus aureus (1x).
Another two patients had MDI that did not involve bacteraemia: one patient had Clostridium 
difficile enteritis and the other had oral herpes infection.
— Clinically defined infection (CDI)
Clinically defined infection solely was reported in nine patients: a pulmonary infiltrate in 
seven patients (of which one in combination with sinusitis), pneumonia and sigmoiditis 
(both n=1).
 In 28 (40%) of the 70 patients with a MDI, also a CDI was identified: pulmonary infiltrates 
(n=18), central line associated thrombosis (n=6) or a combination of both (n=2), CVC exit 
site infection (1x) and probable aspergillosis (1x).
— Unexplained fever
In total 34 febrile episodes (30%) could not be related to MDI or CDI and were defined as 
unexplained fever. Sixteen of these episodes may have been associated with oral mucositis 
and a further two with oesophagitis.
RISK FACTORS FOR PERSISTENT FEVER
On the fourth day of antibacterial therapy, fever persisted in 25 patients (22%). The type 
of chemotherapeutical regimen was significantly different between the groups with and 
without persistent fever (p=0.01, table 3). Persistent fever presented most frequently 
following autologous HSCT; 17/50 (34%). Following allogeneic HSCT and non-HSCT chemo-
therapy persistent fever was seen in 18% and 7% of the patients, respectively.
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Age, gender and underlying diagnosis were not related to persistent fever at t4. There was 
also no difference between those with or without persistent fever in terms of whether or not 
infection had been present at the onset of fever (p=0.47). Persistence of bacteraemia was 
equally distributed over the two groups with and without persisting fever (p=0.79).
Persistent fever
n=25
No persistent fever
n=88
p-value
Demographics
 – Age (years, mean and sd) 52 (±12) 51 (±14) 0.80a
 – Male gender 13 (52%) 55 (63%) 0.36b
Diagnosis 0.26b
 – AML, ALL, MDS 10 (40%) 48 (54%)
 – Other 15 (60%) 40 (46%)
Therapeuti c procedure 0.01b
 – Non-HSCT chemotherapy 2 (8%) 28 (31%)
 – Autologous HSCT 17 (68%) 33 (38%)
 – Allogeneic HSCT 6 (24%) 27 (31%)
Origin of fever 0.47b
Infecti ous (MDI and/or CDI) 16 (64%) 63 (72%)
Unexplained fever 9 (36%) 25 (28%)
Table 3 Inﬂ uencing factors for persistent fever on t4 (n=113)
AML Acute myeloid leukaemia
ALL Acute lymphoblasti c leukaemia
MDS Myelodysplasti c syndrome
HSCT Haematopoieti c stem cell transplant
MDI Microbiologically deﬁ ned infecti on
CDI Clinically deﬁ ned infecti on
a Independent T-test
b Fisher’s exact test
INTENSIVE SUPPORTIVE CARE DURING TREATMENT FOR HAEMATOLOGICAL MALIGNANCIES
▸  FROM DETECTION AND SELECTION TO ACTION
68
SIRS AND R-MEWS AND PERSISTENT FEVER (n=50)
A strong positive correlation was found between the number of SIRS criteria and the calcu-
lated value of R-MEWS at t1 (Spearman’s ρ=0.81, p<0.01) and t4 (Spearman’s ρ=0.75, 
p<0.01) indicating at least equal validity on the haematology ward. The number of SIRS 
criteria as well as the R-MEWS were similar at t1 for patients with and without persisting 
fever (p=0.77 and p=0.56 respectively) but were different at t4, even when body tempera-
ture was excluded. Significantly higher values were found for patients with persistent fever, 
indicating that clinical change occurred more often in those with persistent fever (table  4). 
Figure 1 shows the change in R-MEWS between t1 and t4 for each individual patient. Increase 
of R-MEWS occurs most frequently for those with persisting fever, decrease of R-MEWS was 
most seen in patients without fever at t4.
Persistent fever
n=17
No persistent fever
n=33
p-valuea
Cumulati ve R-MEWS on t1 3 [2-5.5] 3 [2-5] 0.56
Cumulati ve R-MEWS on t4 3 [2-5] 1 [0-2.5] <0.01
Cumulati ve R-MEWS on t4 excl. fever 2 [1-3.5] 1 [0-2] 0.02
SIRS on t1 3 [3-3.5] 3 [3-3.5] 0.77
SIRS on t4 3 [2-4] 1 [1-2] <0.01
SIRS on t4 excl. fever 2 [1-3] 1 [1-2] 0.01
Table 4 Diﬀ erences in clinical inﬂ ammatory scores between SIRS and R-MEWS for pati ents 
with and without persistent fever on t4 (n=50)
R-MEWS Radboudumc Modiﬁ ed Early Warning Score
SIRS Systemic inﬂ ammatory response syndrome
a Mann-Whitney-U test
Data are expressed as median with [IQR]
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Figure 1 Change in Radboudumc Modiﬁ ed Early Warning Score (R-MEWS) between onset of 
fever (t1) and four days later (t4), compared between febrile (left ) and afebrile (right) 
pati ents on day 4. The thickness of the lines represent the number of pati ents 
(range 1-4).
R-MEWS t1
Persistent fever (n=17) No persistent fever (n=33)
R-MEWS t1R-MEWS t4 R-MEWS t4
1 11 1
0
2 22 2
3 33 3
4 44 4
5 55 5
6 6
7
8
6 6
7 7
8
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DISCUSSION
We showed a strong correlation between the number of SIRS criteria and the calculated 
value of R-MEWS, suggesting that R-MEWS is a valid alternative in daily practice to detect 
vital changes early on in the clinical status of febrile patients. R-MEWS can easily be incorpo-
rated into protocols for monitoring patients as it makes use of measurements already taken 
by nurses. R-MEWS is also useful as a dynamic instrument to trigger intensive supportive 
care and optimal resuscitation, including intensive care admission when required 15, 19.
It is worthy of note that approximately a quarter of patients treated with intensive chemo-
therapy have persistent fever despite early appropriate broad-spectrum antibacterial treat-
ment at the onset of fever. In the current study this could not be explained by microbio-
logically or clinically defined infections nor by failing to institute antibacterial treatment 
in a timely manner. This phenomenon has been noted earlier and was assumed to be the 
natural course of fever even when the underlying infection was successfully treated with 
antibiotics 20. This suggests another explanation for fever namely inflammation directly 
caused by chemotherapy. The complex pathobiology that leads to inflammation response 
due to direct toxicity of conditioning regimen has been described by Blijlevens et al. 21. Van 
der Velden et al. also contended that mucotoxicity induced by a given conditioning regimen 
determines the pattern of inflammatory response, irrespective of the presence or absence 
of infection 22. The same study also reported the mucotoxicity of melphalan which was given 
to the autologous HSCT recipients in the current study who suffered from persistent fever 
(34%) 22.
We cannot conclude with certainty that the type of conditioning regimen determines 
persistent fever, not at least because of the retrospective character of the study and the 
size of the population studied. However, the initial group comprised more than 100 first 
episodes of fever all of which developed during neutropenia following chemotherapy. That 
persistent fever affected almost 1 in 4 episodes despite adequate and timely treatment with 
broad spectrum antibacterials is a well known phenomenon 9. Recent literature supports 
our contention that the type of conditioning therapy, and more specifically the muco- 
toxicity of the regimen, play a major role in inflammation which frequently manifests itself 
by persistent fever.
Our finding of higher R-MEWS at t4 and more patients with an increased R-MEWS at t4 
compared to t1 for patients with persistent fever does suggest that this is the group that 
is most likely to develop critical illness. It might be interesting to investigate the relation 
between R-MEWS and clinical outcomes like ICU admission and hospital mortality, which 
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was in the current study not possible to retrospectively analyse because data were gathered 
only for eight days around the initial fever.
Of interest is the recent publication of Hands et al. showing that compliance in recording 
vital signs was better for sicker patients suggesting that nursing staff do manage patients 
with higher early warning scores differently from those with lower values 11. This finding is 
supported in our population where R-MEWS on the fourth day of fever was completed signifi-
cantly more often for those with persistent fever (68 versus 38%). Indeed this suggests that 
fever provides an extra stimulus to nurses to intensify measuring the vital signs. It is also 
recommended that vital signs should be monitored carefully when patients without fever 
are receiving antipyretics and corticosteroids as these suppress body temperature.
In conclusion, R-MEWS looks promising as a tool for determining clinically relevant changes 
in patients being treated with intensive chemotherapy for haematological malignancies. 
Future prospective multi-centre research should focus on further validation of this instru-
ment in the context of neutropenic sepsis and its relation with adequate initiation of inten-
sive supportive care. We were also able to study a population of neutropenic patients and 
identify inflammation due to the preceding therapeutic procedure, and not infection per 
se, as a likely determinant of persistent inflammation. These findings may contribute to a 
better understanding and management of neutropenic patients who develop critical illness 
following intensive treatment.
RECOMMENDATIONS FOR DAILY PRACTICE
1. Persisting fever after four days of adequate antibacterial treatment in neutropenic 
patients following intensive chemotherapy is associated with higher R-MEWS. 
R-MEWS might be a better predictor of clinical deterioration than solely the SIRS 
criteria, allowing to trigger appropriate intensive supportive care to be instituted in a 
timely manner.
2. A modified early warning score such as R-MEWS is feasible to be used in the clinic to 
monitor vital signs so as to detect any clinical deterioration in patients, whatever the 
cause.
3. R-MEWS merits formal investigation in a prospective longitudinal study to evaluate its 
usefulness in daily practice and its clinical utility in improving patient outcomes.
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ABSTRACT
A cohort of 439 haematopoietic SCT recipients was analysed to determine the incidence of 
Gram-positive coccal bacteraemia and thromboembolic events associated with the use of 
central venous catheters (CVCs) and to determine risk factors for these complications. The 
incidences of persistent coagulase-negative staphylococcal (CoNS) bacteraemia, symp-
tomatic thrombosis and thrombophlebitis were 25%, 9.6% and 6.6%, respectively. Dura-
tion of neutropenia (in days, odds ratio (OR) 1.02; p=0.04) and leftsided placement of the 
CVCs (OR 1.73; p=0.03) were independent risk factors for the occurrence of persistent CoNS 
bacteraemia, whereas the use of less mucotoxic conditioning regimens was associated with 
a lower risk (high-dose melphalan (HDM)/BEAM vs. other regimens, OR 0.24; p<0.001). Use 
of TBI, persistent CoNS bacteraemia and tip colonisation were all significantly associated 
with an increased risk of symptomatic thrombosis (OR 6.03, 3.36 and 2.80, respectively; 
p≤0.02). The risk factors found in this cohort of SCT recipients differed from those found in 
the general cancer population, showing an important role for persisting bacteraemia in the 
pathogenesis of CVC-associated thrombosis. Therefore, we constructed a new algorithm in 
order to improve catheter management and prevent these CVC-related complications.
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INTRODUCTION
Central venous catheters (CVCs) are widely used for managing patients receiving inten-
sive chemotherapy to prepare them for an autologous or allo-SCT 1. The use of CVCs is not 
without complications, with some being related to the insertion procedure (for example, 
pneumothorax) and others (for example, infection and thrombosis) occurring later. The CVC 
infection mostly involves coagulase-negative staphylococci (CoNS) that originate from the 
resident commensal flora of skin and gut, and can occur through either an exogenous route 
(for instance, migration from the skin along the catheter tract or via catheter hub) or an 
endogenous route as a result of haematogenous seeding from a distant infection site or 
disrupted mucosal barriers of the oral cavity and gastrointestinal tract 2, 3. The pathogenesis 
of CVC-related thrombosis is complex and is thought to result from activation of coagulation 
pathways by the foreign material in the bloodstream with formation of a thrombin sheath 
covering the CVC, the occurrence of vascular endothelial damage and endothelial cell acti-
vation by disturbed haemodynamics 4. Infection can also stimulate thrombus formation by 
aggravating coagulation, but the presence of a thrombus mass or thrombin sheath around 
the CVC also increases the risk for microbial colonisation and bacteraemia 5. The CVC-re-
lated thrombosis can result in serious complications, including pulmonary embolism and, 
when infected, it increases the risk of endocarditis and septic embolisms considerably 6, 7.
 We employ a conservative approach towards the treatment of a single episode of bacte-
raemia due to CoNS and neither routinely employ antibiotics nor remove the CVC. This 
emanates from our observation that early-onset CoNS bacteraemia results from endoge-
nous spread of the staphylococci from mucosal barrier injury to the oral cavity or gut and 
does not involve a primary infection of the device 8, 9. However, persistent CoNS bacte-
raemia increases the probability of an infection of the CVC and predisposes to device-re-
lated thrombosis of the subclavian vein. However, we wished to determine whether or not 
this hypothesis was justified and hence undertook a retrospective analysis to investigate 
the risk factors for persistent CoNS bacteraemia and thrombosis, define their relationship 
to each other and generate a CVC management algorithm based on our findings.
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MATERIALS AND METHODS
STUDY POPULATION
We reviewed the records of all consecutive patients who had received a SCT from January 
2006 to December 2011 at our tertiary care centre. We selected three groups of SCT 
recipients: group 1: those who had been given a conditioning regimen consisting of high-
dose melphalan (HDM) or BEAM for an autologous SCT; group 2: those who had been 
given a myeloablative conditioning regimen consisting of CY together with either TBI or BU 
with or without idarubicin for an allo-SCT; and group 3: those who had been given a non- 
myeloablative conditioning regimen consisting mainly of CY together with fludarabine for 
an allo-SCT  10. Patients who had received a graft from an unrelated donor had also received 
antithymocyte globulin.
SUPPORTIVE CARE
Patients did not receive haematopoietic growth factors or prophylactic anticoagulants. 
Antimicrobial prophylaxis consisted of 500mg ciprofloxacin and 500mg valaciclovir, both 
given twice daily. In case of fever during neutropenia, empirical therapy was started with 
2000mg ceftazidime given three times daily intravenously. A single episode of CoNS bacte-
raemia was not a ground for modifying empirical therapy by adding a glycopeptide to the 
antimicrobial regimen.
CVC PROCEDURE, MANAGEMENT AND COMPLICATIONS
All patients had been managed using a nontunnelled, three or four lumen, uncuffed, 8.5 
French, polyurethane catheter that was not coated with any antibiotics (Arrow International 
Inc., USA). CVCs had been inserted by trained personnel, namely, haematologists, physi-
cian assistants and nurse specialists. Catheter passports had also been filled out by a 
nurse during insertion to collect data regarding the CVC procedure. After CVC placement, 
the proper positioning and absence of pneumothorax had been confirmed by a chest X-ray. 
Maximal sterile barrier precautions were used during all insertions following Centers for 
Disease Control and Prevention (CDC) guidelines 11. Local CVC management was achieved 
by using chlorhexidine 0.5%/alcohol 75% for disinfection 11, 12. Antibiotic locks were not 
used at any time and glycopeptides were only given when clinically indicated.
 Blood (10 mL) had been routinely drawn for aerobic culture each Monday and Thursday 
from each lumen of the CVC. At the onset of fever, 40mL of peripheral blood had been 
obtained for culture together with 10mL from each lumen of the catheter. A blood culture 
was considered positive if one or more bottles yielded a microorganism, except for CoNS, 
for which two separate positive blood cultures, drawn at the same time, yielding the same 
strain were required 13. Persistent bacteraemia was defined as two or more consecutive 
episodes of bacteraemia, at least 24 h apart, involving the same bacterial species.
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 In case of CVC symptoms and signs of thrombosis, an ultrasonography of the upper 
extremity was performed. In case of a negative ultrasonography and high clinical suspi-
cion of thrombosis, a venography was ordered. Symptomatic thrombosis was defined as a 
thrombus seen on imaging accompanied by signs and symptoms of upper extremity throm-
bosis. Septic thrombophlebitis was defined as symptomatic thrombosis accompanied by 
persistent CoNS 14.
STATISTICAL ANALYSIS
We employed descriptive statistics for patient, SCT procedure and CVC characteristics. Only 
data on the first CVC episode during SCT were included in the analysis. Data were expressed 
as frequencies, mean values with SD or median values with the range. Differences in median 
duration of neutropenia and CVC duration were evaluated using Mann-Whitney U-tests. 
Incidences of CoNS bacteraemia, persistent bacteraemia, symptomatic thrombosis and 
thrombophlebitis were calculated as the proportion of patients experiencing these compli-
cations as well as the rate per 1000 CVC-days.
The first episode of bacteraemia due to Gram-positive bacteria that occurred while the 
CVC was in place was recorded for each patient. Potential risk factors for the occurrence of 
persistent CoNS bacteraemia and thrombosis were evaluated by means of logistic regres-
sion. Potential risk factors were univariately tested with the Wald χ2 test. Those with a 
P-value of <0.20 were included in the multivariate analysis. The final multivariate model 
was selected through a backward selection procedure with P<0.05. Confounders that were 
considered clinically relevant were included in the selection procedure. Crude and adjusted 
odds ratios (ORs) with 95% confidence interval were presented. In addition, in each model, 
the ability to discriminate between patients with and without the complication at issue 
was quantified by the C-index. The association between two dichotomous variables was 
evaluated with the χ2 test. All statistical analyses were carried out in SAS 9.2 (Cary, NC, 
USA).
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RESULTS
PATIENT CHARACTERISTICS
We initially reviewed 506 consecutive SCT recipients. A total of 67 patients were excluded 
from the analysis because of incomplete follow-up due to transfer to another hospital (n=36), 
death within the first week of SCT (n=7), multiple SCTs (n=20) and lack of surveillance blood 
cultures (n=4). The final cohort therefore consisted of 439 patients, of whom 245 (56%) 
had received an auto-SCT and the remaining 194 (44%) an allo-SCT. The characteristics of 
these patients and the SCT and CVC procedures are depicted in table 1. The CVCs of the 439 
patients contributed to a total of 8273 catheter-days. Three-quarters of the CVCs had been 
placed on the right with almost all being positioned in the subclavian vein (95.9%). The 
median duration that CVCs were in place was 18 days (range 6–51). The median time to CVC 
removal was 17, 21 and 16 days for conditioning groups 1, 2 and 3, respectively.
Characteristi cs (n=439a) Median (range)/n (%)
Age at SCT (years) 53 (16-66)
Male gender 265 (60%)
Diagnosis
 – AML/ALL/MDS 148 (34%)
 – NHL 117 (27%)
 – MM 137 (31%)
 – CML/CLL 18 (4%)
 – Other 19 (4%)
Table 1 Pati ent, SCT procedure and central venous catheter characteristi cs
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Conditi oning regimen
 – HDM (group 1) 140 (32%)
 – BEAM (group 1) 73 (17%)
 – CY+ATG+TBI/BU (group 2) 75 (17%)
 – CY+FLu+ATG (group 3) 40 (9%)
 – CY+TBI/BU (group 2) 15 (3%)
 – Ida+CY+TBI/BU (group 2) 87 (20%)
 – Other 9 (2%)
TBI 147 (33%)
Neutropenia durati on (days) 13 (5-89)
 – HDM/BEAM (group 1) 10 (5-31)
 – Allogeneic myeloablati ve (group 2) 15 (5-89)
 – Allogeneic nonmyeloablati ve (group 3) 18 (6-64)
Type of SCT
 – Autologous 245 (56%)
 – Allogeneic, (M)MUD 103 (23%)
 – Allogeneic, MRD 91 (21%)
Stem cell source (n=433)
 – Peripheral blood 382 (88%)
 – BM 51 (12%)
Hospitalisati on durati on (days) 26 (13-218)
Durati on CVC in situ (days) 18 (6-51)
Side of CVC placement (n=436)
 – Right side 328 (75%)
 – Left  side 108 (25%)
(cont. table 1)
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GRAM-POSITIVE BACTERAEMIA
— Incidence of Gram-positive bacteraemia
CoNS bacteraemia was diagnosed in 186 (42.4%) patients during the period the CVC was 
in place, and persisted in 110 (25.1%) cases. Hence, 76 (40.9%) cases of CoNS bacteraemia 
resolved without additional antibiotic therapy. Bacteraemia due to oral viridans strepto-
cocci (OVS) occurred in 146 (33.3%) cases, and persisted in only six cases. There were 
only 17 (3.8%) cases of enterococcal bacteraemia. This corresponds to 22.5 CoNS, 13.3 
persistent CoNS, 17.6 OVS and 2.0 enterococcal bacteraemias per 1000 catheter-days, with 
a median time to occurrence of bacteraemia of respectively 11.0, 11.0, 13.0 and 16 days after 
CVC insertion (figure 1). The peak incidence of CoNS and OVS bacteraemia occurred almost 
simultaneously, on days 10–14 and 11–14, respectively (figure 1). Of the 186 patients who 
did experience a CoNS bacteraemia, 33.9% (63) also experienced a bacteraemia with OVS, 
and in more than two thirds of them both microbes were cultured at the same day. Culture 
of the CVC tip after removal yielded positive results for CoNS in 33.3% (146/439) of cases. 
CVC vessel (n=436)
 – Subclavian vein 418 (96%)
 – Jugular vein 18 (4%)
Inserti on att empts (n=274)
 – 1 166 (61%)
 – >1 108 (39%)
Inserti on ti me (n=265)
 – ≤2 174 (66%)
 – 2-5 91 (34%)
(cont. table 1)
ATG Anti thymocyte globulin
CVC Central venous catheter
HDM High-dose melphalan
Ida Idarubicine
MDS Myelodysplasti c syndrome
MM Multi ple myeloma
MRD Matched related donor
(M)MUD (Mis)matched unrelated donor
NHL Non-hodgkin lymphoma 
a Characteristi cs involve all 439 pati ents except when stated otherwise
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Persistent CoNS bacteraemia was associated with a positive tip culture after CVC removal 
(χ2=82.18; p<0.0001).
— Risk factors for persisting CoNS bacteraemia
In univariate analysis, the risk factors that were associated with persisting CoNS bacte-
raemia (p<0.20) included age at transplantation, conditioning regimen, use of TBI, dura-
tion of neutropenia, stem cell source, side of catheter insertion and the vessel into which 
the device was inserted (table 2). In the multivariate analysis model, only conditioning 
regimens in groups 2 and 3 (OR=4.17), the leftsided placement of CVC insertion (OR=1.73) 
and a longer duration of neutropenia were significantly associated with an elevated risk of 
persistent CoNS bacteraemia (table 2). However, the type of conditioning was the strongest 
explanatory factor for persistent CoNS bacteraemia (group 1 (30/215, 14.0%) vs. groups 2 
and 3 (80/224, 35.7%), p<0.001). The C-index of the multivariate model was 0.761, indi-
cating good discriminatory performance of the incorporated factors for the occurrence of 
persistent CoNS bacteraemia.
Figure 1 First positi ve blood cultures in ti me from placement of CVC and start of conditi oning 
therapy. The upper panel indicates the proporti on (positi ve blood culture/total number 
of blood cultures on that day) of the ﬁ rst positi ve blood cultures yielding CoNS (lighter 
bars) and OVS (darker bars). The lower panel indicates absolute number of the ﬁ rst 
positi ve blood cultures depicted for each days, with peak incidence values in bold (≥15 
blood cultures positi ve). The peak incidence of CoNS and OVS bacteraemia occurred 
almost simultaneously, on days 10-14 and 11-14, respecti vely.
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THROMBOTIC COMPLICATIONS
— Incidence of symptomatic thrombosis and septic thrombophlebitis.
Diagnostics had been performed in 48 (10.9%) of cases because of signs or symptoms 
indicative of an upper extremity thrombosis, and thrombosis was radiologically confirmed 
in 42 cases, giving a rate of 9.6% or 5.0 cases per 1000 catheter-days. Diagnosis had been 
established by ultrasonography alone in 19 cases, and a further 17 cases were diagnosed 
only after subsequent venography. The remaining six cases were diagnosed by either a 
venography or CT scan alone. The diagnosis of thrombosis was made in a median of 21 
days (range 7–33) from CVC insertion. Septic thrombophlebitis occurred in 29 (6.6%) 
cases, which is 69.0% (29/42) of those with symptomatic thrombosis. Persistent CoNS 
bacteraemia had preceded the diagnosis of thrombosis in every case. Severe complica-
tions developed in 2 of these 42 cases: one case of symptomatic pulmonary embolism 
and one case of a superior vena cava syndrome. In two other patients, thrombophlebitis 
was confirmed by positron emission tomography/computed tomography in which septic 
pulmonary emboli were detected (figure 2) 15. No deaths were attributed to the CVC-related 
complications.
 As expected, the occurrence of persistent CoNS bacteraemia and/or thrombosis resulted 
in early removal of the CVC, and hence an overall shorter median time of the CVC remaining 
in situ (16 vs. 19 days, p<0.0001).
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— Risk factors for symptomatic thrombosis
In univariate analysis gender, conditioning type, use of TBI, duration of neutropenia, stem 
cell source, CVC side, occurrence of persistent bacteraemia and CVC tip culture were all 
associated (p<0.20) with the occurrence of symptomatic thrombosis (table 2). In multivar-
iate analysis, only the use of TBI, occurrence of persistent CoNS bacteraemia and a posi-
tive CVC tip culture were significantly associated with increased risk. The C-index of the 
multivariate model was 0.868, indicating that discriminative ability for the occurrence of 
symptomatic thrombosis by these factors was high.
 The occurrence of the persisting bacteraemia and symptomatic thrombosis were signifi-
cantly correlated (χ2, p<0.0001). Patients who experienced a persistent CoNS bacteraemia 
developed a symptomatic thrombosis in 29 (26.4%) of 110 cases, opposed to only 13 (4.0%) 
of the 329 patients who did not (OR 8.70, 95% confidence interval 4.33–17.49, p<0.01). 
Hence, the negative predictive value of persistent CoNS bacteraemia for the occurrence of 
symptomatic thrombosis was high (that is, 96%), whereas the positive predictive value was 
low (that is, 26.5%).
Figure 2 Septi c thrombosis. Positron emission tomography (PET) scan of a pati ent with persisti ng 
fever and CoNS bacteraemia during neutropenia revealing a thrombophlebiti s of the 
left  brachiocephalic vein. This was missed on the initi al ultrasonography that had been 
performed at approximately the same ti me as the PET scan, and only days later a 
second ultrasonography became positi ve (Courtesy of Dr Vos ¹⁵).
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DISCUSSION
We identified several risk factors for persistent CoNS bacteraemia and thrombosis. 
Persistent CoNS bacteraemia was significantly related to the duration of neutropenia, the 
conditioning regimen and a left-sided placement of the CVC. Persistence of bacteraemia 
requires a source of infection and inadequate eradication of the microorganism. This 
probably explains neutropenia being a risk factor, although residing macrophages and 
dendritic cells might sometimes be sufficient to eradicate these indolent opportunistic 
pathogens. This might also explain the fact that 40% of bacteraemias resolved without the 
use of additional antibiotic therapy. The CVC device itself is usually presumed to be the 
source of bacteraemia, whereas the mucosal barrier may well be the origin, as the condi-
tioning regimen proved to be an independent and the strongest risk factor associated with 
persistent bacteraemia. The more myelotoxic regimens are also the most mucotoxic and 
these resulted in a fourfold increased risk. This suggests that, apart from neutropenia, 
persistent bacteraemia might well have been directly related to the mucotoxic effects of 
the conditioning regimen. Moreover, the staphylococci involved may well have originated 
from the gut as these are usually resistant to the quinolones used for prophylaxis and may 
overgrow on the gut surfaces left vacant by the microbiota that have been suppressed by 
the antibiotic. This suggestion is supported by the fact that most of the CoNS bacteraemias 
occurred 10–14 days after CVC insertion as did the occurrence of OVS bacteraemia, which 
is known to originate from oral and intestinal mucosal barriers at the peak of intestinal 
damage 10. In addition, Costa et al. 8 have shown that most CoNS that were cultured from 
the blood of SCT recipients were more similar to those recovered from the mucosal surfaces 
than those from the skin. Although the mucosal barriers might well be the initial source of 
infection, the question remains of whether persistent bacteraemia results from continuing 
haematogenous seeding from the mucosa, a secondary infection of the CVC or, indeed, an 
ongoing primary CVC infection. Importantly, CVC insertion and care measures were imple-
mented according to best practice, and hence colonisation and infection of the CVC via the 
insertion site by the skin flora was less likely 11.
The reason a left-sided placement increased the risk might be related to differences in 
anatomy and disturbed blood flow 1. However, it might also be simply a consequence of our 
preference for a right-sided placement of the CVC over a left-sided placement, as the latter 
is only chosen when problems arose during the procedure or had occurred in the past (for 
example, earlier thrombosis). Using standardised CVC procedures in intensive care units 
has shown that the CVC site of insertion is unimportant, but the setting is not comparable 
to the haematology wards as few patients in the intensive care units suffer from mucositis 
and neutropenia induced by cytotoxic therapy 16.
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 The incidence of catheter-associated thrombosis was relatively high (9.5%), and is in the 
same range as found in prospective studies and retrospective studies of SCT recipients 17-20. 
However, lower incidences have also been reported, although the use of prophylactic anti-
coagulants for CVC thrombosis might have influenced these results 21-23. We found the use 
of TBI, occurrence of persistent CoNS bacteraemia and a positive catheter-tip culture -an 
indication of catheter colonisation- as the strongest risk factors for CVC-associated throm-
bosis. The use of TBI has seldom been noted as a risk factor for venous thrombosis, but has 
a pathophysiological basis as TBI is known to induce damage to the vascular endothelium, 
which is a known risk factor for thrombosis 24, 25. CVC-related infection is a known risk factor 
for CVC associated thrombosis, but it has not been consistently reported in cohort analyses 
among patients with cancer, although it seems to play an important role in haematology 
patients and especially in those receiving a SCT 1. The use of more myelotoxic and muco-
toxic regimens to prepare for an SCT exposes patients to more tissue damage, including 
mucosal and endothelial damage, a higher incidence of bacteraemia, and thus a higher risk 
for thrombosis. Perturbation of endothelial integrity and function resulting from infection 
and the presence of intravascular foreign material and the procoagulant effect of infection 
contribute to enhanced coagulation and thrombus formation culminating in thrombophle-
bitis. As the definition of CVC-related infection is neither consistent nor easy to employ in 
clinical practice, thrombotic risk in SCT patients could be better established by monitoring 
for persistent positive blood cultures. This also obviates contentious discussions on the 
primary infection sources that are impossible to settle and only tend to confuse rather than 
clarify decision making.
We did not explore some risk factors for CVC-related thrombosis reported in a large 
meta-analysis, namely, catheter type, insertion site and catheter-tip position, as the CVCs 
we employed were of the same type, centrally inserted, and the tip position confirmed by 
imaging to ensure proper positioning 26. Nor did we find support for left-sided insertion site 
and hereditary thrombophilia being risk factors for CVC-associated thrombosis as reported 
by Tesselaar et al 19. Hereditary thrombophilia has not been assessed routinely in our 
patients, and the impact of the CVC insertion site was probably overshadowed in the multi-
variate analysis by the presence of persistent CoNS bacteraemia as these two variables 
were highly associated with one another.
In case of suspected deep venous thrombosis or persistent CoNS bacteraemia, the 
presence of thrombosis should be investigated by ultrasonography, although this diag-
nostic approach was not very effective in our cohort as we saw a false-negative rate of 47.2% 
27. Venography seemed more appropriate for establishing the diagnosis and may be more 
useful in haematology patients, although this approach has the disadvantage of detecting 
clinically irrelevant nonobstructive venous thrombi. In case of suspected thrombophlebitis, 
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positron emission tomography/computed tomography is a more attractive approach as it 
offers the possibility of detecting septic embolisms, although this requires more research 15. 
Nevertheless, others have used ultrasonography successfully for the early detection of 
thrombophlebitis in selected groups of patients with CVC-related bacteraemia, thereby 
reducing complications and mortality 6.
As a retrospective analysis, this study has a number of limitations. First, there were missing 
data in some patients, mainly considering the CVC placement procedure, including number 
of insertion attempts and insertion time, and hence risk factors might have been missed. 
Second, the diagnosis of thrombosis depended upon clinical suspicion, as there was no 
active radiographic surveillance. Therefore, the incidence of thrombosis recorded during 
our study might actually be an underestimate. Nevertheless, these results reflect usual 
practice and the clinical significance of asymptomatic catheter-related thrombi remains 
unknown. The study is, however, very different in one respect, namely, by obtaining blood 
for culture twice a week from catheter insertion onwards we were able to detect CoNS bacte-
raemia before there were any signs of fever or infection and ten days before thrombosis was 
diagnosed.
The incidence of bacteraemia and symptomatic thrombosis we found was similar to that 
reported in studies on CVC complications of SCT recipients, even though we restricted 
antibiotic use and used no anticoagulants as prophylaxis 28, 29. Moreover, we experienced 
no mortality related to the occurrence of thrombosis and thrombophlebitis. Nevertheless, 
thrombosis incidence was relatively high and morbidity related to CVC complications was 
still substantial, and hence there is clearly room for improvement. As persistent CoNS 
bacteraemia was a strong predictor for thrombosis, the early detection of persistent bacte-
raemia would likely point to an increased risk for thrombosis sufficiently early to institute 
appropriate interventions. Consequently, we have modified our clinical CVC care protocol 
to manage these complications (figure 3). The same restrictions towards the use of glyco-
peptides is maintained that seems appropriate if costs, toxicity and antibiotic resistance 
are to be minimised. The starting point is the strong association between persistent CoNS 
bacteraemia and subsequent complications. Hence, establishing persistent bacteraemia 
is crucial requiring further blood culture within two to three days of detecting. In case of 
persistent CoNS bacteraemia, the CVC should be removed unless there are cogent reasons 
to retain it. Should this be the case, then thrombosis should be excluded by venography, 
appropriate antibiotics should be started and a strict follow-up plan executed in order to 
monitor for CVC complications.
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Algorithm for the management of CVC-related complicati ons. This algorithm depicts 
our approach to managing CVCs used to manage SCT. Immediately aft er inserti on, 
blood was obtained from culture every Monday and Thursday. When persistent 
bacteraemia due to CoNS is established, the questi on is asked of whether the catheter 
is sti ll needed or not. If not, the catheter is removed. However, if the catheter is 
to be retained, the pati ents is examined for signs or symptoms of thrombosis and, 
if detected, treatment with teicoplanin is started, provided the CoNS isolate is 
suscepti ble. Otherwise the catheter is removed, blood cultures are obtained and 
appropriate anti bioti c treatment is given unti l the infecti on is eradicated.
Figure 3
Monitoring for bacteraemia
on Mondays and Thursdays
Inserti on
Planned removal
CVC sti ll needed?
Conti nue monitoring
Remove CVC
Remove CVC
Remove CVC
No thrombosis?
(neither signs nor symptoms)
CoNS suscepti ble to teicoplanin?
Start teicoplanin
Persistent CoNS bacteraemia?
(= two consecuti ve episodes of 
bacteraemia with the same species)
YES
YES
YES
YES
NO
NO
NO
NO
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ABSTRACT
BACKGROUND
Because of the assumed dismal prognosis there is still reluctance to admit haematological 
patients to the intensive care unit (ICU). This study was conducted to determine trends in 
outcome of allogeneic haematopoietic stem cell transplant (HSCT) recipients transferred to 
the intensive care unit in a Dutch tertiary care hospital.
METHODS
All patients who received allogeneic HSCT between 2004-2010 were included in the 
analyses. Baseline and outcome characteristics were compared and risk factors for ICU 
admission and survival were identified. Changes in outcome over time of three cohorts of 
HSCT recipients were investigated.
RESULTS
Of 319 consecutive HSCT recipients, 49 (15%) were transferred to the ICU for a median (IQR) 
of ten (6-45) days following their transplantation, of whom 43% were severely neutropenic 
and 90% had received systemic immunosuppressive therapy for graft-versus-host disease 
prophylaxis. Univariate logistic regression showed that transplantation from an unrelated 
donor and myeloablative conditioning were significant risk factors for ICU admission. 
Prolonged use of vasopressors, invasive mechanical ventilation and male gender were 
significant predictors for ICU mortality, while neutropenia and graft-versus-host disease 
were not. Over the years, APACHE II severity of illness scores remained unchanged (21.0±7.1, 
20.1±5.6, 21.2±6.6), while 100-day post-transplant mortality of patients who had been 
transferred to the ICU decreased significantly from 78% (2004/2005) to 57% (2006/2007), 
and 35% (2008/2009).
CONCLUSIONS
While for allogeneic HSCT patients the severity of illness on admission to the ICU did not 
change, the 100-day post-transplant survival improved. These data indicate that reluctance 
to submit haematological patients to the ICU is not warranted.
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INTRODUCTION
Patients with haematological malignancies are currently treated with intensive cytotoxic 
therapies often culminating in an allogeneic haematopoietic stem cell transplant (HSCT). 
A clear reduction in transplant-related mortality (TRM) was observed between 1967-2002, 
mainly due to prompt administration of antibiotics at the onset of fever, better prevention 
of infectious complications and improved clinical care 1-3. Life-threatening complications 
now occur more frequently as a result of therapy rather than the haematological disease 
itself 4, 5. These complications occur acutely, typically during the period of neutropenia 
when patients are profoundly immunocompromised 6, or during neutropenia recovery 7. It 
is inevitable that some patients will develop medical problems requiring transfer to the 
intensive care unit (ICU), either for close monitoring or for intensive treatment. In the past, 
neutropenic patients who developed organ failure were considered to have such a dismal 
prognosis that physicians were reluctant to even consider admitting them to an ICU 8. Since 
2002, improved outcomes for these patients have been reported, and the importance of 
neutropenia as a predictor for ICU mortality was debated 9.
Respiratory insufficiency associated with sepsis is the most common indication for admis-
sion from the haematology ward to the ICU 5. Approximately one in four HSCT recipients 
require endotracheal intubation and mechanical ventilation for acute respiratory failure 10. 
Severe sepsis and septic shock are the most frequently observed reason for ICU admission 9.
The outcome of those patients who need critical care appears to have improved 11, although 
in the subgroup of HSCT recipients receiving mechanical ventilation the reported mortality 
rate still exceeds 80% 12 and acute graft-versus-host disease (aGvHD) is reported to be an 
independent predictor for death, specifically in combination with mechanical ventilation 10. 
Early initiation of non-invasive ventilation is associated with significant reductions in the 
rates of endotracheal intubation and serious complications and an improved likelihood of 
survival until hospital discharge 13. These results led to improved awareness of the benefits 
of early admission to an ICU, resulting in more allogeneic stem cell transplant recipients 
being transferred to the ICU. Nevertheless, also in the Netherlands, important differences 
between centres concerning ICU admission policies exist and more evidence is needed to 
show that ICU treatment of this specific transplant group is not futile.
In this study we investigated the changes in outcome over time of three cohorts of HSCT 
recipients and compared the outcome of those that needed intensive care treatment to 
those who did not.
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DESIGN AND METHODS
DESIGN
The records of all consecutive patients admitted to the Department of Haematology of 
Radboud University Medical Center, a tertiary academic hospital, between 1 January 2004 
and 1 January 2010, were retrospectively analysed. HSCT recipients were identified and 
only their first unplanned referral to the ICU (<100 days) was included in the study. An 
unplanned admission was defined as an admission because of acute deterioration and 
not for scheduled activities that needed intensive monitoring (e.g. broncho-alveolar lavage 
with non-invasive ventilation support). Demographic data as well as relevant haemato- 
logical data including underlying disease, donor type, type of transplant and presence of 
GvHD were retrieved from electronic patient files. Risk scores for TRM developed by the 
European Group for Blood and Marrow Transplantation (EBMT) were calculated 14. Clinical 
data during ICU admission and discharge, the reason for admission, the severity of illness 
during the first 24 hours, as well as three outcome measures namely, mortality, and the 
length of ICU admission and hospital stay were collected. The severity of illness on admis-
sion to the ICU was determined by indicators of organ failure and the APACHE II score 15. The 
type and duration of mechanical ventilation, renal replacement therapy and vasopressor 
use were extracted from the medical records. The study has been carried out in the Nether- 
lands in accordance with the applicable rules concerning the review of research ethics 
committees and informed consent.
TREATMENT PROTOCOL
The myeloablative (MA) conditioning regimen consisted mainly of high-dose cyclophos-
phamide with either idarubicin when a sibling donor was available or antithymocyte 
globulin (ATG) when the donor was unrelated, with or without total body irradiation. The 
non-myeloablative (NMA) conditioning regimen consisted mainly of cyclophosphamide 
and fludarabine, completed with ATG in case of an unrelated donor. ATG was added to the 
conditioning regimen to attain T lymphocyte depletion to prevent GvHD. During the study 
period the method of preparation and composition of the stem cell product did not change. 
Patients did not receive haematopoietic growth factors and anti-microbial prophylaxis 
consisted of 500 mg ciprofloxacin given twice daily and 500 mg valaciclovir given three 
times daily. Fluconazole was given at 200 mg a day only to those who were colonised with 
Candida albicans. Vital signs (temperature, heart rate, blood pressure, respiration rate, 
oxygen saturation) were monitored at least four times daily with an overnight control being 
included during severe neutropenia to avoid any delay in starting broad-spectrum anti-
bacterial therapy at the onset of fever 16. Empirical therapy was started once the axillary 
temperature equalled or exceeded 38.5°C.
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ICU TRANSFER CRITERIA
No explicit ICU admission policy was adopted. The decision to admit a patient to one of the 
level 3 general ICUs of our hospital was made by the senior haematologist and the senior 
intensivist.
STATISTICAL ANALYSIS
Continuous variables were summarised using mean values and standard deviations (SD) 
or median values and interquartile range (IQR) if data were not normally distributed. To 
compare characteristics we applied the independent t-test for continuous variables and 
chi-squared or Fisher’s exact tests in case of percentages. Univariate logistic regression 
analyses were used to identify factors associated with ICU admission and ICU mortality. The 
power of this study was inadequate to perform multivariate analyses.
 Two-tailed p-values <0.05 were considered to indicate statistical significance. A hundred 
days post-HSCT survival was presented in a Kaplan-Meier curve comparing the three periods 
using the log-rank test. All statistical analyses were carried out with SPSS version 18.0.
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RESULTS
ICU-group characteristics
Between 1 January 2004 and 1 January 2010, 319 patients received an allogeneic HSCT, of 
whom 49 patients were transferred to the ICU for a median (IQR) of ten (6-45) days following 
their transplantation. The most common underlying diagnoses were acute myeloid 
leukaemia (n=14, 29%), non-Hodgkin’s lymphoma (n=10, 20%) and myelodysplastic 
syndrome (n=8, 16%). The depth of compromised immunity at the moment of ICU transfer 
was emphasised by the fact that 43% of the patients were severely neutropenic (neutrophil 
count of ≤0.5 x109/L) on ICU admission and 90% had received systemic immunosuppres-
sive therapy for GvHD prophylaxis.
Infectious complications were the main reason for ICU admission (86%), with respiratory 
insufficiency reported as the main symptom (67%), followed by haemodynamic instability, 
sepsis and septic shock. Mortality rates at 100-days post-HSCT were significantly higher for 
the patients who required an ICU admission (53 versus 8% in HSCT patients who did not 
need intensive care, p<0.01). Length of stay in the hospital was significantly longer (median 
45 days; range 36-70) for patients requiring an ICU admission compared with those without 
ICU admission (29 days; range 23-39); p<0.01.
RISK FACTORS FOR ICU ADMISSION
The characteristics of ICU patients were compared with those without intensive care treat-
ment. Age and gender were distributed equally in both groups (table 1). Univariate analysis 
identified two haematological risk factors for ICU admission to be significant: an unrelated 
donor graft (OR=2.5, 95% CI 1.3-4.6) and MA conditioning (OR=2.3, 95% CI 1.1-4.7). The 
power of this study was inadequate to perform a multivariate analysis. The onset of aGvHD 
grade 2-4 within 100 days for those admitted to the ICU was 29% (14/49), similar to those 
not admitted to the ICU (30%).
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CHANGES IN ICU CHARACTERISTICS OVER THE YEARS
There were no changes in the number of days from HSCT to ICU admission (median 10, 
IQR 6-45 days after HSCT), length of ICU stay (median 4, IQR 1-12 days) or time post-ICU 
to hospital discharge (median 15, IQR 1-35 days) over time, nor did the APACHE II severity 
of illness on ICU admission and EBMT estimated risk of not surviving for five years change 
during the study period (table 2). The proportion of patients requiring endotracheal intu-
bation tended to decrease, but this did not reach statistical significance. In contrast, the 
number of non-invasive ventilation days increased (p=0.02).
HSCT-recipients without 
ICU admission (n=270)
HSCT-recipients with ICU 
admission (n=49)
p-value OR (95% CI)
Age (years) 48.2 (±11.0) 47.4 (±11.3) 0.64a
Male gender 167 (62%) 29 (59%) 0.75b
Unrelated donor 89 (33%) 27 (55%) <0.01b 2.5 (1.3-4.6)
Myeloablati ve conditi oning 162 (60%) 38 (78%) 0.02b 2.3 (1.1-4.7)
EBMT esti mated risk (n=237/43) 0.54c
 – Low 1 (0%) 0 (0%)
 – Intermediate 63 (27%) 14 (33%)
 – High 173 (73%) 29 (67%)
Table 1 Demographic factors associated with ICU admission before 100 days post-HSCT
(2004-2009, n=319)
Data are expressed as mean (± standard deviati on) or n with (%)
a Independent T-test
b Chi²-test
c Fisher’s exact test
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The number of days that vasopressor medication was required remained unchanged. ICU 
mortality was 44% (2004/2005) to 35% (2006/2007) and 24% (2008/2009) and hospital 
mortality 78% to 52% and 41%, but these trends did not reach statistical significance. 
Figure 1 illustrates the decrease in the 100-day post-HSCT mortality for patients who had 
been admitted to the ICU (p=0.02). A similar decrease was found for patients given MA 
conditioning (78% to 56% and 36%, respectively) and NMA conditioning (no patients in 
first period, 60% and 33% in period 2 and 3, respectively). While these improvements 
did not reach statistical significance, likely due to a type 2 error, they do illustrate that in 
both groups a comparable improvement in outcome is observed over time. The 100-day 
post-transplant mortality of the complete group of patients (n=319) remained constant over 
time between 15-19%.
2004/2005 (n=9) 2006/2007 (n=23) 2008/2009 (n=17)
Age 46.3 (±11.5) 47.6 (±10.3) 47.8 (±13.2)
APACHE II on admission 21.0 (±7.1) 20.1 (±5.6) 21.2 (±6.6)
EBMT esti mated risk 4.0 (±1.0) 3.6 (±1.4) 2.8 (±1.1)
Invasive venti lati on (days) 0.4 [0.0-11.3] 1.5 [0.0-15.5] 1.3 [0.0-6.3]
Non-invasive venti lati on (days) 0.0 [0.0-0.02] 0.3 [0.0-1.0] 0.2 [0.0-0.8]
Vasopressor use (days) 0.2 [0.0-3.9] 0.4 [0.0-3.0] 0.0 [0.0-1.4]
ICU mortality 4 (44%) 8 (35%) 4 (24%)
Hospital mortality 7 (78%) 12 (52%) 7 (41%)
100 day post HSCT mortality 7 (78%) 13 (57%) 6 (35%)
Table 2 Demographics, ICU characteristi cs and outcome of pati ents transferred to an ICU 
within 100 days post-HSCT in two-year periods (n=49)
Data are expressed as mean (± standard deviati on), median [IQR] or n with (%).
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Characteristics were compared between ICU survivors and non-survivors to determine 
the factors that were associated with survival of the patients who needed an ICU admis-
sion (table 3). Age and HSCT-related characteristics including donor type, bacteraemia, 
neutropenia and EBMT estimated risk score were similar in both groups. The duration that 
vasopressor medication was required (p<0.01), the number of days invasive ventilation 
was required (p<0.01) and male gender (p=0.04) were significant univariate predictors for 
ICU mortality. The APACHE II score (p=0.07) and receipt of MA conditioning (p=0.08) also 
tended to be related to ICU mortality. Neutropenia and both the presence of aGvHD grade 
2-4 on ICU admission and the onset of aGvHD within 10 days post-HSCT were not shown to 
be risk factors for ICU survival.
Figure 1 Kaplan-Meier survival curve unti l 100 days post-HSCT for pati ents with 
an ICU admission (n=49)
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ICU survivors 
(n=33)
ICU 
non-survivors 
(n=16)
p-value OR (95% CI)
Demographics
 – Age 47 (±12) 48 (±11) 0.77a
 – Male gender 16 (49%) 13 (81%) 0.04d 0.2 (0.1-0.9)
Haematological parameters
 – EBMT esti mated risk (n=43) 1.00d
 - Intermediate 10 (35%) 4 (29%)
 - High 19 (66%) 10 (71%)
 – Myeloablati ve conditi oning 23 (70%) 15 (94%) 0.08d 0.2 (0.0-1.3)
 – Unrelated donor 17 (51%) 10 (62%) 0.47b
 – Bacteraemia on admission (n=42) 6/27 (22%) 6/15 (40%) 0.29d
 – Neutropenia on admission (n=40) 10/27 (37%) 7/13 (54%) 0.31b
 – GvHD on ICU admission 2 (6%) 2 (13%) 0.59d
 – GvHD <day 100 10 (30%) 4 (25%) 1.00d
ICU parameters
 – APACHE II on admission 19.6 (±5.7) 22.9 (±6.5) 0.07a 1.1 (1.0-1.2)
 – Invasive venti lati on (days) 0.0 [0.0-5.1] 7.9 [1.6-23.7] <0.01c 1.0 (1.0-1.1)
 – Non-invasive venti lati on (days) 0.2 [0.0-0.7] 0.1 [0.0-0.3] 0.68c
 – Vasopressor use (days) 0.0 [0.0-0.7] 2.4 [0.6-5.1] <0.01c 1.5 (1.1-2.0)
Table 3 Demographic, haematological and ICU risk factors for ICU mortality (2004-2009, n=49)
Data are expressed as mean (± standard deviati on), median [IQR] or proporti ons with (n).
a Independent T-test
b Chi²-test
c Mann-Whitney-U test
d Fisher’s exact test
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DISCUSSION
The present study shows that the proportion of HSCT patients admitted to the ICU during 
the last decade has risen. Receiving stem cells from an unrelated donor and MA condi-
tioning were shown to be the major risk factors for ICU admission as one in four required 
ICU admission.
 While their disease severity on ICU admission, as determined by APACHE II, remained 
similar, the 100-day transplant-related mortality decreased. Factors associated with ICU 
mortality were duration of vasopressor therapy, invasive mechanical ventilation and male 
gender. No correlation was found between the presence of neutropenia or GvHD and the 
risk for ICU admission or ICU mortality. ICU and post-ICU hospital mortality was low in our 
population compared with recent literature 17, 18. Improved outcome for HSCT recipients 
might be explained by the fact that ICU treatment in general has improved, as is illustrated 
by higher ICU survival rates for the general adult ICU population 19 as well as in our own 
hospital. In addition, haematologists are more aware of the fact that admission to the ICU 
is feasible and effective, provided it is arranged at an early stage of deterioration.
Nevertheless, APACHE II scores during the study period did not decrease. While this cannot 
be deduced from our data, we have the impression that attitudes changed over time from 
‘no patient to be transferred to the ICU, unless….’ to ‘if needed, every patient should be 
transferred to the ICU, unless…’. Some authors propose that ‘unlimited ICU treatment for 
a limited period’, with full ICU support for e.g. four days and re-evaluation on day 5 could 
be an appropriate strategy of care for those patients with an unknown disease status or 
disease recurrence with available treatment options 20. Our data show that 39% of the 
100-day survivors needed six days or more on the ICU with a range for ICU survivors of 1-50 
ICU days, implying that a decision about futility of treatment cannot be made within 4-6 
days. Long-term physical, mental and social consequences of prolonged ICU admission and 
the effects of more extensive use of mechanical ventilation are now being studied in larger 
populations to determine the long-term effects of ICU treatment.
The finding that the duration of invasive mechanical ventilation and duration of vaso-
pressor use predict ICU mortality is not surprising or new. It is well known that respiratory 
failure that requires mechanical ventilation and vasopressors indicates sepsis and shock 
and predicts mortality in almost all patient populations. Several studies have reported the 
use of mechanical ventilation in this profoundly immunocompromised population to be 
predictive for ICU mortality 21 and this is supported by the high mortality rates reported 22. 
In our study population the use of non-invasive ventilation increased, relative to invasive 
ventilation over the years, and probably contributed to the better survival rates. However, 
prolonged use of non-invasive ventilation is still controversial 23.
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 The benefit of organ support in patients with late-onset complications related to aGvHD 
and high-dose corticosteroid treatment is contentious 24. GvHD is regarded a poor prog-
nostic factor for the critically ill HSCT recipient 10, 12. It is remarkable that we found no indi-
cation that GvHD was related to ICU admission, nor ICU mortality. However, with the use of 
partially T-cell depleted grafts the overall incidence of GvHD was modest and the incidence 
of severe and refractory aGvHD was low. So, at least in this context, there should be no 
restrictions imposed on transferring these patients to an ICU when indicated.
As most ICU indications are associated with an infectious cause, haematology wards 
should optimise their procedures for early recognition and adequate treatment of infec-
tious complications and their haemodynamic sequelae 25. ICU survival seems importantly 
related to the extent of organ dysfunction 26, so employing monitoring systems such as vital 
signs based early warning scores to recognise acute clinical deterioration 11, 18 should be 
encouraged. Clearly, guidelines are needed to help haematologists decide when to transfer 
a patient to the ICU. As long as no explicit criteria for admission to the ICU are available, 
early consultation of intensive care physicians might improve accessibility to the ICU at an 
early stage of deterioration. The APACHE II might also help as it provides a clear indication 
of the severity of illness once the patient is admitted to the ICU even though it has not been 
validated for patients with haematological malignancies nor for HSCT recipients 27, 28.
Several limitations of our study need to be addressed. Obviously, caution is required as 
our study was retrospective in nature and the cohorts were relatively small in size. The 
absence of statistical significance of some endpoints, for example influence of MA/NMA 
conditioning on ICU mortality, is likely the result of limited power. Nevertheless, we were 
able to show an effect on clinically relevant outcome measures using a homogeneous 
cohort of haematological patients. The decrease in ICU and post-ICU hospital mortality did 
not reach statistical significance, possibly due to the limited power of the study. However, 
the impact of this decrease over time is relevant and shows better survival rates of HSCT 
patients requiring ICU treatment. In addition, the increased use of NMA regimens may be 
a confounder as the number of patients with NMA conditioning increased simultaneously 
with the observed decrease in mortality. Nevertheless, the reduction in mortality was 
similar for both patients given MA and NMA conditioning, indicating that the type of condi-
tioning regimen is unlikely to explain the observed improvement in survival.
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CONCLUSIONS
In line with general medical ICU patients, outcomes appear to have improved for allogeneic 
HSCT recipients who required intensive care treatment. Neutropenia and aGvHD were not 
associated with ICU survival. It appears plausible that an early transfer to the ICU could 
further improve short- and long-term survival. ICU admittance criteria and guidelines for 
early transfer to the ICU should be developed.
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ABSTRACT
PURPOSE
To explore trends over time in admission prevalence and (risk-adjusted) mortality of criti-
cally ill haematological patients and compare these trends to those of several subgroups of 
patients admitted to the medical intensive care unit (medical ICU patients).
METHODS
A total of 1,741 haematological and 60,954 non-haematological patients admitted to the 
medical ICU were analysed. Trends over time and differences between two subgroups of 
haematological medical ICU patients and four subgroups of non-haematological medical 
ICU patients were assessed, as well as the influence of leukocytopenia.
RESULTS
The proportion of haematological patients among all medical ICU patients increased over 
time [odds ratio (OR) 1.06; 95% confidence interval (CI) 1.03–1.10 per year; p<0.001]. Risk 
adjusted mortality was significantly higher for haematological patients admitted to the ICU 
with white blood cell (WBC) counts of <1.0 x 109/L (47%; 95% CI 41–54%) and ≥1.0 x 109/L 
(45%; 95% CI 42–49%), respectively, than for patients admitted with chronic heart failure 
(27%; 95% CI 26–28%) and with chronic liver cirrhosis (38%; 95% CI 35–42%), but was not 
significantly different from patients admitted with solid tumours (40%; 95% CI 36–45%). 
Over the years, the risk-adjusted hospital mortality rate significantly decreased in both the 
haematological and non-haematological group with an OR of 0.93 (95% CI 0.92–0.95) per 
year. After correction for case-mix using the APACHE II score (with WBC omitted), a WBC 
<1.0 x 109/L was not a predictor of mortality in haematological patients (OR 0.86; 95% CI 
0.46–1.64; p=0.65). We found no case-volume effect on mortality for haematological ICU 
patients.
CONCLUSIONS:
An increasing number of haematological patients are being admitted to Dutch ICUs. While 
mortality is significantly higher in this group of medical ICU patients than in subgroups 
of non-haematological ones, the former show a similar decrease in raw and risk-adjusted 
mortality rate over time, while leukocytopenia is not a predictor of mortality. These results 
suggest that haematological ICU patients have benefitted from improved intensive care 
support during the last decade.
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INTRODUCTION
Treatment for haematological malignancies is known to cause serious toxicity resulting in 
prolonged immune insufficiency and impaired mucocutaneous barriers 1. Patients under-
going these intensive treatments are prone to infections and frequently require intensive 
care unit (ICU) monitoring and/or treatment. The most common indication for ICU admis-
sion is respiratory insufficiency 2. Recent studies show that 15-28% of recipients of induc-
tion chemotherapy for acute myeloid leukaemia need to be admitted to the ICU during treat-
ment 3, 4. For haematopoietic stem cell transplant recipients, ICU admission rates vary from 
5 to 55% 5.
Extremely high mortality rates underlie the reticent attitude among both haematologists 
and intensivists to unplanned transfers of haematological patients to an ICU 6. This contro-
versial attitude towards ICU admission is comparable to that of clinicians with regards to 
patients with solid tumours, heart failure or liver cirrhosis. During the last decade perspec-
tives on critically ill cancer patients have changed 7 and led, together with improved survival 
rates of patients admitted to general ICUs 8, to less reluctance on the behalf of haemato- 
logists and intensivists to admit patients with haematological malignancies to an ICU 9, 10. 
Where formerly neutropenic patients who developed organ failure were initially considered 
to have a dismal prognosis, nowadays the notion that neutropenia is predictive for ICU 
mortality is the subject of ongoing debate 11. Recent studies have found that predominantly 
the need for mechanical ventilation, presence of invasive fungal infection, development of 
multi-organ failure and high severity of illness scores at admission are additional prognostic 
factors for mortality among cancer patients 2, 12.
We investigated whether these new perspectives on ICU survival actually do influence the 
admission prevalence and outcome of haematological patients admitted to the ICU. There-
fore, the aim of this study was to explore trends over time in admission prevalence and 
outcomes of critically ill haematological patients and to compare these data with those of 
non-haematological patients admitted to the medical ICU (medical ICU patients), specifi-
cally with patients with chronic heart failure, chronic liver cirrhosis and solid tumours.
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DESIGN AND METHODS
PATIENT DATA
All consecutive patients admitted to ICUs participating in the Dutch National Intensive 
Care Evaluation (NICE) database between January 2004 and January 2012 were included 
in this study. To diminish bias by changes in case-mix, only ICUs that submitted patient 
data during the complete period were included. Admissions were considered to be due to 
a haematological disorder(s) when a haematological malignancy was recorded in the NICE 
or when ICU admission was requested by a haematologist. Patients for whom the recorded 
APACHE II (Acute Physiology and Chronic Health Evaluation II) score at admission made 
it impossible for the disorder to be related to a haematological disease were considered 
to be non-haematological patients. Patients admitted to the ICU for non-medical reasons 
(e.g. surgery, trauma) were excluded from entry into the study, as were patients admitted 
for diagnostic procedures generally performed in the ICU (e.g. bronchoalveolar lavage) and 
those with an ICU length of stay (LOS) of <24 h. Those patients who were readmitted to the 
ICU and patients with an unknown leukocyte count were also excluded.
The NICE registry contains information on patient admissions to >90% of all ICUs in the 
Netherlands. Data from the first 24 h of ICU admission are collected, including informa-
tion on acute and chronic diagnoses, mechanical ventilation, minimum and maximum 
physiology and laboratory values, such as number of leukocytes, and need to calculate 
the APACHE II score 13. In this study, the lowest white blood cell (WBC) count was used to 
define subgroups of haematological patients, with WBC <1.0 x 109/L and WBC ≥1.0 x 109/L, 
because leukocytopenia is considered to negatively affect ICU outcome. No information 
was available on the ICU admission policies of the participating hospitals nor on specific 
haematological parameters, such as level of neutropenia, underlying haematological diag-
nosis, disease status and type and phase of haematological treatment, including whether 
or not haematopoietic stem cell transplant was performed.
We compared the haematological subgroup with other subgroups of severely ill patients 
for whom ICU admission is traditionally considered to be controversial, namely, those with 
solid tumours, chronic liver cirrhosis (defined as positive liver biopsy in combination with 
documented portal hypertension odds ratio OR earlier episodes of gastrointestinal bleeding 
caused by portal hypertension OR earlier episodes of liver failure, coma or encephalopathy) 
and chronic heart failure (New York Heart Association Class IV).
The NICE registry further records outcome data on LOS in the ICU and hospital, respec-
tively, ICU readmission rate and ICU and in-hospital mortality. A number of measures have 
been implemented to improve data quality: the collected data are subject to several quality 
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checks, onsite data quality audits take place on a regular basis and data collectors partici-
pate in training sessions 14. Site visits to ICUs are performed on a regular basis to investigate 
the number, types and causes of errors made in in-hospital mortality registration 15.
This study was carried out in the Netherlands in accordance with current regulations 
pertaining to review by research ethics committees and patient informed consent.
DATA ANALYSIS
We compared APACHE II scores, incidence of comorbidities (diabetes, chronic obstruc-
tive pulmonary disease (COPD), cardiovascular insufficiency, acute renal failure), the 
use of procedures/treatments in the ICU (mechanical ventilation, vasopressive medica-
tion) and LOS between two subgroups of haematological patients (WBC <1.0 x 109/L and 
WBC ≥1.0 x 109/L) and four subgroups of non-haematological medical ICU patients (solid 
tumours, chronic liver cirrhosis, chronic heart failure and other medical ICU admissions). 
APACHE II scores were compared both with and without including the subscore for WBC. 
LOS is separately reported for survivors and non-survivors, and for both stay in the ICU and 
hospital, respectively.
Absolute and risk-adjusted hospital mortality rates were compared between haemato- 
logical and non-haematological patients. The risk-adjusted mortality rate (RAMR) was 
calculated as the fraction of the number of deaths actually observed and the number of 
deaths predicted by the APACHE II model, multiplied by the average hospital mortality rate 
in the entire study cohort. It can be interpreted as the hospital mortality rate after correction 
for case-mix, using the APACHE II model. The RAMR has the same statistical properties as 
the standardised mortality ratio but allows for a better comparison of adjusted mortality 
rates between studies.
Three logistic regression analyses were carried out. To analyse the prevalence of haemato-
logical patients admitted to the ICU among medical ICU admissions over time, we used the 
mixed model logistic regression analysis for the entire cohort using haematological status 
(yes vs. no) as the response variable and calendar time as the covariate. To account for 
clustering in ICUs, we used a random coefficient model that allowed each ICU to have its 
own trend in prevalence over time. For comparison, trends over time were also analysed in 
the same way as for medical ICU patients with chronic liver cirrhosis, chronic heart failure 
and solid tumours.
To analyse whether trends in risk-adjusted hospital mortality over time differed between 
haematological and non-haematological patients, we used fixed-effects logistic regres-
sion analysis with hospital mortality as the response variable and the logit-transformed 
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APACHE II mortality risk score (to adjust for patient case-mix), calendar time and haemato-
logical ICU admission (yes vs. no) as covariates. We also included an interaction between 
calendar time and admission of haematological patients to the ICU. For comparison, trends 
in risk adjusted hospital mortality over time were similarly analysed for subgroups of 
patients with chronic liver cirrhosis, chronic heart failure and patients with a solid tumour, 
but without inclusion of ‘haematological ICU admission’ and its interaction with calendar 
time as covariates.
Finally, a similar fixed-effect logistic regression analysis was conducted within the group of 
haematological patients to assess the association between leukocytopenia at ICU admis-
sion and risk-adjusted hospital mortality. In this analysis, the logit-transformed APACHE II 
mortality risk, calendar time, leukocytopenia (modelled as WBC <1.0 x 109/L) and an interac-
tion between calendar time and leukocytopenia were included in the model. Furthermore, 
to correct for volume–outcome effects, we added the number of haematological ICU admis-
sions that took place in the same centre and same month as the ICU admission in question, 
as the continuous covariate to this model.
 All statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS) version 20.01 (SPSS Inc., Chicago, IL) and R, version 2.14 16.
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RESULTS
PATIENTS
A total of 288,568 patients admitted to 36 ICUs participating in the Dutch NICE during the 
entire study period were included in our study, of which 2,935 admissions were identified 
as haematological patients. Following exclusion of those patients who did not fulfil our 
criteria (flowchart shown in figure 1), data of 1,741 patients with a haematological disease 
admitted for the first time to the ICU were included in the analyses: 1,673 of these patients 
(96%) were registered in the NICE as having a haematological malignancy, and 68 (4%) 
were admitted to the ICU admission upon request of the haematologist. Data on a group 
of 60,954 patients without a haematological malignancy admitted to the medical ICU were 
available for further analysis. The median [interquartile range (IQR)] WBC for haemato-
logical and non-haematological patients was 5.8 x 109/L [IQR 1.1–12.7] and 10.6 x 109/L 
[IQR 7.6–14.6], respectively.
1
2
3
4
Flowchart illustrati ng the inclusion and exclusion criteria for entry into the study and 
for classiﬁ cati on into haematological and non-haematological pati ent subgroups
WBC White blood cells
ICU Intensive care unit
Figure 1
ICU admissions
2004–2012
n=288,568
Re-admissions n=19,896 (7%)n=375 (13%)
Exclusion-criteria
Non-medical ICU admissions n=162,809 (57%)n=146 (5%)
ICU admission <24 hours n=38,362 (13%)n=611 (21%)
Unknown WBC n=3,612 (1%)n=62 (2%)
Haematological pati ents
n=2,935 (1%)
Haematological pati ents
n=1,741 (3%)
Haematological malignancy
n=1,673 (96%)
ICU admission requested by haematologist
n=68 (4%)
WBC <1.0x10⁹
n=405 (23%)
WBC �1.0x10⁹
n=1,336 (77%)
Non-haematological pati ents
n=285,633 (99%)
Non-haematological pati ents
n=60,954 (97%)
Solid tumours
n=602 (1%)
Chronic liver cirrhosis
n=1,246 (4%)
Chronic cardiovascular insuﬃ  ciency
n=3,628 (6%)
Other medical ICU admissions
n=55,533 (91%)
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Among all patients admitted to the medical ICU, 2.8% were due to haematological condi-
tions, and this prevalence increased over time at 6% per year [odds ratio (OR) 1.06 annually; 
95% confidence interval (CI) 1.03–1.10]. The number of patients with chronic liver cirrhosis 
admitted to the ICU (n=1,264; 2.0% of all medical admissions) also increased over time (OR 
1.06; 95% CI 1.03–1.09), as did the number of admissions of patients with solid tumours 
(n=737, 1.1%; OR 1.16; 95% CI 1.10–1.22). The number of patients with chronic heart failure 
admitted to the ICU (n=3,672; 5.9%) decreased over time (OR 0.95, 95% CI 0.91–0.99).
Demographic and clinical characteristics of included patients, categorised according to 
subgroup (n=6), are shown in table 1. APACHE II scores at ICU admission (with and without 
omission of the WBC value) were 28.2 ±7.7 and 24.6 ±7.7 points, respectively, and gener-
ally higher for haematological patients with WBC <1.0 x 109/L than for the other subgroups 
of patients. For the haematological subgroup, APACHE II scores did not change over time, 
illustrating that on average the severity of illness at admission to the ICU did not change 
during the study period. Haematological patients, as well as patients with liver cirrhosis 
and heart failure, were more likely to suffer from acute renal failure, while a medical history 
of COPD and diabetes was more frequently present in the non-haematological patient 
groups (table 1).
ICU TREATMENT AND OUTCOME
Haematological patients and patients with liver cirrhosis were more likely to need vaso-
pressor therapy than the other medical ICU patients, but less likely than patients with solid 
tumours and chronic heart failure. Mechanical ventilation was less frequently needed for 
patients with solid tumours (table 1).
Haematological patients had longer ICU and hospital LOS than non-haematological patients 
(both for survivors and non-survivors). For haematological patients, the longest LOS in the 
ICU and hospital was found for patients with leukocytopenia (WBC <1.0 x 109/L) (table 1). ICU 
readmission rates were higher in both haematological subgroups compared to non-haema-
tological subgroups (table 1).
Absolute ICU (33.8%) and hospital (47.4%) mortality was higher for the whole group of 
haematological patients than for the whole group of non-haematological patients (ICU 
mortality 17.9%, hospital mortality 26.3%) and most specific for patients with leukocyto-
penia (WBC <1.0 x 109/L), with a mortality of 40.0 and 52.3%, respectively (table 2).
RAMR was higher for the whole group of haematological patients admitted to the ICU (RAMR 
46%; 95% CI 42–49%) than for the whole group of non-haematological medical ICU patients 
(RAMR 18%; 95% CI 18–18%). Comparison of the subgroups revealed that risk-adjusted 
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mortality was higher for haematological medical ICU patients with WBC <1.0 x 109/L (47%; 
95% CI 41–54%) and with WBC ≥1.0 x 109/L (45%; 95%CI 42–49%), respectively, than for 
non-haematological patients with chronic heart failure (RAMR 27%; 95% CI 26–28%) or 
with chronic liver cirrhosis (38%; 95%CI 35–42%), but it was not significantly different from 
that of patients with solid tumours (RAMR 40%; 95% CI 36–45%; table 2). The Kaplan-Meier 
plot for hospital survival of the six subgroups is shown in figure 2. Differences in absolute 
and risk-adjusted hospital mortality per subgroup for patients receiving mechanical venti-
lation or not in the first 24 h of ICU admission is reflected in figure 3.
For both haematological ICU patients and medical ICU patients, risk-adjusted mortality 
decreased over time, at 7% per calendar year (OR 0.93; 95% CI 0.92–0.95) (figure 4). 
This decrease over time was similar in both groups (p=0.79). Risk-adjusted mortality also 
decreased over time for patients with chronic heart failure (OR 0.93; 95% CI 0.88–0.98), 
patients with chronic liver cirrhosis (OR 0.90; 95% CI 0.82–0.98) and patients with solid 
tumours (OR 0.93; 95% CI 0.75–0.99). There was no significant difference in decrease over 
time for each subgroup compared to patients admitted to the ICU for haematological condi-
tions. After correction for case-mix using the APACHE II score (with WBC omitted), leukocy-
topenia (WBC <1.0 x 109/L) was not a predictor of mortality (OR 0.86; 95% CI 0.46–1.64).
VOLUME-OUTCOME EFFECT HAEMATOLOGICAL ICU ADMISSIONS
A total of 36 centres admitted 1,741 haematological patients to their ICUs during the study 
period. When divided into four volume quartiles (each with nine hospitals), these volume 
quartiles have (raw) hospital mortality rates of 37.1% (median 18 admissions [IQR 15–21]), 
44.7% (median 28 admissions [IQR 26–29]), 46.2% (median 35 admissions [IQR 34–39]) 
and 50.0% (median 90 admissions [IQR 64–141]), respectively. There was no effect of 
haematological patient-volume on risk-adjusted hospital mortality (OR 1.01; 95% CI 0.98–
1.04; p=0.38).
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Characteristi cs Haematological pati ent subgroups
Haematology
WBC<1.0x10⁹/L
n=405
Haematology
WBC≥1.0x10⁹/L
n=1,336
Demographics
 – Age, median (IQR) 58 (47-65) 64 (54-72)
 – Male gender (%) 60.5 62.0
 – WBC, median (IQR)b 0.2 (0.1-0.5) 7.1 (3.2-13.6)
 – APACHE II severity of illness score (points)-with WBC (mean±SD)  28.2 ±7.7 25.7 ±8.1
 – APACHE II severity of illness (points)-without WBC (mean±SD) 24.6 ±7.7 23.0 ±7.6
Chronic co-morbidity (%)
 – COPDc 2.2 5.5
 – Renal insuﬃ  ciency 4.0 8.9
 – Cardiovascular insuﬃ  ciency 1.7 2.8
 – Diabetes 9.1 10.6
 – Chronic dialysis 8.9 2.2
ICU treatment (%)b
 – Acute renal failure 20.7 19.0
 – Vasopressors 56.0 55.8
 – Mechanical venti lati on 69.4 66.8
LOS ICU (days), median (IQR)
 – Survivorsd 5.1 (2.1-10.7) 4.1 (2.0-9.5)
 – Non-survivors 5.7 (2.4-11.2) 5.1 (2.4-11.0)
LOS in hospital (days), median (IQR)
 – Survivorsd 36.5 (21.3-54.0) 22.0 (12.8-41.0)
 – Non-survivors 23.3 (10.0-38.8) 15.0 (7.0-29.4)
Re-admission rate (%) 14.3 12.4
Table 1 Characteristi cs of pati ents’ subgroups
IQR Interquarti le range
APACHE II Acute Physiology and Chronic Health Evaluati on II
WBC White blood cells
SD Standard deviati on
LOS Length of stay
a Overlapping subgroups (55 pati ents had >1 subgroup diagnosis)
b During the ﬁ rst 24h of ICU admission
c Chronic obstructi ve pulmonary disease (COPD) registered from 2007 onwards
d LOS was calculated for hospital survivors
e All medical ICU pati ents with cardiovascular insuﬃ  ciency were included in the subgroup chronic heart failure.
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Characteristi cs Haematological pati ent subgroups
Haematology
WBC<1.0x10⁹/L
n=405
Haematology
WBC≥1.0x10⁹/L
n=1,336
Demographics
 – Age, median (IQR) 58 (47-65) 64 (54-72)
 – Male gender (%) 60.5 62.0
 – WBC, median (IQR)b 0.2 (0.1-0.5) 7.1 (3.2-13.6)
 – APACHE II severity of illness score (points)-with WBC (mean±SD)  28.2 ±7.7 25.7 ±8.1
 – APACHE II severity of illness (points)-without WBC (mean±SD) 24.6 ±7.7 23.0 ±7.6
Chronic co-morbidity (%)
 – COPDc 2.2 5.5
 – Renal insuﬃ  ciency 4.0 8.9
 – Cardiovascular insuﬃ  ciency 1.7 2.8
 – Diabetes 9.1 10.6
 – Chronic dialysis 8.9 2.2
ICU treatment (%)b
 – Acute renal failure 20.7 19.0
 – Vasopressors 56.0 55.8
 – Mechanical venti lati on 69.4 66.8
LOS ICU (days), median (IQR)
 – Survivorsd 5.1 (2.1-10.7) 4.1 (2.0-9.5)
 – Non-survivors 5.7 (2.4-11.2) 5.1 (2.4-11.0)
LOS in hospital (days), median (IQR)
 – Survivorsd 36.5 (21.3-54.0) 22.0 (12.8-41.0)
 – Non-survivors 23.3 (10.0-38.8) 15.0 (7.0-29.4)
Re-admission rate (%) 14.3 12.4
Table 1 Characteristi cs of pati ents’ subgroups
IQR Interquarti le range
APACHE II Acute Physiology and Chronic Health Evaluati on II
WBC White blood cells
SD Standard deviati on
LOS Length of stay
a Overlapping subgroups (55 pati ents had >1 subgroup diagnosis)
b During the ﬁ rst 24h of ICU admission
c Chronic obstructi ve pulmonary disease (COPD) registered from 2007 onwards
d LOS was calculated for hospital survivors
e All medical ICU pati ents with cardiovascular insuﬃ  ciency were included in the subgroup chronic heart failure.
Non-haematological pati ent subgroups
Solid tumours
n=602a
Chronic liver 
cirrhosis
n=1,246a
Chronic heart 
failure
n=3,628a
Medical ICU, 
other
n=55,533
67 (58-74) 58 (50-65) 72 (63-78) 64 (51-75)
63.3 64.3 63.7 57.3
10.8 (7.3-15.4) 8.5 (5.6-13.1) 11.2 (8.3-14.9) 10.6 (7.6-14.6)
20.0 ±7.2 25.6 ±7.7 25.9 ±7.6 19.9 ±8.1
19.2 ±8.1 21.0 ±8.4 21.9 ±8.1 17.9 ±8.2
14.6 9.1 15.1 10.8
4.8 7.6 19.1 6.1
2.2 3.2 100.0 0.0e
11.6 15.2 18.9 11.8
0.3 0.7 3.5 1.7
11.0 26.0 21.0 12.0
66.6 52.5 65.8 46.8
44.4 62.4 65.0 60.2
3.0 (1.8-5.9) 2.9 (1.7-6.6) 3.3 (1.9-6.6) 3.2 (1.8-7.0)
3.1 (1.8-6.8) 4.3 (2.0-9.3) 3.9 (2.0-8.0) 4.2 (2.2-9.2)
16.0 (8.0-27.0) 15.0 (7.0-29.0) 16.0 (9.0-29.0) 15.0 (8.0-28.0)
7.0 (4.0-14.0) 10.0 (4.4-17.0) 8.0 (3.9-18.7) 8.0 (3.6-18.0)
5.8 7.9 9.3 7.0
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Figure 2 Kaplan-Meier plot for hospital survival for haematological and 
non-haematological medical pati ents admitt ed to the ICU
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Absolute and risk-adjusted hospital mortality rates for subgroups of haematological 
and non-haematological medical pati ents admitt ed to the ICU without and with 
mechanical venti lati on during the ﬁ rst 24h
Figure 3
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Figure 4 Absolute and risk-adjusted hospital mortality rates over ti me for the admission of 
haematological (n=1,741) and non-haematological (n=60,954) medical pati ents 
to the ICU
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DISCUSSION
We report here on the changes over time in ICU admission prevalence and outcomes of 
more than 1,700 critically ill haematological patients and these changes in more than 
60,000 non-haematological medical ICU patients, all admitted to 36 Dutch ICUs during the 
last decade. The main findings of our study are threefold. First, the proportion of haema-
tological patients among all medical ICU admissions increased over time, suggestive of 
a change in ICU admission policy. Second, the prognosis of haematological ICU patients 
significantly improved to a similar extent as that of several subgroups of non-haemato- 
logical medical ICU patients. Third, our data convincingly confirm that a WBC count of <1.0 
x 109/L was not a predictor of in-hospital mortality in our ICU patients with haematological 
disorders. In addition to these findings, it is important to realise that the hospital mortality 
rate of haematological patients admitted to the ICU was approximately twofold higher than 
that of the non-haematological medical ICU patients, but similar to that of ICU patients with 
solid tumours. When mechanical ventilation was needed, mortality was higher for all of the 
subgroups investigated. The higher mortality of haematological patients was likely related 
to their underlying disease, its treatment and the need for more rigorous ICU therapy and 
was also reflected by the longer LOS in the ICU and hospital by our haematological patients. 
Our results on both ICU and hospital mortality rates are within the ranges of those for 
critically ill haematological patients in ICUs in France and Belgium 17, as well as for a cohort 
of critically ill haematological patients in the UK 18. Taken together, these results not only 
indicate that the denial of ICU treatment to haematological patients is not warranted, but 
they also emphasise the need for appropriate criteria for referring this specific group of 
patients to an ICU and that intensive supportive care for haematological patients should be 
considered irrespective of the degree of leukocytopenia.
The improvement over time we observed is in accordance with the results of a recent publi-
cation in which 428 neutropenic patients with sepsis were studied 19. While the compa-
rable improvement in hospital survival between haematological and non-haematological 
patients might suggest that improved ICU care accounted for this improved prognosis, 
changes in haematological treatment regimens may also have contributed to this trend. 
Less organ damage, infection and severe acute graft versus host disease related to allo-
geneic hematopoietic stem cell transplantation has been reported 20, and non-myelo- 
ablative therapies are associated with improved ICU survival compared to myeloablative 
therapies 21. The absence in the current study of a case-volume/outcome relationship is 
however surprising. Two previous studies describe that survival is higher in ICUs that admit 
larger numbers of critically ill haematological patients with acute respiratory failure and 
septic shock compared to ICUs that admit fewer haematological patients 22, 23. We found an 
increase in crude mortality rates for hospitals with more admissions, but after adjusting for 
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casemix this association was no longer apparent, indicating that larger centres treat more 
severely ill patients, but do not have better or worse outcome results.
Until recently, published outcomes of haematological ICU patients were generally poor 
despite a growing number of studies demonstrating improvement 24, 25. The perception that 
transfer to an ICU may be futile and that long-term outcomes for those who survive critical 
illness are rather poor has led to a reluctance among both haematologists and inten- 
sivists to admit patients to an ICU. In our view, this reluctance might delay ICU admission, 
resulting in a self-fulfilling prophecy of a detrimental outcome for haematological patients, 
as illustrated by the fact that the number of failing organs in patients upon ICU admission is 
directly related to ICU mortality among patients with haematological malignancies 26. More-
over, in their recent publication Azoulay et al. report that among patients who were denied 
ICU admission because they were considered too sick to benefit from the ICU, approxi-
mately one of four survived until hospital discharge; in contrast, among patients who were 
considered too well to benefit from ICU admission, one of ten patients eventually died 17. 
These results emphasise the need for a better specification of ICU admission criteria for 
haematological patients.
In addition, we feel that improved general ICU treatment options, such as those, for 
example, in sepsis and septic shock management 27 and in the field of mechanical (non)
invasive ventilation 28, as well as more specific applicable haematological treatments, 
such as anti-fungal drugs and more aggressive diagnostic strategies, account for the better 
outcome in general medical ICU patients 8. Such treatment options and diagnostic strate-
gies have contributed to an awareness that ICU admission may not be futile for critically ill 
haematological patients. Importantly, haematological treatment and ICU admission have 
an irrefutable impact on the perceived quality of life, which is increasingly considered to be 
a major measure of outcome. However, the quality of life after a 1-year rehabilitation period 
has been found to be below the average of that of a generally healthy population 29, while it 
appears to be similar in haematological and non-haematological patients admitted to the 
ICU and in haematological patients who were not treated in the ICU 30.
We found that severity of illness on ICU admission, expressed by the APACHE II score, did not 
change during the study period. This observation suggests that the increase in admission of 
patients with haematological diseases was likely the result of a change in admission policy 
over time and that haematological patients were not admitted earlier (and were not less 
severely ill) to the ICU. Recently, a significant association was demonstrated in critically ill 
cancer patients between early intervention prior to ICU admission before the development 
of severe organ failure and a decreased hospital mortality rate. This finding is in accordance 
with our observed association between mechanical ventilation and increased mortality. It 
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also highlights the importance of early identification of any decline in vital organ function 
as the usual reason for ICU admission in critically ill cancer patients is the need to support 
failing organs 31. The beneficial effects of earlier ICU admission and aggressive ICU treat-
ment were also suggested by Hampshire et al., who found an increased hospital mortality 
for patients with an increasing length of hospital stay prior to ICU admission and those 
with severe sepsis 18. Therefore, there may be room for improvement if guidelines for timely 
admission are established. An important role herein might be played by medical emergency 
outreach teams.
Several limitations to our study need to be addressed. Clinical registries, such as the NICE 
registry, provide unique opportunities to study very large cohorts over longer periods of 
time, as our study illustrates. Because of the large numbers, chance findings due to varia-
tions in case-mix are unlikely. However, the set of clinical variables that is recorded in the 
registry database must be determined beforehand; it will also often have limitations when 
specific subgroups, such as the haematological ICU population, are studied. A number 
of important confounding haematological variables, such as level of neutropenia, under-
lying haematological diagnosis, disease status and type and phase of haematological 
treatment, including whether or not haematopoietic stem cell transplant was performed, 
were not available for our analyses. Also, intensity and mucotoxicity of the applied chemo- 
therapeutical treatment determines the pattern of inflammatory response, irrespective of 
the presence of infection 32, and these issues are unknown in our patients.
Nevertheless, we were able to compare haematological subgroups with several other groups 
of severely ill patients for whom ICU admission is traditionally considered to be contro- 
versial. We were able to demonstrate changes in clinically relevant outcomes of haemato-
logical patients transferred to an ICU, as well as a significant decrease in mortality over the 
years, and to compare this trend with those of other specific patient groups. In our view, 
it would be useful to evaluate ICU admission policies with the aim to facilitate decision 
making regarding patient admission to ICUs and thereby help avoid situations in which 
patients who may benefit from intensive treatment are deprived of life-saving therapies. 
We advise caution in generalising the results of our study, as well as those of published 
studies, due to possible variations in ICU admission policy and levels of ICU care provided, 
as well as differences in discharge criteria and settings and timing for the implementation 
of end-of-life decisions 33.
CONCLUSIONS AND FUTURE RECOMMENDATIONS
The results of this observational study show that the critically ill haematological patients 
in our study cohort had a higher mortality rate than specific subgroups of non-haemato-
logical medical ICU patients, but a similar one to patients with solid tumours. In our study, 
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differences between groups were most pronounced in those patients that required mecha-
nical ventilation. We conclude that the hospital and ICU survival of haematological patients 
has improved over time in the Netherlands, similarly to that of non-haematological medical 
ICU patients and that leukocytopenia itself is not a predictor of mortality. Our results indi-
cate that intensive supportive care for patients with haematological malignancies should 
be available without delay, irrespective of the degree of leukocytopenia. Further research 
is needed to define the best timing for transfer to the ICU in order to provide the patient 
with the best chance of survival and to determine the influence of specific haematological 
conditions, such as graft versus host disease and disease status.
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ABSTRACT
OBJECTIVE
Long-term health related quality of life (HRQoL) was determined for patients admitted to the 
haematology ward who needed intensive care treatment (H-IC+) and compared with those 
who did not (H-IC-) as well as with that for patients admitted to the general ICU (nH-IC+).
METHODS
A cross-sectional study was carried out median 18 months after admission by employing 
the short form-36, checklist for individual strength, cognitive failure questionnaire and 
hospital anxiety and depression scale.
RESULTS
27 (79%) of the 34 H-IC+ patients approached, and 93 (85%) of the 109 H-IC- patients 
approached replied. Data were adjusted for relevant covariates and matched with those 
of 149 patients in the general ICU. Apart from the lower rolephysical functioning score for 
H-IC+ (p=0.04) no other differences were found between H-IC+ and H-IC-. Groups H-IC+ and 
nH-IC+ evaluated their HRQoL on SF-36 similarly, except for the lower aggregated physical 
component summary (PCS) for H-IC+ (p<0.0001). After adjusting for PCS, no significant 
differences in CIS, CFQ and HADS were observed between the groups.
CONCLUSIONS
Eighteen months after admission, patients treated for haematological malignancies 
reported similar HRQoL, whether or not they had received intensive care treatment, but 
reported a lower PCS than those of patients in the general ICU. Hence, there is no reason 
to assume that admission to the ICU has a negative impact on long-term HRQoL, so this 
should not affect the decision whether or not to transfer patients with haematological 
malignancies to the ICU.
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INTRODUCTION
Survivors of critical illnesses are frequently left with a legacy of long-term physical, neuro-
psychiatric and quality of life impairments 1. Patients who survive critical illness report 
significantly lower health related quality of life (HRQoL) after a year compared to their well 
being before intensive care unit (ICU) admission as well as that of the general population 2, 3.
 Treatment of patients with haematological malignancies has become increasingly 
intensive consisting of several cycles of high-dose chemotherapy, often followed by an 
allogeneic or autologous haematopoietic stem cell transplant (HSCT). As a consequence, 
these patients are at risk for critical illness. In the last decade the contribution of ICU’s 
during treatment of haematological malignancies has significantly improved 4. ICU physi-
cians have been successful in improving survival beyond the acute stage of critical illness 
by emphasizing the importance of early recognition of clinical deterioration. Improved 
insight into the treatment of sepsis and the introduction of non-invasive and protective 
positive pressure ventilation strategies to overcome respiratory failure have also played a 
role 5-7.
Long-term HRQoL of patients being treated for haematological malignancies is relevant to 
assist physicians in their decision whether or not to admit the patient to the ICU. Recent 
reports are conflicting, as both persistent impaired HRQoL 3 and restorement of HRQoL 
90 days following ICU discharge in 80% of survivors was determined 8. No comparisons 
to haematological patients that did not need intensive care and non-haematological ICU 
patients were made.
With the current study we aim to determine long-term selfreported HRQoL, including fatigue, 
cognitive functioning, anxiety and depression of patients being treated for a haemato- 
logical disease who were given intensive care and to compare these HRQoL scores with 
those of haematological patients who did not receive intensive care as well as those of a 
group of general medical ICU patients.
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PATIENTS AND METHODS
ETHICS STATEMENT
The Committee on Research Involving Human Subjects (Arnhem-Nijmegen region CMO) 
approved the study protocol (study number 2010/306) and waived the need for informed 
consent since the objective of this study was to evaluate regular patient care. Patient 
privacy was guaranteed as all data were anonimised and evaluated in a blinded fashion.
PATIENTS WITH HAEMATOLOGICAL DISEASE
All consecutive patients who were admitted for five days or more to our tertiary care medical 
centre for treatment of a haematological malignancy during a one year period were eligible 
for the survey. Survivors were divided into two groups depending upon whether or not they 
had been admitted to the ICU. A HRQoL questionnaire was sent to them a median of 18 
months after admission (range of 12-24 months). This same procedure was carried out twice 
on two consecutive years for those who were admitted to the ICU during treatment in order 
to enlarge the group (figure 1). Non-responders were sent a reminder six weeks later. Demo-
graphic and medical data were collected from the patient files.
Flowchart on inclusionFigure 1
142 pati ents
– 108 (died before inclusion)
34 questi onnaires sent
27 respondents
(79%)
431 pati ents
– 88 admissions <5 days
– 234 (died before inclusion)
Haematology pati ents
without ICU admission
(H-IC–)
November 2008 – November 2009
Haematology pati ents
with ICU admission
(H-IC+)
February 2008 – February 2010
General ICU pati ents
(nH-IC+)
February 2008 – February 2009
109 questi onnaires sent 401 pati ents
149 pati ents
93 respondents
(85%)
Matched with H–IC+ for
•  age
•  gender
•  APACHE II score
•  length of stay
285 respondents
(71%)
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GENERAL ICU PATIENTS
Data of general ICU patients without a haematological malignancy were retrieved from 
a group of 401 medical admission patients between February 2008 and February 2009. 
These patients were approached in a similar way as the haematological groups and non-re-
sponders were sent a reminder six weeks later. A total of 285 (71%) patients responded and 
149 of these were meticulously matched with their haematological ICU counterparts for age, 
gender, APACHE II score and ICU length of stay. The methods of HRQoL measurement for this 
group was similar to that for the haematological groups 9.
ICU CHARACTERISTICS
There was no explicit ICU admission policy at the time and the decision to admit a patient to 
one of the level 3 general ICUs was made by the senior haematologists and intensivists. ICU 
characteristics and reason for ICU admission were extracted from patient files.
QUESTIONNAIRES
The following four different validated questionnaires were used to measure health related 
quality of life. The short form-36 (SF-36) contains eight multi-item dimensions covering 
various aspects of physical, social, emotional and mental health. Missing values were 
imputed according to the health survey manual 10 and aggregated summary scores were 
expressed in a physical component summary (PCS) and a mental component summary 
(MCS) ranging between 0–100, a higher score indicating a higher level of functioning 11. 
The shortlist of the checklist individual strength-fatigue (CIS-fatigue), consisting of eight 
questions scoring on a 7-point Likert scale. The range of CIS-fatigue is 8–56, a higher score 
indicating more pronounced fatigue 12. The validated Dutch translation of the cognitive 
failure questionnaire (CFQ) is self-reported 13 and consists of 25 questions on memory, 
distractibility, social blunders and names 14. Each question was scored on a 5-point Likert 
scale. The total score on the CFQ ranges from 0–100, a higher score indicating more self-re-
ported cognitive impairment. The hospital anxiety and depression scale (HADS) is a 14-item 
self-reporting measure of psychological distress and widely used for cancer patients 15. The 
HADS has two subscales (anxiety and depression), each ranging from 0 to 21. Each item 
is rated on a scale from 0 (‘not at all’) to 3 (‘very much’) and higher scores indicate more 
anxiety and depression 16. The non-haematological ICU patients did not receive the HADS 
questionnaire.
Thus, our self-reported HRQoL survey consisted of a total of 83 questions. The data obtained 
were recoded and subsequently scored according to their manuals. To guarantee patients’ 
privacy, the survey was sent out anonymously and assigned a number. This allowed the 
primary and supervising investigator to match the returned survey with the patient’s registry 
number held in a separate confidential database.
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STATISTICAL ANALYSIS
All data were analyzed using SPSS version 20.0.0.1 (SPSS, Chicago, IL). The t-test was used 
for normally distributed variables, Mann-Whitney U test for variables that were not normally 
distributed and the Chi-square test for binary variables. Correlations between physical 
component summary and mental component summary were determined using Pearson’s 
correlation coefficient.
 Significant differences between the variables were considered as covariates. Since data 
were not normally distributed, a logtransformation was performed in order to perform a 
multivariate analysis of covariance. Since this was an exploratory study, and to increase 
sensitivity for putative differences between the groups, there was no correction for multiple 
testing. Statistical significance was defined as a p-value <0.05.
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RESULTS
CHARACTERISTICS OF PATIENTS WITH HAEMATOLOGICAL DISEASE
In total 573 patients were eligible, of which 143 patients could be approached for the 
study (figure 1). Mortality during this long-term follow-up was significantly higher for H-IC+ 
(108/142, 76%), compared to group H-IC- (234/431, 45%) (p<0.0001).
In H-IC+ 34 questionnaires were sent out and 27 questionnaires (79%) were completed, 
median 15 months [Inter Quartile Range (IQR) 12-20] following admission. The mean 
APACHE II score was 18.5±9.2 (table 1). In total 109 questionnaires were sent to haema-
tological patients that did not need ICU treatment and 93 questionnaires (85%) were 
completed, median 16 months [IQR 13-20] following admission. In both groups the propor-
tion of patients admitted for an allogeneic or autologous haematopoietic stem cell trans-
plant, chemotherapy or complications were comparable. No significant differences in 
demographic characteristics were found between the groups, except for the proportion of 
acute leukaemia/MDS which was higher in H-IC+ (p=0.008, table1). Hospital length of stay 
was significantly longer for H-IC+ (median 33 days [interquartile range 25-42]), compared to 
H-IC- (21 days [11-27], p<0.001) or nH-IC+ (18 days [10–37], p<0.001).
CHARACTERISTICS OF GENERAL ICU PATIENTS
In total 149 general ICU patients were matched with the haematological patients that 
needed ICU treatment. Twenty-six (17%) patients had a proven infection of which eighteen 
patients had a sepsis. The mean APACHE II score was 19±5.4 (table 1).
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Haematology pati ents 
with ICU admission
(n=27)
Haematology pati ents 
without ICU admission
(n=93)
General ICU pati ents 
(n=149)
Age 52.8 (±14.2) 53.5 (±13.3) 56.9 (±16.7)
Gender (M) 17 (63%) 54 (58%) 72 (48%)
APACHE II score 18.5 (±9.2) n.a. 19.0 (±5.4)
LOS-hospital (days) 33 [25-42]a 21 [11-27] 18 [10-37]b
LOS-ICU (days) 5 [2-10] n.a. 4 [2-10]
Diagnosis (n, %)
 – Acute leukaemia and MDS (AML, ALL 
and MDS)
13 (48)a 20 (22)
 – Malignant lymphoma (NHL, 
M.Hodgkin and M.Waldenström)
7 (26) 28 (30)
 – Multi ple myeloma 4 (15) 28 (30)
 – Chronic leukaemia (CML and CLL) 1 (4) 13 (14)
 – Other 2 (7) 4 (4)
Hospital admission reason (n, %)
 – Allogeneic HSCT (SIB, VUD and SIB-RIC) 6 (22) 15 (16)
 – Autologous HSCT 4 (15) 29 (31)
 – Non-HSCT chemotherapy 7 (26) 16 (17)
 – Complicati ons (aft er non-HSCT 
chemotherapy, aft er HSCT or without 
preceding treatment)
10 (37) 33(36)
Table 1 Demographic characteristi cs of responding pati ents with and without ICU admission
Data are expressed as mean with (±) standard deviati on or median with IQR unless other reported.
AML Acute myeloid leukaemia
ALL Acute lymphoblasti c leukaemia
MDS Myelodysplasti c syndrome
NHL Non-Hodgkin lymphoma
SIB Sibling donor
VUD Volunteer unrelated donor
SIB-RIC Sibling donor, reduced intensity conditi oning
a Stati sti cally signiﬁ cantly diﬀ erent (P<0.05) compared with haematology pati ents without ICU admission
b Stati sti cally signiﬁ cantly diﬀ erent (P<0.05) compared with haematology pati ents with ICU admission
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HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRES
Haematological diagnosis and length of hospital stay served as covariates for the SF-36 
analysis and were complemented by the Physical Component Summary as covariate for the 
analyses of CIS-fatigue, CFQ and HADS differences between the groups.
— Short Form-36
H-IC+ respondents reported a similar HRQoL to H-IC- in almost all domains of the SF-36, 
with the exception of a difference in the Role Physical dimension namely, H-IC+ reported 
more problems with work or other daily activities as a result of physical health (p=0.04) 
(table 2). Compared to nH-IC+, H-IC+ reported a lower score on the resulting aggregated PCS 
(p<0.001), while the aggregated MCS was not different between the groups. The results for 
the other domains of the SF-36 were similar (figure 2). No correlations were found between 
the PCS and MCS as Pearson correlation coefficients were r=0.22 for H-IC+ (p=0.30), r=0.14 
for H-IC- (p=0.90) and r=0.10 for nH-IC+ (p=0.28). Both H-IC+ and H-IC- survivors evaluated 
their HRQoL on several domains of the SF-36 worse compared with the age-adjusted general 
Dutch population of which the reference values are reflected in table 2.
SF-36† Haematology 
pati ents with ICU 
admission
(n=27)
Haematology 
pati ents without 
ICU admission
(n=93)
General ICU 
pati ents 
(n=149)
General populati on 
subgroup 
age 41-60¹¹
(reference values)
Physical functi oning 52.9 ±27.6 64.6 ±27.6 52.2 ±32.0 84.0 ±19.6
Role-physical 35.2 ±35.5a 40.3 ±42.8 38.0 ±41.1 74.5 ±36.8
Bodily pain 71.8 ±25.1 74.1 ±24.5 68.7 ±28.5 71.8 ±24.1
General health 45.6 ±21.5 46.3 ±23.4 48.8 ±22.0 69.7 ±20.6
Social functi oning 72.7 ±26.4 66.1 ±26.3 67.0 ±25.8 83.5 ±22.1
Vitality 56.0 ±16.7 54.7 ±20.5 54.3 ±19.6 68.6 ±20.2
Role-emoti onal 65.4 ±40.8 76.0 ±37.9 61.0 ±43.2 81.6 ±33.2
Mental health 75.4 ±19.0 74.0 ±17.7 68.8 ±19.2 75.6 ±18.5
Physical component summary 36.7 ±8.5 39.1 ±11.6 48.0 ±9.7b n.a.
Mental component summary 49.6 ±11.2 48.4 ±10.7 47.9 ±9.8 n.a.
Table 2 Results of Short Form-36 measurements median 16 months aft er ICU discharge, 
adjusted for covariates
Data are expressed as mean with (±) standard deviati on.
† Adjusted for diagnose acute leukaemia and MDS and LOS-in hospital using log transformed data (not shown)
a Stati sti cally signiﬁ cantly diﬀ erent (P<0.05) compared with haematology pati ents without ICU admission
b Stati sti cally signiﬁ cantly diﬀ erent (P<0.05) compared with haematology pati ents with ICU admission
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— Checklist individual strength-fatigue
No significant differences between H-IC+ and H-IC- or H-IC+ and nH-IC+ were found for self 
evaluated fatigue score after adjusting for covariates (table 3).
— Cognitive Failure Questionnaire
Cognitive failure was similar after adjusting for covariates on all measured cognitive dimen-
sions between H-IC+ and H-IC-. The overall cognitive functioning tended to be better for 
H-IC+ than for nH-IC+ (p=0.06) (table 3).
— Hospital anxiety and depression scale
Adjusted results showed no differences in anxiety or depression between H-IC+ and H-IC- a 
median 16 months after admission (table 3). For nH-IC+ were no data available.
Spider graph of the Short Form-36 measurements median 16 months 
aft er ICU discharge, adjusted for covariates
Physical functi oning
Vitality
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H–IC–
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Role - physicalMental component summary
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Figure 2
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Haematology pati ents with 
ICU admission
(n=27)
Haematology pati ents 
without ICU admission
(n=93)
General ICU pati ents 
(n=149)
CIS†Ж
CIS - total 31.4 ±12.8 28.8 ±13.4 33.3 ±13.9
CFQ†Ж
Memory 7.3 ±4.1 7.1 ±4.6 8.2 ±5.4
Distracti bility 10.2 ±5.9 10.8 ±5.6 11.7 ±6.9
Social blunders 6.0 ±4.1 6.5 ±3.8 7.9 ±5.4
Names 3.6 ±2.0 3.1 ±2.0 3.2 ±2.1
CFQ - total 27.5 ±16.0 26.7 ±13.8 28.8 ±16.0
HADS†Ж
Anxiety 5.4 ±5.2 4.9 ±4.2 n.a.
Depression 4.3 ±4.1 4.6 ±3.7 n.a.
HADS - total 9.4 ±8.9 9.5 ±7.2 n.a.
Table 3 Results of Checklist Individual Strength, Cogniti ve Failure Questi onnaire and 
Hospital Anxiety and Depression Scale.
Measurements median 16 months aft er ICU discharge, adjusted for covariates
Data are expressed as mean with (±) standard deviati on.
† Adjusted for diagnose acute leukaemia and MDS and LOS-in hospital using log transformed data (not shown)
Ж Adjusted for PCS
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DISCUSSION
The main finding of the present study is that a median of 18 months after admission to 
an ICU, patients who had been treated for a haematological disease and were admitted 
to an ICU experienced only a lower quality in the physical aspects of their life compared 
with those admitted to the ICU without a haematological disease. Patients treated for a 
haematological malignancy who had not been admitted to the ICU reported only better role- 
physical functioning. In addition, the long-term health related mental quality of life as well 
as fatigue, cognition, anxiety and depression was similar between the groups. As we did 
not correct for multiple testing, the small differences between groups appear not to be of 
clinical relevance.
It is likely that complications following haematological treatment and HSCT both influence 
physical functioning and the ability to perform social activities 17. The fact that the only 
differences in HRQoL concerned physical aspects may have been due to complications 
during haematological treatment that necessitated the ICU admission 18.
The recent publication by Oeyen et al 3, in which long-term quality of life was prospec-
tively assessed in haematological patients one year after ICU discharge, reports poor QoL 
outcomes at one year, particularly for the haematological subgroup. However, physical 
complications of haematological treatment are likely to be related to the severity of the 
underlying disease, its treatment and need for more rigorous ICU therapy and seem to 
require longer rehabilitation periods than one year and also exceeds the median 18 months 
reported in our current study. This is what may distinguish patients with haematological 
malignancies from general ICU patients and seems confirmed in a recent study 19 where 
the PCS at five years post-HSCT was similar to those of nH-IC+ in our study at 18 months. 
These studies represent the limited amount of evidence available on long-term HRQoL. ICU 
survival and subsequent hospital survival have improved the past decade to such extent 
that long-term HRQoL becomes more important in the decision to admit or not admit a 
critically ill patient to the ICU. Our finding that long-term HRQoL is comparable in haema-
tological patients with and without an ICU admission is of relevance. This emphasizes the 
need for more long-term HRQoL studies that may correct the assumption that patients 
should not be admitted to the ICU assuming that the long-term outcome will be poor.
The absence of any correlation between the physical and mental component summary 
scores in all subgroups is remarkable, but has been described earlier 20. Curbow et al found 
that recipients of stem cell transplant reported more positive changes in relationship and 
existential/psychological domains and more negative changes in the physical health 
domain 21. The same has been observed for survivors of meningococcal septic shock, who, 
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despite suffering from severe skin scarring or extensive amputation, did not show more 
behavioural problems as predictor for poorer HRQoL, nor more cognitive dysfunction 22. In 
fact, cancer survivorship is a well-recognized phenomenon in which patients confronted 
with a life threatening illness are faced with the necessity to accommodate to the disease 
leading to acceptance of and adjustment to the illness 23. These patients might experience 
a similar condition higher than they would have if they had not experienced a serious 
illness 24.
The strength of the current study is the explorative character and clinical relevance of the 
results, comparing H-IC+ with both H-IC- and nH-IC+ patients. However, there are also rele-
vant limitations that need to be addressed. Despite the high response rate on the question-
naires, the possibility of non-response bias 25 cannot ruled out. Also the study was under-
taken in such a specific population that only a relatively small number of patients could be 
analyzed. As a consequence, it was not feasible to analyze data for the subgroup of allo-
geneic HSCT recipients who may be more likely to experience treatment-related physical 
complications such as graft-versus-host-disease (GvHD), that are known to influence 
HRQoL 26. The type of conditioning regimen, female gender, younger age, inadequate social 
support and pre-transplant psychological distress have also been reported to be predictors 
for a poorer HRQoL following HSCT 27. Disease status and performance status preceding 
intensive treatment for haematological diseases can usually be assumed to be good to be 
qualified, but further baseline characteristics such as social status and pre-existing distress 
could not be considered as the study was retrospective. Moreover, we only measured 
HRQoL once where serial measures would have been more informative on changes over 
time. Nevertheless, patients with haematological malignancies form a unique subpopu-
lation of ICU patients and our cohort represents one of the largest with long-term HRQoL 
evaluations currently available. This is increasingly becoming considered to represent a 
relevant measure of outcome.
CONCLUSIONS
In conclusion, there is no support for the assumption that patients undergoing treatment 
for a haematological malignancy who are admitted to the ICU have a worse long-term HRQoL 
than those who are not. Therefore the risk of a poorer long term quality of life should no 
longer be used as an argument not to admit these patients to the ICU.
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SUMMARY
High-dose chemotherapy alone or combined with radiotherapy, followed by haematopoietic 
stem cell transplantation (HSCT) is, in many cases, still the only way to cure haematological 
malignancies. Such treatment is known to cause serious toxicity including bone marrow 
aplasia, mucosal barrier injury and inflammation as well as infection that might escalate to 
life-threatening septic shock. Treatment consists of adequate and timely antimicrobial and 
supportive care that requires early detection, selection and action.
To address the question ‘Can we further improve our standards of care in the management 
of fever in neutropenic haematological patients?’, the first part of this thesis focussed on 
the initial management of the febrile neutropenic haematological patient. Chapter 2 sought 
answer to the question how to detect fever immediately at its onset when patients are 
hospitalised for intensive chemotherapy, since fever is still regarded the most important 
way of identifying an inflammatory process during neutropenia 1 and clinical practice guide-
lines focus on prompt institution of empirical broad-spectrum antibacterial therapy 2, 3. We 
described the results of an audit performed in allogeneic HSCT recipients in which the body 
temperature was determined by the standard method via the axilla compared to that using 
a device that measures temperature continuously via the groin since this is most likely 
to be isolated from outside air. We found that patients experienced only slight problems 
with the device over time and that the values of both methods correlated well. Moreover, 
empirical antibacterial therapy could be started 2.5 hours sooner as a result of the earlier 
detection of fever using this device. Chapter 3 focussed on the initiation of empirical anti-
bacterial treatment at the onset of fever during neutropenia. An audit was performed on the 
haematology ward to determine whether there was any delay in starting antibiotic treat-
ment and to define the main reasons for this delay. Based on that evaluation, standing 
orders for initiating antibacterial treatment and a new approach to taking blood cultures 
were developed, implemented and evaluated with respect to short- and long-term impli- 
cations. In the initial audit, the mean time interval between the onset of fever and the 
administration of antibacterial therapy was 75 minutes (standard deviation(SD) ±46.1). This 
could be shortened significantly to 32 minutes (SD±17.6) by implementing the modified 
protocol. Chapter 4 explored the value of two instruments developed to detect changes 
in vital signs that occur during systemic inflammation. We found that the Modified Early 
Warning Score, R-MEWS adopted by the Radboud University Medical Center, was practical 
and appeared promising as a tool to determine clinical deterioration following the systemic 
inflammation that occurs after treatment with intensive chemotherapy. As inflammation can 
be caused by bacterial infection, a cohort of 439 HSCT recipients was analysed in Chapter 
5 to determine the incidence of Gram-positive bacteraemia and thrombo-embolic events 
associated with the use of central venous catheters (CVC). The incidences of persistent 
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coagulase-negative staphylococcal (CoNS) bacteraemia, symptomatic thrombosis and 
thrombophlebitis were 25%, 9.6% and 6.6%, respectively. The duration of neutropenia 
(odds ratio (OR) 1.02) and left-sided placement of the CVCs (OR 1.73) were independent 
risk factors significantly associated with the occurrence of persistent CoNS bacteraemia, 
whereas the use of less mucotoxic conditioning regimens was associated with a lower risk 
(HDM/BEAM versus other regimens, OR 0.24). Use of Total Body Irradiation, persistent 
CoNS bacteraemia and tip colonisation were all significantly associated with an increased 
risk of symptomatic thrombosis (OR 6.0, 3.4 and 2.8, respectively). The risk factors found 
in this cohort of HSCT recipients differed from those found in the general cancer popu-
lation, suggesting an important role for persisting bacteraemia in the pathogenesis of 
CVC-associated thrombosis in haematological patients.
Patients with cancer were generally not considered to benefit from ICU treatment but recent 
publications report a marked improvement of ICU survival of patients with solid tumours 
as well as those undergoing intensive haematological treatment including haemato- 
poietic stem cell transplantation. Currently, ICU admission policies are being developed for 
this population. To address the question ‘What are the trends in ICU admissions of critically 
ill haematological patients and what is their outcome?’, the second part of the thesis 
focussed on the outcome over time of critically ill haematological patients who required 
ICU admission. Chapter 6 explored trends in outcome of allogeneic HSCT recipients trans-
ferred to the intensive care unit in a Dutch tertiary care hospital. All patients who had 
received an allogeneic HSCT between 2004 and 2010 were included in the analyses. Base-
line and outcome characteristics were compared and risk factors for ICU admission and 
survival were identified. Changes in outcome over time of three cohorts of HSCT recipients 
were investigated. This showed that transplantation from an unrelated donor and myelo- 
ablative conditioning treatment were significant risk factors for ICU admission. Prolonged 
use of vasopressors, invasive mechanical ventilation and male gender were significant 
predictors for ICU mortality, while the presence of neutropenia and graft-versus-host disease 
were not. Over the years, APACHE II severity of illness scores at ICU admission remained 
unchanged (21.0±7.1, 20.1±5.6, 21.2±6.6), while the 100 day post-transplant mortality of 
patients who were transferred to the ICU significantly decreased from 78% (2004/2005) 
to 57% (2006/2007) and 35% (2008/2009). Chapter 7 explored trends over time in admis-
sion prevalence and outcome of 1,741 critically ill haematological patients admitted to 
ICUs in the Netherlands and entered into the National Intensive Care Evaluation database 
and compared these trends to those of several subgroups of patients suffering from other 
severe diseases, that were also admitted to the ICU. Trends over time and differences 
between two subgroups of haematological medical ICU patients and four subgroups of 
non-haematological medical ICU patients were assessed, as well as the influence of leuco-
penia. Over the years, the risk-adjusted hospital mortality rate significantly decreased in 
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both the haematological and non-haematological group with an OR of 0.93 (95%CI 0.92–
0.95) per year. After correction for case-mix using the APACHE II score at ICU admission, a 
leucocyte count <1.0x109/L was not a predictor of mortality for haematological patients (OR 
0.86; 95%CI 0.46–1.64). We found no case-volume effect of ICU admissions on mortality for 
haematological ICU patients. While mortality is significantly higher in the haematological 
group of medical ICU patients than in subgroups of non-haematological patients, the former 
showed a similar decrease in raw and risk-adjusted mortality rate over time, while leuco-
penia was not a predictor of mortality. In Chapter 8, the long-term health related quality of 
life (HRQoL) was determined in a single centre tertiary hospital, for patients admitted to the 
haematology ward who needed intensive care treatment and compared to those who did 
not as well as with that for non-haematological patients admitted to the general ICU. Data 
were adjusted for relevant covariates and matched with those of 149 patients admitted in 
a general ICU. Eighteen months after admission, patients treated for haematological malig-
nancies who needed intensive care reported similar HRQoL compared to haematological 
patients that did not. Nevertheless, a lower Physical Component Summary was reported 
compared to non-haematological patients of the general ICU. Hence, there is no reason to 
assume that admission to the ICU has a negative impact on long-term HRQoL of patients 
with a haematological malignancy, so this assumption should not affect the decision to 
withhold transferring patients with haematological malignancies to the ICU when necessary.
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Failure to recognise and appropriately respond to signs of inflammation/infection in 
patients treated for haematological malignancies who are clinically deteriorating is clearly 
a clinically relevant issue. A 3-step approach was proposed to address this.
STEP 1 — TO DETECT (PREDICTORS OF) CLINICAL DETERIORATION AT THEIR ONSET
The overall care and outcome of patients with cancer, especially haematological 
malignancies, have improved significantly over the years 4, not in the least because of better 
diagnosis and management of systemic inflammation due to cytotoxic treatment whether 
or not accompanied by opportunistic infections. Further improvement depends on tracking 
and tracing signs of clinical deterioration due to sepsis as early as possible.
Recent literature provides better information about which patients are most likely to suffer 
from haematological and mucosal toxicity 5. Therefore intensified monitoring of vital signs 
is required because of expected clinical deterioration where early recognition is of vital 
interest. This requires an individual monitoring plan in which the frequency of vital signs 
measurements can be increased up to continuous measurements for high risk patients. 
When temperature measurements are unreliable, for example during steroid treatment, it is 
important to monitor changes in other vital signs as well.
During neutropenia, respiratory insufficiency is the main indication for ICU admission. So, 
respiratory rate, oxygen saturation, but also other early signs of sepsis including hypo- 
tension and tachycardia should be monitored during the whole period of risk. In the near 
future this may be expanded to other parameters such as blood viscosity 6 or biomarkers 
7. Innovative technology may help such as wireless devices and other e-tools that monitor 
vital signs continuously without hindering patient mobility.
The onset of fever is more or less predictable for certain cohorts and tends to present 
outside office hours. It was shown that initiation of empirical antibacterial treatment by 
nurses is safe and effective as it averts serious delays in the start of sepsis resuscitation 
bundles. Moreover, the continuous presence of nurses, who are familiar with patients’ 
baseline characteristics, may further improve the adequate guideline-based initial treat-
ment of early sepsis, especially if the following suggestions are taken into account.
FUTURE PERSPECTIVES
1. Define risk periods individually, per treatment, based on: underlying disease, type of 
treatment and comorbidity. During the risk periods intensified monitoring of vital signs is 
warranted in order to initiate the sepsis resuscitation bundle at the first sign of sepsis.
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2. Develop and validate minimal invasive means to continuously monitor inflammation 
and organ dysfunction, such as body temperature, respiratory and haemodynamic 
changes.
3. Nurses should have delegated authority to initiate treatment of inflammation/
infection when changes in any of the vital signs is detected, to avoid any delay. 
Appropriate protocols and guidelines need to be developed and evaluated and 
knowledge and skills should be guaranteed by adequate education.
STEP 2 — TO SELECT THOSE AT RISK FOR CRITICAL ILLNESS AS EARLY AS POSSIBLE
The management of critically ill cancer patients requires specialized skills of professionals 
and close collaboration between the intensivist and haematologist. The improvement in 
the outcome of critically ill cancer patients is, to a certain extent, the direct result of better 
multidisciplinary collaboration between intensive care and haematology wards. ICU clini-
cians are more experienced in setting aims of critical care based on the presence of organ 
failure and the potential to reverse this. In case of clinical deterioration, the medical emer-
gency team (MET) should be aware of how vulnerable the patient with a malignant disease 
is and not wait too long to decide that intensive care treatment is warranted. A clear institu-
tional protocol will improve the outcomes for these patients.
ICU admission criteria for patients with or without haematological malignancies are essen-
tially the same but it might be important to take into account the risk of rapid clinical 
deterioration associated with severe neutropenia. There is a need for a specific instrument 
to predict clinical changes in the haematological neutropenic population. Neither R-MEWS 
nor APACHE seem sufficient for this purpose. The change in R-MEWS over time (Δ R-MEWS) 
might prove a better instrument but further clinical studies are required.
FUTURE PERSPECTIVES
1. Adequate selection of those at risk for critical illness is needed to define tailor-
made monitoring plans, leading to an improved track-and-triggering system defined 
specifically for the population and to grade clinical changes aiming to detect and treat 
respiratory and haemodynamic changes before becoming irreversible.
2. As such, close collaboration between intensivists and haematologists is needed to 
increase the expertise required for all aspects of the general management of patients 
with haematological malignancies and to provide optimal care to this population.
3. More studies are needed to provide more insight into the relevance of type and status 
of malignancy, the timing and reason for admission to the ICU, and to determine the 
impact of the nature and number of organ failure for the prediction of the outcome of 
patients admitted to the ICU. 
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4. Interventional studies are also needed to demonstrate the potential benefit of a given 
approach, e.g. use of specific admission and discharge criteria.
STEP 3 — ACTION; ADEQUATE EN TIMELY
The APACHE II severity-of-illness scores taken on admission of patients with haematological 
malignancies who were transferred to the ICU were quite high, being approximately 21 in 
our single-centre study 8 and 24 in the national ICU evaluation database 9. A higher APACHE 
score is also associated with a poorer prognosis, but does not necessarily translate this 
into a quantitative and individual chance of survival 10. Referral at an earlier stage of clinical 
deterioration may prove more effective by providing a better chance of survival and a reduc-
tion in the number of unplanned ICU days 11. The Slippery Slope diagram (figure 1) shows 
how to intervene in the process of patient deterioration with two key interventions, namely 
Clinical Review and Rapid Response 12.
In situations when a patient can stay in the haematology unit, the medical and nursing staff 
should be aware of the critical condition of this specific patient. Meticulous evaluation two 
or three times daily with appreciation of the different organ systems and vital signs should 
be performed.
Graphical view of the natural course of clinical deteriorati on (adapted from 
dr. Charles Hawkhurst Pain at the 2014 Managing the Deteriorati ng Pati ent Conference)
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FUTURE PERSPECTIVES
1. Multidisciplinary training for the initial treatment of respiratory insufficiency, as the 
major indication for ICU referral, should be mandatory for medical and nursing staff on 
haematology wards where high-risk patients (like those with acute myeloid leukaemia 
or HSCT recipients) are treated. All staff members should be familiar with applying the 
basic principles of airway management including oxygen administration and the first 
steps of basic life support.
2. Earlier ICU referral resulting in lower severity-of-illness on ICU admission should be 
encouraged at the onset of organ failure and preferably before treatment with inva-
sive ventilation or vasopressor medication is inevitable. For some malignancies, 
where deterioration due to disease or initial treatment (caused by e.g. tumour lysis 
syndrome or diffuse intravascular coagulation) can be expected, there might be indi-
cation to start treatment under strict monitoring already on an ICU.
3. In case a patient is transferred to an ICU, continuity of care and cure should be 
guaranteed favourably by using the same (electronic) patient file, evidence based 
checklists e.g. on antibacterial treatment or transfusion and mutual multidisciplinary 
consultation at least once daily.
4. More studies should focus on the impact of structural multidisciplinary rehabilitation 
programs immediately following ICU admission, critical illness and ICU care on the 
long-term survival of patients with cancer, including performance status, quality of life 
and ability to receive further treatment for the underlying malignancy.
MAIN MESSAGE
We fully endorse that ICU admission should not be withheld from critically ill patients with 
haematological malignancies. Therefore, it is crucial that the critical illness which requires 
monitoring or organ support, is detected at its onset and treated adequately at the earliest 
stage with the intention of limiting further damage to organ systems so as to provide the 
best possible chance of survival and recovery within a limited rehabilitation period.
 In order to achieve this, evidence-based guidelines should be developed to provide 
uniformity concerning the detection of the onset of critical illness when patients are still 
on the haematology ward, the selection of patients, as well the timing of consulting an 
intensivist or medical emergency team as the timing of ICU admission and action taken to 
provide adequate treatment of severe sepsis and septic shock and any necessary intensive 
supportive care.
 To strive for optimal illness-related survival rates while maintaining an acceptable quality 
of life, we need to learn more about optimal detection and treatment of inflammation and 
sepsis, how to better select patients who are actually offered ICU treatment and the time-
frames within which adequate action should take place to provide the best healthcare in the 
best equipped location for these purposes. Future studies should aim to provide guidance 
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to clinicians to allow timely decisions to be made about whether ICU care is required, e.g. 
to develop a prognostic tool in which the phase of treatment and haematological disease 
status are incorporated, to minimise unnecessary procedures.
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SAMENVATTING
Hoge dosis chemotherapie gevolgd door een hematopoëtische stamceltransplantatie 
(HSCT) is voor veel patiënten nog steeds de enige kans om van een hematologische malig-
niteit te genezen. Een dergelijke behandeling gaat vaak gepaard met ernstige toxiciteit 
waaronder beenmergaplasie en beschadiging van de slijmvliesbarrières. Daarnaast treedt 
inflammatie op en hebben patiënten een verhoogde kans op infectie. Deze infectie kan 
zich ontwikkelen tot een septische shock, een levensbedreigende situatie. De behande-
ling bestaat uit antimicrobiële behandeling gecombineerd met supportieve zorg en vereist 
onmiddellijke detectie van de eerste signalen van sepsis, bij een vroege en juiste selectie 
van patiënten die daar voordeel van zullen hebben.
Het eerste deel van dit proefschrift richt zich op de behandeling van de neutropene hemato-
logische patiënt met koorts. Om de vraag ‘Kunnen we de zorg voor febriele neutropene pati-
enten die worden behandeld voor een hematologische maligniteit nog verder verbeteren?´ 
te beantwoorden, zochten we in hoofdstuk 2 naar een methode om koorts meteen bij het 
ontstaan ervan te kunnen detecteren. Koorts wordt in de neutropene fase namelijk nog steeds 
beschouwd als de belangrijkste aanwijzing voor een systemisch inflammatoir proces  1. 
Klinische richtlijnen benadrukken het onmiddellijk starten met empirische breed-spectrum 
antibacteriële therapie bij neutropene patiënten met koorts 2, 3. Wij beschreven een pilot 
waarbij op twee manieren de lichaamstemperatuur werd gemeten bij 33 patiënten die een 
allogene HSCT ondergingen. De lichaamstemperatuur werd zowel gemeten met de stan-
daard axillaire methode vijf keer per dag alsmede met een sensor in de lies die continue de 
temperatuur weergaf en alarmeerde bij de vooraf ingestelde grenswaarde. Patiënten gaven 
aan slechts in geringe mate hinder te ondervinden van de continue metingen. We vonden 
een goede correlatie tussen de waarden van deze twee methoden. Bovendien vond dankzij 
de continue temperatuurmetingen een snellere detectie van koorts plaats en kon de empi-
rische antibacteriële therapie 2,5 uur eerder worden gestart. Hoofdstuk 3 was gericht op het 
proces van starten met empirische antibacteriële behandeling nadat bij een patient koorts 
was gedetecteerd. We onderzochten op verpleegafdeling hematologie middels een eerste 
audit of er sprake was van vertraging bij het starten van een behandeling met antibiotica, 
om daarna de mogelijke oorzaken te onderzoeken. Op basis van de resultaten van deze 
evaluatie werd een gedelegeerde opdracht voor het starten van antibacteriële behande-
ling door verpleegkundigen ontwikkeld alsmede een nieuwe werkwijze voor het afnemen 
van bloedkweken. Beide interventies werden vervolgens geïmplementeerd en zowel na zes 
maanden als vier jaar opnieuw geëvalueerd. In de initiële audit was de gemiddelde tijd 
tussen het optreden van koorts en de eerste toediening van levensreddende antibacteriële 
therapie 75 minuten. Deze tijd werd aanzienlijk verkort tot 32 minuten door de correcte 
uitvoering van het gewijzigde protocol. Hoofdstuk 4 onderzocht de bruikbaarheid van een 
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Modified Early Warning Score (MEWS), een instrument dat wordt gebruikt om klinisch rele-
vante verandering te herkennen gebaseerd op verandering van de vitale functies. In deze 
studie vergeleken we de waarde van de R-MEWS (de MEWS zoals deze in het Radboudumc 
wordt toegepast) met het aantal Systemic Inflammatory Response Syndrome (SIRS) criteria 
dat optrad tijdens de neutropene koortsepisode van 113 patiënten, gedurende de behan-
deling van een hematologische ziekte. We vonden dat de waarde van de R-MEWS goed 
correleert met het aantal SIRS-criteria en veelbelovend is als indicator om patiënten met 
een verhoogd risico op ontwikkeling van sepsis te selecteren.
Omdat een inflammatoire respons zowel kan worden veroorzaakt door slijmvliesbescha-
diging ten gevolge van de cytotoxische therapie als door een bacteriële infectie werd een 
cohort van 439 HSCT-patiënten geanalyseerd in hoofdstuk 5. Centraal veneuze katheters 
(CVK’s) worden vaak gebruikt als veneuze toegang bij patiënten die worden behandeld met 
een hoge dosis chemotherapie om de gevolgen van de slijmvliesbeschadiging (mucositis) 
te kunnen behandelen. Het gebruik van een CVK is echter een risicofactor voor infectie 
met onder meer coagulase-negatieve Stafylococcen (CoNS) en Staphylococcus aureus en 
kan zelfs leiden tot trombose. Het doel van de studie was om de incidentie van Gram-po-
sitieve bacteriëmie en trombo-embolische gebeurtenissen, gerelateerd aan het gebruik 
van centraal veneuze katheters, te bepalen. De incidentie van persisterende (in 2 of meer 
opeenvolgende kweken aanwezige) CoNS bacteriëmie, symptomatische trombose en trom-
boflebitis was respectievelijk 25%, 9,6% en 6,6%. De duur van neutropenie (odds ratio (OR) 
1,02 per dag) en linkszijdige plaatsing van de centraal veneuze katheter (OR 1,73) werden 
als onafhankelijke risicofactoren significant geassocieerd met het optreden van persiste-
rende CoNS bacteriëmie. Het gebruik van minder mucotoxische conditioneringsschema’s 
werd juist geassocieerd met een lager risico (HDM / BEAM versus andere regimes, OR 0,24). 
Het gebruik van totale lichaamsbestraling, persisterende CoNS bacteriëmie en kathetertip 
kolonisatie waren allemaal significant geassocieerd met een verhoogd risico op sympto-
matische trombose (OR 6,0, 3,4 en 2,8 respectievelijk). De risicofactoren in dit cohort van 
HSCT-patiënten suggereren een belangrijke rol voor persisterende bacteriëmie in de patho-
genese van CVK-geassocieerde trombose bij hematologische patiënten.
Van patiënten die behandeld worden voor kanker werd lange tijd gedacht dat ze geen 
voordeel zouden hebben van een behandeling op een intensive care (IC). Recente publi-
caties melden echter een verbetering van de IC-overleving van zowel patiënten met solide 
tumoren als patiënten die een intensieve hematologische behandeling zoals hematopo-
ietische stamceltransplantatie hebben ondergaan. Om de vraag te kunnen beantwoorden 
‘Welke trends zijn er met betrekking tot de behandeling van ernstig zieke patiënten met 
hematologische maligniteiten op een intensive care afdeling?’ richt het tweede deel 
van het proefschrift zich op de veranderende uitkomsten van IC-opname. Hoofdstuk  6 
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onderzocht trends in de uitkomst van allogene HSCT-patiënten die werden opgenomen 
op de intensive care van een tertiair centrum, te weten het Radboudumc. Alle patiënten 
die een allogene HSCT hadden ondergaan tussen 2004 en 2010 zijn opgenomen in de 
analyses. Baseline kenmerken en uitkomsten van de IC-behandeling werden vergeleken 
en risicofactoren voor een IC-opname en overleving werden geïdentificeerd. Hieruit 
bleek dat zowel een HSCT met stamcellen van een niet-verwante donor als myeloabla-
tieve conditionering belangrijke risicofactoren voor IC-opname waren. Langdurig gebruik 
van vasopressoren en invasieve beademing op de IC alsmede het mannelijk geslacht 
bleken significante voorspellers voor overlijden op de IC, terwijl de aanwezigheid van 
neutropenie en graft-versus-host ziekte bij opname op de IC dat niet was. In de loop der 
jaren bleef de ziekte-ernst bij opname op een IC volgens APACHE II (Acute Physiology And 
Chronic Health Evaluation) vergelijkbaar, waarbij de transplantatie gerelateerde morta-
liteit van HSCT-patiënten daalde van 78% (2004/2005) naar 57% (2006/2007) en 35% 
(2008/2009). Mogelijk is er verdere winst te behalen door het aanpassen van IC-opna-
mecriteria. Hoofdstuk 7 onderzocht trends in de tijd in de prevalentie en mortaliteit van 
1741 hematologische patiënten die werden opgenomen op een IC in Nederland tussen 
2004 en 2012. Gegevens die in de Nationale Intensive Care Evaluatie (NICE) databank 
waren ingevoerd werden geanalyseerd en vergeleken met vier subgroepen van patiënten 
die ook waren opgenomen op een IC, te weten patiënten met solide tumoren, chronische 
levercirrose, chronisch hartfalen en overige medische IC-patiënten. Veranderingen in de 
tijd en verschillen tussen de twee hematologische subgroepen en vier subgroepen van 
niet-hematologische patiënten werden beoordeeld, evenals de invloed van leukopenie. 
In de loop der jaren daalde het voor risico gecorrigeerde ziekenhuis sterftecijfer aanzien-
lijk voor zowel de hematologische als niet-hematologische groep met een OR van 0,93 
per jaar. Na correctie voor de relevante klinische kenmerken van de populatie met behulp 
van de APACHE II score bleek dat een leukocyten aantal van kleiner dan 1,0x109 / L geen 
voorspeller was van mortaliteit voor hematologische patiënten (OR 0,86). We vonden 
bovendien geen volume-effect op de mortaliteit voor de hematologische IC-patiënten. 
We concludeerden dat de mortaliteit significant hoger was in de groep van hematologi-
sche patiënten dan in de subgroepen van niet-hematologische patiënten, waarbij beide 
groepen een vergelijkbare afname in zowel het ruwe als het risico gecorrigeerde sterfte-
cijfer lieten zien en leukopenie geen voorspeller bleek van mortaliteit. In hoofdstuk 8 werd 
gekeken naar de aan gezondheid gerelateerde kwaliteit van leven (QoL), 18 maanden na 
een opname op de IC tijdens behandeling van een hematologische ziekte. Dit werd verge-
leken met de QoL van hematologische patiënten die geen IC-opname nodig hadden, en 
ook met die van niet-hematologische patiënten die werden opgenomen op de IC. De gege-
vens werden gecorrigeerd voor relevante co-variaten en gematched op leeftijd, geslacht, 
APACHE II score en opnameduur met die van 149 patiënten die waren opgenomen op een 
algemene IC. Achttien maanden na de opname gaven patiënten die behandeld werden 
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voor hematologische maligniteiten en IC-zorg nodig hadden gehad, een vergelijkbare QoL 
aan in vergelijking met hematologische patiënten die geen IC-opname nodig hadden. 
Er werd wel een lagere Physical Component Score (verzamelscore van de fysieke items 
van de vragenlijst) gerapporteerd in vergelijking met niet-hematologische patiënten. We 
vonden dat er geen reden is om aan te nemen dat opname op de IC een negatief effect 
heeft op de ervaren Qol van patiënten met hematologische maligniteiten, 18 maanden na 
de IC-opname. We concluderen dat deze aanname niet van invloed zou moeten zijn op de 
beslissing om patiënten met hematologische maligniteiten over te plaatsen naar een IC 
wanneer dat nodig is.
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ALGEMENE DISCUSSIE EN TOEKOMSTPERSPECTIEVEN
Het niet of te laat herkennen van tekenen van ontsteking / infectie of niet adequaat reageren 
bij patiënten die klinisch verslechteren tijdens de behandeling van een hematologische 
maligniteit is een klinisch relevant probleem. Een 3-staps-benadering wordt voorgesteld 
om dit te verbeteren:
STAP 1 – ONMIDDELLIJKE DETECTIE VAN (VOORSPELLERS VAN) KLINISCHE VERSLECHTERING
De zorg voor en de uitkomsten van patiënten met kanker, met name hematologische malig-
niteiten, is aanzienlijk verbeterd de afgelopen jaren 4, niet in het minst door de verbeterde 
diagnostiek en behandeling van systemische inflammatie die optreedt als een direct gevolg 
van de cytotoxische behandeling. Verdere verbetering is mogelijk door het zo vroeg moge-
lijk traceren en behandelen van klinische verslechtering voordat deze resulteert in multi-or-
gaan falen.
Recente literatuur laat zien welke patiëntengroepen het grootste risico lopen op hemato-
logische en mucosale toxiciteit 5 die leidt tot koorts en klinische verslechtering. Intensie-
vere controle van de vitale functies is nodig omdat bij klinische verslechtering vroegtijdige 
herkenning van vitaal belang is. Dit vereist een individueel plan voor monitoring van de 
vitale functies, waarbij de frequentie van metingen kan worden opgebouwd tot continue 
metingen bij patiënten in de risicoperiode. Hierbij moet er rekening mee worden gehouden 
dat temperatuurmetingen onbetrouwbaar kunnen zijn, bijvoorbeeld tijdens een behande-
ling met corticosteroïden, waardoor het belangrijk is om ook veranderingen in andere vitale 
functies nauwgezet te volgen. 
Tijdens een periode van neutropenie is respiratoire insufficiëntie de belangrijkste risi-
cofactor voor een IC-opname. Ademhaling en zuurstofsaturatie, maar ook andere vroege 
tekenen van sepsis waaronder hypotensie en tachycardie moeten in de gaten worden 
gehouden tijdens de gehele risicoperiode. Het gebruik van innovatieve technologie zoals 
draadloze apparatuur en andere e-tools die vitale functies voortdurend controleren zonder 
van invloed te zijn op de bewegingsvrijheid van patiënten kan hierbij van waarde zijn.
De periode waarin koorts optreedt is redelijk voorspelbaar en gebeurt veelal buiten kantoor-
uren waardoor niet altijd direct een arts beschikbaar is. Er werd in hoofdstuk 3 aangetoond 
dat het starten met empirische antibacteriële behandeling door verpleegkundigen veilig en 
effectief is en vertraging in het opstarten van de sepsisresuscitatiebundels kan voorkomen. 
Bovendien pleit de 24-uurs aanwezigheid van verpleegkundigen, die vertrouwd zijn met de 
uitgangskenmerken van de patiënt, voor een grotere rol in het initiëren van de behandeling 
van sepsis. Hiertoe worden de volgende suggesties gedaan.
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AANBEVELINGEN
1. De te verwachten risicoperiode definiëren voor elke patient op basis van onder-
liggende ziekte, type behandeling en comorbiditeit. Tijdens deze risicoperiode is 
intensieve bewaking van vitale functies noodzakelijk om de sepsisresuscitatiebundel 
te kunnen starten bij de eerste tekenen van sepsis.
2. Het ontwikkelen en valideren van minimaal invasieve apparatuur om de eerste 
signalen van ontsteking en het ontstaan van orgaanfalen zoals verandering van 
lichaamstemperatuur, ademhaling en hemodynamische veranderingen continu 
inzichtelijk te hebben met een minimale beperking van de bewegingsvrijheid van de 
patient.
3. Verpleegkundigen moeten de gedelegeerde bevoegdheid hebben om de initiële 
behandeling van ontsteking / infectie op te starten, zodra er een verandering in een 
van de vitale functies wordt gedetecteerd, om vertraging te voorkomen. Passende 
protocollen en richtlijnen moeten daartoe worden ontwikkeld en geëvalueerd. Kennis 
en vaardigheden van verpleegkundigen moeten door adequaat onderwijs worden 
gegarandeerd.
STAP 2 - ZO VROEG MOGELIJK SELECTEREN WELKE PATIËNTEN RISICO LOPEN
De zorg voor ernstig zieke kankerpatiënten vereist specialistische vaardigheden van profes-
sionals en een nauwe samenwerking tussen de intensivist en hematoloog. De verbetering 
in de uitkomsten van intensive care opnames bij patiënten met kanker is tot op zekere 
hoogte het directe gevolg van betere multidisciplinaire samenwerking tussen intensive care 
en hematologie afdelingen. IC-artsen hebben deskundigheid en ervaring in de zorg voor 
patiënten met orgaanfalen en de mogelijkheden om deze te behandelen. In het geval van 
beginnende klinische verslechtering, moet het Medical Emergency Team (MET) zich bewust 
zijn van de kwetsbaarheid van patiënten met een kwaadaardige ziekte en voortvarend 
zijn met de beslissing of intensive care behandeling gerechtvaardigd is. Duidelijke richt-
lijnen op het gebied van de timing van MET-consultatie en IC-opnamecriteria op landelijk 
en instellingsniveau zullen de uitkomsten voor deze patiënten mogelijk verder verbeteren.
De criteria om op een IC te worden opgenomen zijn voor patiënten met of zonder hemato-
logische maligniteit in essentie gelijk. Het kan echter van belang zijn om te anticiperen op 
een versnelde klinische achteruitgang die wordt geassocieerd met ernstige neutropenie. Er 
is behoefte aan een specifiek instrument dat klinische verandering in de hematologische 
neutropene populatie beter kan objectiveren. R-MEWS is niet toereikend voor dit doel en de 
APACHE score is niet bedoeld als risico-inschatter per patient. Een snelle verandering van 
R-MEWS in de tijd (Δ R-MEWS) zou wellicht een betere indicator kunnen zijn, maar verdere 
klinische studies zijn nodig om dit te bevestigen.
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AANBEVELINGEN
1. Een adequate selectie is nodig van hematologische patiënten die het risico lopen 
op verdere klinische achteruitgang en moet leiden tot op de individu afgestemde 
bewaking van vitale functies. Er is behoefte aan een beter track-and-trigger systeem 
om de patiënten die zouden profiteren van intensievere ondersteunende zorg op het 
goede moment te selecteren. Dit instrument zou zich met name moeten richten op het 
graderen van respiratoire en hemodynamische veranderingen, zodat deze adequaat 
behandeld kunnen worden voordat ze onomkeerbaar worden.
2. Nauwe samenwerking tussen intensivisten en hematologen is nodig om voor alle 
aspecten van de behandeling van patiënten met hematologische maligniteiten 
de deskundigheid te verhogen en optimale zorg voor deze populatie te kunnen 
aanbieden.
3. Meer onderzoek is nodig om beter inzicht te verkrijgen in de rol van de onderliggende 
ziekte en mate van respons op de behandeling, het moment en de reden van de IC- 
opname en de impact van de mate van orgaanfalen op de uitkomst van patiënten die 
worden opgenomen op een intensive care.
4. Interventiestudies zijn nodig om het effect van specifieke opname en ontslagcriteria 
te kunnen beoordelen.
STAP 3 - ADEQUATE EN TIJDIGE ACTIE
De APACHE II ernst-van-ziekte scores, bij opname op een IC, voor patiënten met hematologi-
sche maligniteit waren vrij hoog: rond de 21 in ons single-center onderzoek 6 en rond de 24 
in de nationale IC-evaluatie database 7. Een hogere APACHE II score wordt geassocieerd met 
een slechtere prognose, maar vertaalt zich niet noodzakelijk in een kwantitatieve en indivi-
duele kans om te overleven 8. Verwijzing in een vroeger stadium van klinische achteruitgang 
zou effectief kunnen zijn en een grotere overlevingskans bieden met een vermindering van 
het aantal ongeplande IC-dagen 9. Het zogenaamde ‘Slippery slope’-diagram (figuur 1) geeft 
een indruk hoe en wanneer er ingegrepen kan worden in het proces van klinische achteruit-
gang. Een sleutelrol is hierbij weggelegd voor ‘klinische controle’ en ‘snelle interventie’ 10.
 
In de situatie dat een patiënt na beoordeling door een intensivist of het MET op de hema-
tologieafdeling kan blijven moet het medisch en verpleegkundig personeel zich continu 
bewust zijn van de kritische toestand van deze specifieke patiënt. Nauwgezette multidisci-
plinaire evaluatie van de verschillende orgaansystemen en vitale functies moet structureel 
minimaal twee of drie keer per dag worden uitgevoerd.
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AANBEVELINGEN
1. Multidisciplinaire training van de initiële behandeling van respiratoire insufficiëntie, 
de belangrijkste indicatie voor IC-opname tijdens neutropenie, zou verplicht moeten 
zijn voor medisch en verpleegkundig personeel op de afdelingen hematologie waar 
hoog-risico patiënten behandeld worden. Alle medewerkers moeten vertrouwd zijn 
met de basisprincipes van luchtwegmanagement, inclusief het toedienen van zuurstof 
en de eerste stappen van basic life support.
2. IC-verwijzing met een lagere ernst van ziekte moet worden aangemoedigd. Bij 
voorkeur zo spoedig mogelijk na het ontstaan van orgaanfalen en zeker vóórdat een 
behandeling met invasieve beademing of bloeddrukverhogende medicatie  
onvermijdelijk is. Wanneer klinische verslechtering verwacht kan worden als gevolg 
van de onderliggende ziekte dan wel de initiële behandeling (zoals tumorlyse 
syndroom of diffuse intravasale stolling) kan dat een indicatie zijn om de behandeling 
al op een IC te beginnen.
3. Continuïteit van zorg en behandeling moet gegarandeerd blijven bij overplaatsing 
naar een IC. Dit kan worden gewaarborgd door gebruik van hetzelfde (bij voorkeur 
Graﬁ sche weergave van het natuurlijke beloop van klinische verslechtering (gedeeltelijk 
overgenomen van dr. Charles Hawkhurst Pain ti jdens de ‘Managing the deteriorati ng 
pati ent conference’ in 2014)
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elektronische) patiëntendossier, evidence based checklists aangaande antibacteriële 
behandeling of transfusie en een wederzijds multidisciplinair overleg ten minste 
eenmaal per dag.
4. Meer onderzoek moet zich richten op het effect van multidisciplinaire revalidatiepro-
gramma’s en op de lange termijn kwaliteit van leven van patiënten met kanker na een 
IC-opname. Hierbij moeten de performance status en de mogelijkheid om verdere 
behandeling van de onderliggende ziekte te kunnen ondergaan worden meegenomen.
TAKE HOME MESSAGE
We dragen de opvatting uit dat een IC-opname per definitie niet mag worden onthouden 
aan ernstig zieke patiënten met een hematologische maligniteit. Hierbij is het cruciaal 
dat de levensbedreigende aandoening die intensieve monitoring of orgaanvervangende 
behandeling vereist in een zo vroeg mogelijk stadium wordt gedetecteerd en behandeld 
met de bedoeling om verdere schade aan de orgaansystemen te beperken teneinde de best 
mogelijke overlevingskansen te verkrijgen met een beperkte herstelperiode. De uiteinde-
lijke lange termijn prognose wordt bepaald door een geslaagde behandeling van de hema-
tologische maligniteit.
Om dit te bereiken moeten evidence based richtlijnen worden ontwikkeld om uniformiteit te 
verkrijgen in de detectie van levensbedreigende complicaties wanneer patiënten nog op de 
hematologie afdeling verblijven, de selectie van patiënten bij wie het consulteren van een 
intensivist of interventieteam noodzakelijk is en de acties die moeten worden uitgevoerd 
om adequate behandeling van ernstige sepsis en septische shock met optimale onder- 
steunende zorg mogelijk te maken.
Toekomstige studies moeten gericht zijn op de tijdige beslissing of IC-behandeling van 
meerwaarde is, om onnodige opname en behandeling op een IC te minimaliseren. Dit 
door bijvoorbeeld het ontwikkelen van een prognostisch instrument waarin naast de mate 
van orgaanfalen ook de fase van de behandeling en de hematologische ziektestatus zijn 
opgenomen.
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DANKWOORD
Ooit ben ik aan dit promotietraject begonnen met de gedachte dat we de zorg voor mensen 
met een hematologische ziekte zouden kunnen verbeteren. Het ging me daarbij vooral om 
de mensen die, tijdens de toch al loodzware en onzekere route naar genezing, geconfron-
teerd werden met een levensbedreigende situatie als direct gevolg van de behandeling. Om 
dit tot een goed einde te kunnen brengen heb ik mogen samenwerken met zeer gedreven 
personen van verschillende afdelingen in en buiten het Radboudumc zonder wie dit boekje 
er nooit was gekomen. Nu het eenmaal zo ver is wil ik op deze plek iedereen die op welke 
manier dan ook behulpzaam of anderszins betrokken is geweest heel hartelijk bedanken. 
Zonder iemand tekort te willen doen wil ik de volgende mensen in het bijzonder bedanken:
MENSEN VAN HET EERSTE UUR
Toen het idee eenmaal geboren was om promotieonderzoek te gaan doen was het natuur-
lijk nog maar de vraag of naast mij daar ook nog iemand anders in zou geloven? Als eerste 
sprak ik hierover met Marie-José Jorna, mijn toenmalige leidinggevende en Nicole Blij- 
levens, medisch mentor tijdens en na de MANP opleiding. Samen gingen wij praten met 
Prof. dr. Theo de Witte en Prof. dr. Theo van Achterberg. Beiden bleken bereid om samen 
met ons het avontuur aan te gaan en zo werd een promotietraject geboren. Achteraf besef ik 
pas echt hoe bijzonder het is om dit als verpleegkundige te hebben mogen doen.
PROMOTOREN
Prof. dr. Nicole Blijlevens  — Beste Nicole, vanaf het allereerste begin wás je er simpelweg 
voor me als dat nodig was. Tijdens de MANP opleiding als medisch mentor, als stuwende 
kracht achter ons onderzoek en ook als mens op je geheel eigen wijze. Zelfs toen ik besloot 
om afdeling hematologie te verlaten reageerde je warm en menselijk, wat me toen raakte 
en waar ik nog altijd dankbaar voor ben.
Prof. dr. Peter Pickkers  — Beste Peter, zonder te overdrijven is het aan jou te danken dat ik 
hier vandaag daadwerkelijk sta. Op het diepste dieptepunt van mijn diepste dal tijdens dit 
traject nam je me bij de hand en heb je eigenhandig en met volle overtuiging gezorgd dat de 
publicatie alsnog een feit werd. Het ‘als je mij toch niet had…’ is nog nooit zo waar geweest. 
CO-PROMOTOREN
Dr. J. Peter Donnelly  — Beste Peter, wat heb je mij veel geleerd de afgelopen jaren over 
het doen van onderzoek en over de beginselen van de microbiologie. Onze vele afspraken 
de afgelopen jaren waren nooit voorspelbaar en dus ook nooit saai, maar bovenal hartelijk 
en gemeend. Altijd een anekdote paraat om het punt dat je duidelijk wilde maken te illu-
streren. Ik heb me zeer gesteund gevoeld de afgelopen jaren.
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Dr. Walter van der Velden  — Beste Walter, je gedrevenheid en enthousiasme om goede 
patiëntenzorg te realiseren met oog voor de menselijke kant spreekt mij enorm aan. Je altijd 
snelle en no-nonsense reactie op wéér een laatste conceptversie heeft me vaak bij de les 
en op het goede spoor gehouden. Het artikel dat we samen met Anke hebben geschreven is 
een mooi voorbeeld waar multidisciplinair onderzoek toe kan leiden.
MANUSCRIPTCOMMISSIE
Beste prof. dr. Kullberg, prof. dr. Van Achterberg, prof. dr. Van der Graaf en prof. dr. Gerritsen, 
dank dat jullie bereid waren om plaats te nemen in de manuscriptcommissie en dank voor 
de kritische beschouwing en goedkeuring van het manuscript.
MEDE-AUTEURS
Naast de promotoren en co-promotoren wil ik ook alle anderen die een rol hebben gespeeld 
bij het tot stand komen van de artikelen hartelijk danken voor hun bijdrage (in alfabetische 
volgorde): Mark van den Boogaard, Marielle van der Burgt, Andrea Evers, Bernard Fikkers, 
Ton de Haan, Hans van der Hoeven, Nicolette de Keizer, Britta Laros, Niels Peek, Nelly Peer, 
Floor Ploos van Amstel, Carin Potting, Anke Richters, Patrick Sturm, Ilona Verburg, Paul 
Verweij. Veel dank!
MEDEWERKERS AFDELING HEMATOLOGIE
Als stagiaire kwam ik in 1993 op A51 binnenwandelen. Ik wist nog maar heel weinig van 
het ziekenhuis en de patiënten op kamer 15 schoten spontaan in een lachstuip toen ik de 
thermometer ging zoeken en de koelkast opentrok. Dat het toch nog goed kwam is voor 
een groot deel te danken aan Eva, die me door de stage heen heeft gesleept. De jaren die 
volgden waren fascinerend, vaak intensief qua patiëntenzorg, maar bovenal ook gezellig 
en in een professionele, patiëntgerichte atmosfeer en met aandacht voor elkaar. Ik denk 
met veel plezier terug aan de wisselende diensten, de nachten waarin het kon spoken maar 
waar soms ook nog een spelletje Risk gespeeld kon worden. Er is op dat gebied veel veran-
derd de afgelopen jaren vrees ik…
Als verpleegkundig specialist besloot ik in 2014 om mijn professionele geluk elders te 
zoeken. Dat neemt niet weg dat een warme herinnering blijft bestaan aan een bijzondere 
afdeling, een mooi dynamisch specialisme en de bijzondere mooie mensen die zich tot dit 
specialisme aangetrokken voelen: je weet pas wat je mist als het er niet meer is. Allemaal 
heel erg bedankt, met een speciale vermelding voor het ‘hert’ van de afdeling (you know 
who you are!). Vandaag is ook de dag dat ik echt afscheid kan nemen van de afdeling, ik 
hoop jullie allemaal te zien!
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VRIENDEN EN FAMILIE
Beste allemaal, de afgelopen jaren is er in steeds sterkere mate ruimtegebrek geweest: in 
mijn agenda, in mijn hoofd, in mijn sociale leven. Des te aangenamer waren de momenten 
dat ik wél wist te ontsnappen aan SPSS, Word, Excel, reference manager en concept- 
artikelen, laatste concepten, allerlaatste concepten, revisies en drukproeven. Of het nu 
ging om een wedstrijd in De Goffert (Jan, Paul, Antal), een optreden in het onvolprezen 
Doornroosje (Anton, Remco) of de buitenschoolse activiteiten van FC Biercelona. Het was 
een genoegen, een fijne afleiding van wat (te) lang (te) veel van mijn aandacht in beslag 
heeft genomen.
Bijzonder verfrissend zijn de buitenlandse uitstapjes met Toine, Peter en Patrick. Vanuit de 
gedachte dat we mooie voetbalwedstrijden wilden zien (wat soms ook lukte, zo herinner 
ik me nog een Real Madrid – Barcelona in 1997) zijn we nu bijna cultuurhistorisch bezig en 
schromen we zelfs niet om een museum binnen te gaan. Ik hoop nog veel van de wereld met 
jullie te zien en er achter te komen wie destijds de linksback van Oranje had moeten zijn… 
Geweldig dat jullie er ook vandaag bij zijn.
Beter een goede buur… Bachstreet Boys (and girls), wat hebben we het eigenlijk gezellig 
samen: spontane borrels in het park, een winter-BBQ bij -15°C en naar Oranje op het WK 
kijken, telkens in een andere tuin met bij de landen passende gerechten. Dank daarvoor en 
voor alle andere gezelligheid.
Lieve Aad en Riet, Simone, Eveline, Alexander. Jullie hebben het hele traject van nabij 
meegemaakt met alle ups en downs. Dank voor de support en interesse, en de Brabantse 
gezelligheid. Ook voor de praktische hulp als we het eens niet geregeld kregen met de plan-
ning of oppas.
Mam, pap (volgens de kids ben je een sterretje in de ruimte) en Alexandra: jullie stonden 
letterlijk aan de wieg van wie en wat ik nu ben. Daar doet dit proefschrift niets aan af. 
Normaal doen is al gek genoeg heb ik vaak gehoord en dat is ook zo. Bedankt daarvoor.
Lieve lieve lieve Anna en Dennis: het boek is af en dat is reden voor feest. Jullie zijn er al 
tijden klaar voor. Nog even een uurtje stil zijn en daarna ben ik er weer helemaal voor jullie 
en maken we het extra gezellig. Door jullie weet ik dat werk toch ook maar relatief is en het 
echte geluk heel dichtbij en gemakkelijk te vinden is.
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Lieve Ingrid, je zou gaan beginnen met de master geriatrische fysiotherapie als voor mij 
het afronden van het proefschrift in zicht was. Op de dag van de verdediging ben je alweer 
halverwege het derde jaar… zo gaan die dingen bij ons nu eenmaal. De afgelopen jaren 
waren druk en we hebben zeker gemerkt dat niets vanzelf gaat. Toch zijn we er in geslaagd 
om alle hoofden boven water te houden en dat is grotendeels jouw verdienste geweest. 
Dank voor alle support en het warme nest dat het bij ons thuis altijd is en hopelijk nog heel 
lang zal blijven.
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AFKORTINGENLIJST 
(H)SCT (Haematopoietic) stem cell transplantation
(M)MUD (Mis)matched unrelated donor
AA Aplastic anaemia
ALL Acute lymphoblastic leukaemia
AML Acute myeloid leukaemia
APACHE II Acute physiology and chronic health evaluation II
ATG Anti-thymocyte globulin
BEAM BCNU, etoposide, cytarabine, melphalan
CDI Clinically defined infection
CML Chronic myeloid leukaemia
CoNS Coagulase-negative staphylococcus
COPD Chronic obstructive pulmonary disease
CST Continuous measurement of the skin temperature
CVC Central venous catheter
Cyclo Cyclophosphamide
EAT Episodic axillary temperature measurement
GvHD Graft-versus-host disease
HDM High dose melphalan
HEPA High-efficiency particulate air
HL Hodgkin Lymphoma
HRQoL Health related quality of life
ICU Intensive care unit
Ida Idarubicin
LOS Length of stay
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MA Myeloablative
MDI Microbiologically defined infection
MDS Myelodysplastic syndrome
MEWS Modified early warning score
MM Multiple myeloma
NHL Non-Hodgkin lymphoma
NICE National intensive care evaluation
NMA Non-myeloablative
OVS Oral viridans streptococci
PET Positron emission tomography
RAMR Risk adjusted mortality rate
SIB Sibling
SIRS Systemic inflammatory response syndrome
SSC Surviving sepsis campaign
TBI Total body irradiation
TLI Total lymphoid irradiation
TRM Transplant related mortality
VUD Voluntary unrelated donor
WBC White blood cell count
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CURRICULUM VITAE
Maarten van Vliet werd op 31 juli 1971 geboren in Nijmegen. Na het behalen van het athe-
neumdiploma aan het toenmalige Elshof college in Nijmegen (1990) studeerde hij verpleeg-
kunde aan de Hogeschool van Nijmegen, alwaar hij in 1994 zijn diploma behaalde. Hierna 
heeft hij twee jaar gewerkt op de intensieve behandelunit van Maria Roepaan in Ottersum, 
voor mensen met zowel een verstandelijke beperking als ernstige gedragsproblematiek. 
Daarnaast werkte hij op invalbasis op de afdeling hematologie van het Radboudumc waar 
hij in 1996 een vaste aanstelling kreeg als verpleegkundige. Aldaar begon Maarten in 2001 
aan de masteropleiding advanced nursing practice (MANP) welke hij in 2003 met goed 
resultaat afrondde. Hiermee werd hij geregistreerd als verpleegkundig specialist intensieve 
zorg bij somatische aandoeningen.
 In deze functie werd de vitaal bedreigde hematologische patiënt zijn belangrijkste 
aandachtsgebied met als doelstelling het verhogen van de patiëntveiligheid en kwaliteit 
van zorg. Hij heeft een rol gespeeld bij de implementatie van het medical emergency team 
(MET) en continue monitoring van vitale functies op de verpleegafdeling. Daarnaast heeft 
hij verpleegkundig consulentschap opgezet met als doel continuïteit van zorg te bieden aan 
patiënten die op de intensive care werden opgenomen.
Naast patiëntenzorg en onderzoek was Maarten tot en met 2015 als docent actief op de 
Radboud Zorgacademie binnen zowel de complementmodule hematologie verpleegkunde 
(CHV) als de opleiding tot intensive care verpleegkundige (VICV).
Binnen het Radboudumc is Maarten lid van de coördinatiegroep verpleegkundig specia-
listen. Daarnaast is hij sinds 2008 met tussenpozen lid van de landelijke congresredactie 
van de ‘VenVN oncologiedagen’ en was hij één van de initiatiefnemers van het landelijk 
netwerk verpleegkundig specialisten hematologie. Dit netwerk ging later op in de special 
interest group hematologie van VenVN oncologie, waarna hij nog vier jaar in het dagelijks 
bestuur heeft gezeten. Vanaf 2013 is Maarten lid van de werkgroep die een landelijke richt-
lijn over de plaatsing en behandeling van de hemato-oncologische patiënt op de intensive 
care afdeling ontwikkelt. Sinds 2014 maakt hij deel uit van de werkgroep deskundigheids-
bevordering van het netwerk verpleegkundig specialisten oncologie.
Vanaf augustus 2014 is Maarten werkzaam op afdeling medische oncologie van het 
Radboudumc met als aandachtsveld de urologische oncologie.
Maarten woont samen met Ingrid en samen hebben zij twee kinderen: Dennis en Anna.

